CN1893911B - 含有四肽和三肽混合物的配方 - Google Patents
含有四肽和三肽混合物的配方 Download PDFInfo
- Publication number
- CN1893911B CN1893911B CN2003801109853A CN200380110985A CN1893911B CN 1893911 B CN1893911 B CN 1893911B CN 2003801109853 A CN2003801109853 A CN 2003801109853A CN 200380110985 A CN200380110985 A CN 200380110985A CN 1893911 B CN1893911 B CN 1893911B
- Authority
- CN
- China
- Prior art keywords
- agent
- compositions
- acid
- skin
- tetrapeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 255
- 239000002537 cosmetic Substances 0.000 claims abstract description 39
- 230000032683 aging Effects 0.000 claims abstract description 24
- -1 humidizer Substances 0.000 claims description 248
- 210000003491 skin Anatomy 0.000 claims description 158
- 239000003795 chemical substances by application Substances 0.000 claims description 146
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 60
- 239000004094 surface-active agent Substances 0.000 claims description 53
- 239000003995 emulsifying agent Substances 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 41
- 239000002253 acid Substances 0.000 claims description 40
- 210000004209 hair Anatomy 0.000 claims description 34
- 229920000642 polymer Polymers 0.000 claims description 34
- 239000003921 oil Substances 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 25
- 239000003974 emollient agent Substances 0.000 claims description 22
- 230000000475 sunscreen effect Effects 0.000 claims description 21
- 239000000516 sunscreening agent Substances 0.000 claims description 21
- 239000002562 thickening agent Substances 0.000 claims description 21
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 20
- 239000011782 vitamin Substances 0.000 claims description 16
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 claims description 15
- 229940088594 vitamin Drugs 0.000 claims description 15
- 229930003231 vitamin Natural products 0.000 claims description 15
- 235000013343 vitamin Nutrition 0.000 claims description 15
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 14
- 239000003605 opacifier Substances 0.000 claims description 14
- 239000004615 ingredient Substances 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 230000003203 everyday effect Effects 0.000 claims description 11
- 102000012422 Collagen Type I Human genes 0.000 claims description 10
- 108010022452 Collagen Type I Proteins 0.000 claims description 10
- CKFFCVRAFMDZTC-VOXJJDTJSA-N N[C@@H](CCCCN)C(=O)O.N[C@@H](CC1=CNC=N1)C(=O)O.C(CCCCCCCCCCCCCCC)NCC(=O)O Chemical compound N[C@@H](CCCCN)C(=O)O.N[C@@H](CC1=CNC=N1)C(=O)O.C(CCCCCCCCCCCCCCC)NCC(=O)O CKFFCVRAFMDZTC-VOXJJDTJSA-N 0.000 claims description 10
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 10
- CTXFYOWBROEHDR-VKFHRLDHSA-N N[C@@H](CCCNC(N)=N)C(=O)O.N1[C@@H](CCC1)C(=O)O.N[C@@H](CCC(N)=O)C(=O)O.C(CCCCCCCCCCCCCCC)NCC(=O)O Chemical group N[C@@H](CCCNC(N)=N)C(=O)O.N1[C@@H](CCC1)C(=O)O.N[C@@H](CCC(N)=O)C(=O)O.C(CCCCCCCCCCCCCCC)NCC(=O)O CTXFYOWBROEHDR-VKFHRLDHSA-N 0.000 claims description 9
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 8
- 230000003115 biocidal effect Effects 0.000 claims description 8
- 239000000049 pigment Substances 0.000 claims description 8
- 239000000080 wetting agent Substances 0.000 claims description 8
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 7
- 229960000458 allantoin Drugs 0.000 claims description 7
- 235000011399 aloe vera Nutrition 0.000 claims description 7
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 7
- 229940093265 berberine Drugs 0.000 claims description 7
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 7
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- 239000005515 coenzyme Substances 0.000 claims description 7
- 239000003248 enzyme activator Substances 0.000 claims description 7
- 239000002532 enzyme inhibitor Substances 0.000 claims description 7
- 239000006260 foam Substances 0.000 claims description 7
- 239000002304 perfume Substances 0.000 claims description 7
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 6
- 239000000118 hair dye Substances 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 235000013599 spices Nutrition 0.000 claims description 6
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 5
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 5
- 239000000058 anti acne agent Substances 0.000 claims description 5
- 230000002421 anti-septic effect Effects 0.000 claims description 5
- 229940124340 antiacne agent Drugs 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 239000012459 cleaning agent Substances 0.000 claims description 5
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 5
- 230000003779 hair growth Effects 0.000 claims description 5
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 5
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 5
- 235000005493 rutin Nutrition 0.000 claims description 5
- 229960004555 rutoside Drugs 0.000 claims description 5
- 231100000419 toxicity Toxicity 0.000 claims description 5
- 230000001988 toxicity Effects 0.000 claims description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002250 absorbent Substances 0.000 claims description 4
- 230000002745 absorbent Effects 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 230000036783 anaphylactic response Effects 0.000 claims description 4
- 208000003455 anaphylaxis Diseases 0.000 claims description 4
- 239000002518 antifoaming agent Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000003139 biocide Substances 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 239000003398 denaturant Substances 0.000 claims description 4
- 230000002500 effect on skin Effects 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000010408 film Substances 0.000 claims description 4
- 239000003630 growth substance Substances 0.000 claims description 4
- 229940055726 pantothenic acid Drugs 0.000 claims description 4
- 235000019161 pantothenic acid Nutrition 0.000 claims description 4
- 239000011713 pantothenic acid Substances 0.000 claims description 4
- 239000000419 plant extract Substances 0.000 claims description 4
- 239000003380 propellant Substances 0.000 claims description 4
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 4
- 230000035807 sensation Effects 0.000 claims description 4
- 230000002087 whitening effect Effects 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 3
- 239000000975 dye Substances 0.000 claims description 2
- 210000004927 skin cell Anatomy 0.000 claims description 2
- 235000003074 Acacia farnesiana Nutrition 0.000 claims 3
- 241001116389 Aloe Species 0.000 claims 3
- 241000892659 Opopanax Species 0.000 claims 3
- 239000003082 abrasive agent Substances 0.000 claims 3
- 230000001537 neural effect Effects 0.000 claims 3
- 239000012744 reinforcing agent Substances 0.000 claims 3
- 239000003352 sequestering agent Substances 0.000 claims 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims 2
- 239000010409 thin film Substances 0.000 claims 2
- 230000037303 wrinkles Effects 0.000 abstract description 18
- 208000031439 Striae Distensae Diseases 0.000 abstract description 3
- 206010040925 Skin striae Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 77
- 150000001413 amino acids Chemical class 0.000 description 59
- 229940024606 amino acid Drugs 0.000 description 57
- 235000001014 amino acid Nutrition 0.000 description 57
- 239000000194 fatty acid Substances 0.000 description 57
- 239000000463 material Substances 0.000 description 56
- 235000014113 dietary fatty acids Nutrition 0.000 description 54
- 229930195729 fatty acid Natural products 0.000 description 54
- 239000004743 Polypropylene Substances 0.000 description 53
- 229920001155 polypropylene Polymers 0.000 description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 52
- 239000000839 emulsion Substances 0.000 description 51
- 241001597008 Nomeidae Species 0.000 description 50
- 150000004665 fatty acids Chemical class 0.000 description 48
- 150000002148 esters Chemical class 0.000 description 43
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 40
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 40
- 239000000126 substance Substances 0.000 description 40
- 125000000217 alkyl group Chemical group 0.000 description 37
- 239000002585 base Substances 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 37
- 230000003213 activating effect Effects 0.000 description 36
- 239000000047 product Substances 0.000 description 36
- 239000004205 dimethyl polysiloxane Substances 0.000 description 33
- 230000000694 effects Effects 0.000 description 33
- 239000000284 extract Substances 0.000 description 30
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 29
- 229920001296 polysiloxane Polymers 0.000 description 29
- 229940008099 dimethicone Drugs 0.000 description 27
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 26
- 239000007788 liquid Substances 0.000 description 26
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 26
- 235000019198 oils Nutrition 0.000 description 26
- 239000012071 phase Substances 0.000 description 26
- 238000009472 formulation Methods 0.000 description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 21
- 125000002252 acyl group Chemical group 0.000 description 21
- 239000001654 beetroot red Substances 0.000 description 21
- 235000012677 beetroot red Nutrition 0.000 description 21
- 235000002185 betanin Nutrition 0.000 description 21
- UEJYSALTSUZXFV-SRVKXCTJSA-N Rigin Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UEJYSALTSUZXFV-SRVKXCTJSA-N 0.000 description 20
- 239000000178 monomer Substances 0.000 description 20
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 19
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 19
- 239000004475 Arginine Substances 0.000 description 19
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 18
- 239000004472 Lysine Substances 0.000 description 18
- 239000000499 gel Substances 0.000 description 18
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 17
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 17
- 229920002125 Sokalan® Polymers 0.000 description 17
- 229930006000 Sucrose Natural products 0.000 description 17
- 229930003935 flavonoid Natural products 0.000 description 17
- 235000017173 flavonoids Nutrition 0.000 description 17
- 239000005720 sucrose Substances 0.000 description 17
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 16
- 108010091078 rigin Proteins 0.000 description 16
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 15
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 102000008186 Collagen Human genes 0.000 description 14
- 108010035532 Collagen Proteins 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- 229910019142 PO4 Inorganic materials 0.000 description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 229920001436 collagen Polymers 0.000 description 14
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 14
- 235000021317 phosphate Nutrition 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 13
- 229960000541 cetyl alcohol Drugs 0.000 description 13
- 229920001577 copolymer Polymers 0.000 description 13
- 239000006210 lotion Substances 0.000 description 13
- 229920001223 polyethylene glycol Polymers 0.000 description 13
- 239000003760 tallow Substances 0.000 description 13
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000002202 Polyethylene glycol Substances 0.000 description 12
- 229940121363 anti-inflammatory agent Drugs 0.000 description 12
- 239000002260 anti-inflammatory agent Substances 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 229940036350 bisabolol Drugs 0.000 description 12
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 12
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 12
- 239000006071 cream Substances 0.000 description 12
- 150000002215 flavonoids Chemical class 0.000 description 12
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 12
- 230000009759 skin aging Effects 0.000 description 12
- 235000019156 vitamin B Nutrition 0.000 description 12
- 239000011720 vitamin B Substances 0.000 description 12
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 11
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 11
- 229930003270 Vitamin B Natural products 0.000 description 11
- 125000002091 cationic group Chemical group 0.000 description 11
- 150000001768 cations Chemical class 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 229910052710 silicon Inorganic materials 0.000 description 11
- 239000010703 silicon Substances 0.000 description 11
- QUCHWTCTBHQQDU-UHFFFAOYSA-N 2-amino-4-oxopentanoic acid Chemical compound CC(=O)CC([NH3+])C([O-])=O QUCHWTCTBHQQDU-UHFFFAOYSA-N 0.000 description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 10
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 10
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 10
- 230000001153 anti-wrinkle effect Effects 0.000 description 10
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 10
- 229960001631 carbomer Drugs 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000008367 deionised water Substances 0.000 description 10
- 229910021641 deionized water Inorganic materials 0.000 description 10
- 229930003949 flavanone Natural products 0.000 description 10
- 235000011981 flavanones Nutrition 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 239000010452 phosphate Substances 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 229920002545 silicone oil Polymers 0.000 description 10
- YHRUHBBTQZKMEX-YFVJMOTDSA-N (2-trans,6-trans)-farnesal Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\C=O YHRUHBBTQZKMEX-YFVJMOTDSA-N 0.000 description 9
- YHRUHBBTQZKMEX-UHFFFAOYSA-N (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-al Natural products CC(C)=CCCC(C)=CCCC(C)=CC=O YHRUHBBTQZKMEX-UHFFFAOYSA-N 0.000 description 9
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 9
- YHRUHBBTQZKMEX-FBXUGWQNSA-N E,E-Farnesal Natural products CC(C)=CCC\C(C)=C/CC\C(C)=C/C=O YHRUHBBTQZKMEX-FBXUGWQNSA-N 0.000 description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 9
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 9
- 125000000129 anionic group Chemical group 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 9
- 239000003925 fat Substances 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 235000019136 lipoic acid Nutrition 0.000 description 9
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 9
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 9
- 239000002674 ointment Substances 0.000 description 9
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 9
- 229920002050 silicone resin Polymers 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- 229940083542 sodium Drugs 0.000 description 9
- 235000015424 sodium Nutrition 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229940012831 stearyl alcohol Drugs 0.000 description 9
- 229960002663 thioctic acid Drugs 0.000 description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 8
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 8
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- 239000004471 Glycine Substances 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 8
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 8
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 8
- 239000004721 Polyphenylene oxide Substances 0.000 description 8
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 8
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 239000002280 amphoteric surfactant Substances 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229940086555 cyclomethicone Drugs 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 150000002191 fatty alcohols Chemical class 0.000 description 8
- 229960002449 glycine Drugs 0.000 description 8
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 8
- 210000000088 lip Anatomy 0.000 description 8
- 230000000474 nursing effect Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 229920000570 polyether Polymers 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000002888 zwitterionic surfactant Substances 0.000 description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 7
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 7
- VEVRNHHLCPGNDU-MUGJNUQGSA-N (2s)-2-amino-5-[1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-4-yl]pentanoate Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-N 0.000 description 7
- GVSPXQVUXHMUMA-MDWZMJQESA-N (e)-3-(3,5-ditert-butyl-4-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 GVSPXQVUXHMUMA-MDWZMJQESA-N 0.000 description 7
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 7
- 239000004166 Lanolin Substances 0.000 description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- 239000003240 coconut oil Substances 0.000 description 7
- 235000019864 coconut oil Nutrition 0.000 description 7
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 7
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 7
- 229960000735 docosanol Drugs 0.000 description 7
- 239000003349 gelling agent Substances 0.000 description 7
- 239000003292 glue Substances 0.000 description 7
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 7
- 229920002674 hyaluronan Polymers 0.000 description 7
- 229960003160 hyaluronic acid Drugs 0.000 description 7
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 7
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 7
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 7
- 235000008696 isoflavones Nutrition 0.000 description 7
- 235000019388 lanolin Nutrition 0.000 description 7
- 229940039717 lanolin Drugs 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 239000002516 radical scavenger Substances 0.000 description 7
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 7
- 229960004889 salicylic acid Drugs 0.000 description 7
- 239000000344 soap Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 6
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 6
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 6
- 229960001040 ammonium chloride Drugs 0.000 description 6
- 239000003093 cationic surfactant Substances 0.000 description 6
- 229960002173 citrulline Drugs 0.000 description 6
- 235000013477 citrulline Nutrition 0.000 description 6
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 6
- 150000005690 diesters Chemical class 0.000 description 6
- YVQXPCWPLBNVGT-RVOGATNRSA-L dipotassium;(2e,4e)-hexa-2,4-dienoate Chemical compound [K+].[K+].C\C=C\C=C\C([O-])=O.C\C=C\C=C\C([O-])=O YVQXPCWPLBNVGT-RVOGATNRSA-L 0.000 description 6
- XGZRAKBCYZIBKP-UHFFFAOYSA-L disodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[Na+] XGZRAKBCYZIBKP-UHFFFAOYSA-L 0.000 description 6
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229940043259 farnesol Drugs 0.000 description 6
- 229930002886 farnesol Natural products 0.000 description 6
- 229930003944 flavone Natural products 0.000 description 6
- 235000011949 flavones Nutrition 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 230000006651 lactation Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 229960004488 linolenic acid Drugs 0.000 description 6
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 6
- 239000011859 microparticle Substances 0.000 description 6
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 229960004063 propylene glycol Drugs 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 6
- 239000002453 shampoo Substances 0.000 description 6
- 230000037075 skin appearance Effects 0.000 description 6
- 235000010199 sorbic acid Nutrition 0.000 description 6
- 239000004334 sorbic acid Substances 0.000 description 6
- 229940075582 sorbic acid Drugs 0.000 description 6
- 239000008117 stearic acid Substances 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 6
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 6
- 229960001727 tretinoin Drugs 0.000 description 6
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 6
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 5
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 5
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 5
- 206010040844 Skin exfoliation Diseases 0.000 description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 125000005466 alkylenyl group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 230000003255 anti-acne Effects 0.000 description 5
- 230000000843 anti-fungal effect Effects 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 239000000084 colloidal system Substances 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 5
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 229940117927 ethylene oxide Drugs 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 235000001968 nicotinic acid Nutrition 0.000 description 5
- 239000011664 nicotinic acid Substances 0.000 description 5
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 5
- 235000019865 palm kernel oil Nutrition 0.000 description 5
- 239000003346 palm kernel oil Substances 0.000 description 5
- 229940101267 panthenol Drugs 0.000 description 5
- 235000020957 pantothenol Nutrition 0.000 description 5
- 239000011619 pantothenol Substances 0.000 description 5
- 229940100460 peg-100 stearate Drugs 0.000 description 5
- 229960005323 phenoxyethanol Drugs 0.000 description 5
- CGIHFIDULQUVJG-UHFFFAOYSA-N phytantriol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C(O)CO CGIHFIDULQUVJG-UHFFFAOYSA-N 0.000 description 5
- CGIHFIDULQUVJG-VNTMZGSJSA-N phytantriol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(O)[C@H](O)CO CGIHFIDULQUVJG-VNTMZGSJSA-N 0.000 description 5
- 235000002949 phytic acid Nutrition 0.000 description 5
- 229940068041 phytic acid Drugs 0.000 description 5
- 239000000467 phytic acid Substances 0.000 description 5
- 229920000058 polyacrylate Polymers 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 5
- 229920005862 polyol Polymers 0.000 description 5
- 150000003077 polyols Chemical class 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 229950008882 polysorbate Drugs 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 235000019155 vitamin A Nutrition 0.000 description 5
- 239000011719 vitamin A Substances 0.000 description 5
- 229940045997 vitamin a Drugs 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 4
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 4
- MDMNSAVSQAHVLC-MDTVQASCSA-N 2-aminoacetic acid;(2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCC(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CNC=N1 MDMNSAVSQAHVLC-MDTVQASCSA-N 0.000 description 4
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 4
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 4
- 244000144927 Aloe barbadensis Species 0.000 description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 4
- 241000195940 Bryophyta Species 0.000 description 4
- 244000060011 Cocos nucifera Species 0.000 description 4
- 235000013162 Cocos nucifera Nutrition 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- 108010016626 Dipeptides Proteins 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Natural products O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 4
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 4
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- 108010077895 Sarcosine Proteins 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 229960002749 aminolevulinic acid Drugs 0.000 description 4
- 239000003945 anionic surfactant Substances 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940073669 ceteareth 20 Drugs 0.000 description 4
- 229940085262 cetyl dimethicone Drugs 0.000 description 4
- 150000001788 chalcone derivatives Chemical class 0.000 description 4
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 4
- 229920006037 cross link polymer Polymers 0.000 description 4
- 229960000958 deferoxamine Drugs 0.000 description 4
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 4
- 229940120503 dihydroxyacetone Drugs 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 4
- 229960003720 enoxolone Drugs 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 150000002212 flavone derivatives Chemical class 0.000 description 4
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 4
- 229960004369 flufenamic acid Drugs 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 4
- 229940075529 glyceryl stearate Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 150000001261 hydroxy acids Chemical class 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 235000020778 linoleic acid Nutrition 0.000 description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 235000011929 mousse Nutrition 0.000 description 4
- 229960002009 naproxen Drugs 0.000 description 4
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 4
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 4
- 229960000601 octocrylene Drugs 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 238000007665 sagging Methods 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 229940075554 sorbate Drugs 0.000 description 4
- 229940035044 sorbitan monolaurate Drugs 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 229940098760 steareth-2 Drugs 0.000 description 4
- 229940100458 steareth-21 Drugs 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- AETKQQBRKSELEL-UHFFFAOYSA-N (2E)-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one Natural products OC1=CC=CC=C1C(=O)C=CC1=CC=CC=C1 AETKQQBRKSELEL-UHFFFAOYSA-N 0.000 description 3
- FGLRWHNZUBAWJK-MDZDMXLPSA-N (e)-3-(3-hydroxyphenyl)-1-phenylprop-2-en-1-one Chemical compound OC1=CC=CC(\C=C\C(=O)C=2C=CC=CC=2)=C1 FGLRWHNZUBAWJK-MDZDMXLPSA-N 0.000 description 3
- YZAZXIUFBCPZGB-QZOPMXJLSA-N (z)-octadec-9-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O YZAZXIUFBCPZGB-QZOPMXJLSA-N 0.000 description 3
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 3
- AETKQQBRKSELEL-ZHACJKMWSA-N 2'-hydroxychalcone Chemical compound OC1=CC=CC=C1C(=O)\C=C\C1=CC=CC=C1 AETKQQBRKSELEL-ZHACJKMWSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)-3,4-dihydroxy-2h-furan-5-one Chemical compound OCC(O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-UHFFFAOYSA-N 0.000 description 3
- XMBFBONQTDARNY-UHFFFAOYSA-N 2-(2-ethylhexylamino)-3-methylbenzoic acid Chemical class CCCCC(CC)CNC1=C(C)C=CC=C1C(O)=O XMBFBONQTDARNY-UHFFFAOYSA-N 0.000 description 3
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 3
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 3
- BYMMIQCVDHHYGG-UHFFFAOYSA-N Cl.OP(O)(O)=O Chemical compound Cl.OP(O)(O)=O BYMMIQCVDHHYGG-UHFFFAOYSA-N 0.000 description 3
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 3
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 239000005639 Lauric acid Substances 0.000 description 3
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 3
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 3
- 235000019082 Osmanthus Nutrition 0.000 description 3
- 241000333181 Osmanthus Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- MSKSOBAQMWJYTJ-UHFFFAOYSA-N [Mg].OP(O)(O)=O Chemical compound [Mg].OP(O)(O)=O MSKSOBAQMWJYTJ-UHFFFAOYSA-N 0.000 description 3
- IRXBYWKTMHXZQW-UHFFFAOYSA-N [NH4+].C(CCCCCCCCCCCCCCCCC)(=O)NCCCC(C(C(=O)[O-])(O)C)C Chemical compound [NH4+].C(CCCCCCCCCCCCCCCCC)(=O)NCCCC(C(C(=O)[O-])(O)C)C IRXBYWKTMHXZQW-UHFFFAOYSA-N 0.000 description 3
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- KHIHBOPGYSBYJJ-UHFFFAOYSA-N azane;toluene Chemical compound N.CC1=CC=CC=C1 KHIHBOPGYSBYJJ-UHFFFAOYSA-N 0.000 description 3
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 235000005513 chalcones Nutrition 0.000 description 3
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 239000008406 cosmetic ingredient Substances 0.000 description 3
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 3
- HABLENUWIZGESP-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O HABLENUWIZGESP-UHFFFAOYSA-N 0.000 description 3
- LVXUNJWLKCUTNF-UHFFFAOYSA-N dimethyl-[3-(octadecanoylamino)propyl]azanium;chloride Chemical compound Cl.CCCCCCCCCCCCCCCCCC(=O)NCCCN(C)C LVXUNJWLKCUTNF-UHFFFAOYSA-N 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 3
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 3
- AGDANEVFLMAYGL-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCCCCCC(O)=O AGDANEVFLMAYGL-UHFFFAOYSA-N 0.000 description 3
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 3
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 229960001493 etofenamate Drugs 0.000 description 3
- 210000004905 finger nail Anatomy 0.000 description 3
- 150000002208 flavanones Chemical class 0.000 description 3
- 229960002011 fludrocortisone Drugs 0.000 description 3
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 239000004519 grease Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 3
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 3
- 229940100463 hexyl laurate Drugs 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical class C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 229960000448 lactic acid Drugs 0.000 description 3
- 229940074358 magnesium ascorbate Drugs 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229960002509 miconazole Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- WVJVHUWVQNLPCR-UHFFFAOYSA-N octadecanoyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCC WVJVHUWVQNLPCR-UHFFFAOYSA-N 0.000 description 3
- 235000014593 oils and fats Nutrition 0.000 description 3
- 229940049964 oleate Drugs 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 229940066675 ricinoleate Drugs 0.000 description 3
- 229940043230 sarcosine Drugs 0.000 description 3
- 229950011392 sorbitan stearate Drugs 0.000 description 3
- 235000019337 sorbitan trioleate Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940100459 steareth-20 Drugs 0.000 description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 229920001897 terpolymer Polymers 0.000 description 3
- ZTUXEFFFLOVXQE-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O ZTUXEFFFLOVXQE-UHFFFAOYSA-N 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 239000002569 water oil cream Substances 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- QWWPCQGHWWNGET-LCVVDEIYSA-N (2r,3r,4s,5s,6r)-2-[[(2r,4as,4br,7s,10as)-7-[(1r)-1,2-dihydroxyethyl]-1,1,4a,7-tetramethyl-3,4,4b,5,6,9,10,10a-octahydro-2h-phenanthren-2-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O([C@H]1C([C@H]2CCC3=C[C@](C)(CC[C@H]3[C@]2(C)CC1)[C@@H](O)CO)(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWWPCQGHWWNGET-LCVVDEIYSA-N 0.000 description 2
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 2
- CZJXBZPJABCCRQ-BULBTXNYSA-N (8s,9r,10s,11s,13s,14s,17r)-9,11-dichloro-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1C=C[C@]2(C)[C@@]3(Cl)[C@@H](Cl)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 CZJXBZPJABCCRQ-BULBTXNYSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- FDHNLHLOJLLXDH-JIYHLSBYSA-N (e)-3-(3-hydroxy-4-methoxyphenyl)-1-[2-hydroxy-6-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxyphenyl]prop-2-en-1-one Chemical group C1=C(O)C(OC)=CC=C1\C=C\C(=O)C(C(=C1)OC)=C(O)C=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 FDHNLHLOJLLXDH-JIYHLSBYSA-N 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 2
- 239000005968 1-Decanol Substances 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- OAAZUWWNSYWWHG-UHFFFAOYSA-N 1-phenoxypropan-1-ol Chemical compound CCC(O)OC1=CC=CC=C1 OAAZUWWNSYWWHG-UHFFFAOYSA-N 0.000 description 2
- IBLKWZIFZMJLFL-UHFFFAOYSA-N 1-phenoxypropan-2-ol Chemical compound CC(O)COC1=CC=CC=C1 IBLKWZIFZMJLFL-UHFFFAOYSA-N 0.000 description 2
- LALVCWMSKLEQMK-UHFFFAOYSA-N 1-phenyl-3-(4-propan-2-ylphenyl)propane-1,3-dione Chemical compound C1=CC(C(C)C)=CC=C1C(=O)CC(=O)C1=CC=CC=C1 LALVCWMSKLEQMK-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- GKZDQKGQPDYTSL-UOIUBEPWSA-N 2-aminoacetic acid (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid (2S)-2,5-diamino-5-oxopentanoic acid (2S)-pyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H](N)CCC(N)=O.OC(=O)[C@@H](N)CCCNC(N)=N GKZDQKGQPDYTSL-UOIUBEPWSA-N 0.000 description 2
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 2
- SBYMUDUGTIKLCR-UHFFFAOYSA-N 2-chloroethenylbenzene Chemical compound ClC=CC1=CC=CC=C1 SBYMUDUGTIKLCR-UHFFFAOYSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- FSEXLNMNADBYJU-UHFFFAOYSA-N 2-phenylquinoline Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=N1 FSEXLNMNADBYJU-UHFFFAOYSA-N 0.000 description 2
- BODRLKRKPXBDBN-UHFFFAOYSA-N 3,5,5-Trimethyl-1-hexanol Chemical compound OCCC(C)CC(C)(C)C BODRLKRKPXBDBN-UHFFFAOYSA-N 0.000 description 2
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 2
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 2
- UAHGNXFYLAJDIN-UHFFFAOYSA-N 4'-Hydroxychalcone Natural products C1=CC(O)=CC=C1C(=O)C=CC1=CC=CC=C1 UAHGNXFYLAJDIN-UHFFFAOYSA-N 0.000 description 2
- UAHGNXFYLAJDIN-IZZDOVSWSA-N 4'-hydroxychalcone Chemical compound C1=CC(O)=CC=C1C(=O)\C=C\C1=CC=CC=C1 UAHGNXFYLAJDIN-IZZDOVSWSA-N 0.000 description 2
- LGRQYAIQTHIDNW-UHFFFAOYSA-N 4-(2-methyl-1,3-dioxolan-2-yl)butan-1-ol Chemical class OCCCCC1(C)OCCO1 LGRQYAIQTHIDNW-UHFFFAOYSA-N 0.000 description 2
- YDIYEOMDOWUDTJ-UHFFFAOYSA-N 4-(dimethylamino)benzoic acid Chemical compound CN(C)C1=CC=C(C(O)=O)C=C1 YDIYEOMDOWUDTJ-UHFFFAOYSA-N 0.000 description 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 241001044369 Amphion Species 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
- DTBAKLABXMQLPZ-UHFFFAOYSA-N C(CCCC)O.CC1OCCO1 Chemical compound C(CCCC)O.CC1OCCO1 DTBAKLABXMQLPZ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010065839 Capreomycin Proteins 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 235000004866 D-panthenol Nutrition 0.000 description 2
- 239000011703 D-panthenol Substances 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- QWWPCQGHWWNGET-ZPGRLJJOSA-N Darutoside Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O1)[C@H]1C(C)(C)[C@H]2[C@](C)([C@@H]3C(=C[C@]([C@H](O)CO)(C)CC3)CC2)CC1 QWWPCQGHWWNGET-ZPGRLJJOSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 241001446187 Kermes Species 0.000 description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004147 Sorbitan trioleate Substances 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- RIQIJXOWVAHQES-UNAKLNRMSA-N Tocoretinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C RIQIJXOWVAHQES-UNAKLNRMSA-N 0.000 description 2
- 241000219793 Trifolium Species 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- 241001148683 Zostera marina Species 0.000 description 2
- PZQBWGFCGIRLBB-NJYHNNHUSA-N [(2r)-2-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1O PZQBWGFCGIRLBB-NJYHNNHUSA-N 0.000 description 2
- XAQHXGSHRMHVMU-UHFFFAOYSA-N [S].[S] Chemical compound [S].[S] XAQHXGSHRMHVMU-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 150000003926 acrylamides Chemical class 0.000 description 2
- 150000001253 acrylic acids Chemical class 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 2
- 229960002916 adapalene Drugs 0.000 description 2
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 2
- GUAFOGOEJLSQBT-UHFFFAOYSA-N aesculetin dimethyl ether Natural products C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229920000180 alkyd Polymers 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229960005193 avobenzone Drugs 0.000 description 2
- 229950000210 beclometasone dipropionate Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 2
- 239000012965 benzophenone Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 2
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 2
- 150000004777 chromones Chemical class 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229940071160 cocoate Drugs 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 239000008294 cold cream Substances 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000007854 depigmenting agent Substances 0.000 description 2
- 125000005345 deuteroalkyl group Chemical group 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 229960003949 dexpanthenol Drugs 0.000 description 2
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical compound C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 2
- 229950009888 dichlorisone Drugs 0.000 description 2
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 2
- WLCFKPHMRNPAFZ-UHFFFAOYSA-M didodecyl(dimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCC WLCFKPHMRNPAFZ-UHFFFAOYSA-M 0.000 description 2
- 229940031766 diethanolamine cetyl phosphate Drugs 0.000 description 2
- 229940031578 diisopropyl adipate Drugs 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- RSHHCURRBLAGFA-UHFFFAOYSA-M dimethyl-di(tetradecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCC RSHHCURRBLAGFA-UHFFFAOYSA-M 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- PGQAXGHQYGXVDC-UHFFFAOYSA-N dodecyl(dimethyl)azanium;chloride Chemical compound Cl.CCCCCCCCCCCCN(C)C PGQAXGHQYGXVDC-UHFFFAOYSA-N 0.000 description 2
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000004016 elaidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])/C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 2
- WBJQGBBEPJLNKP-UHFFFAOYSA-N ethyl-dimethyl-[3-(octadecanoylamino)propyl]azanium;ethyl sulfate Chemical compound CCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC WBJQGBBEPJLNKP-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 229960000192 felbinac Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229960000785 fluocinonide Drugs 0.000 description 2
- 229960003238 fluprednidene Drugs 0.000 description 2
- YVHXHNGGPURVOS-SBTDHBFYSA-N fluprednidene Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](C(=C)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 YVHXHNGGPURVOS-SBTDHBFYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229940074047 glyceryl cocoate Drugs 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 239000008266 hair spray Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 2
- GKKMCECQQIKAHA-UHFFFAOYSA-N hexadecyl dihydrogen phosphate;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.CCCCCCCCCCCCCCCCOP(O)(O)=O GKKMCECQQIKAHA-UHFFFAOYSA-N 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000002563 ionic surfactant Substances 0.000 description 2
- 239000000797 iron chelating agent Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical class CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- CXORMDKZEUMQHX-UHFFFAOYSA-N kermesic acid Chemical compound O=C1C2=C(O)C(O)=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C CXORMDKZEUMQHX-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 229960003803 meclofenamic acid Drugs 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- QUAMTGJKVDWJEQ-UHFFFAOYSA-N octabenzone Chemical compound OC1=CC(OCCCCCCCC)=CC=C1C(=O)C1=CC=CC=C1 QUAMTGJKVDWJEQ-UHFFFAOYSA-N 0.000 description 2
- RQFLGKYCYMMRMC-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O RQFLGKYCYMMRMC-UHFFFAOYSA-N 0.000 description 2
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229940098695 palmitic acid Drugs 0.000 description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical class CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940106026 phenoxyisopropanol Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- NFIYTPYOYDDLGO-UHFFFAOYSA-N phosphoric acid;sodium Chemical compound [Na].OP(O)(O)=O NFIYTPYOYDDLGO-UHFFFAOYSA-N 0.000 description 2
- 229950001046 piroctone Drugs 0.000 description 2
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- LMWHCJFWODXSMN-UHFFFAOYSA-M sodium;1-dodecoxydodecane;octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCOCCCCCCCCCCCC LMWHCJFWODXSMN-UHFFFAOYSA-M 0.000 description 2
- 229960000391 sorbitan trioleate Drugs 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000005987 sulfurization reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- 229960000565 tazarotene Drugs 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- UUJLHYCIMQOUKC-UHFFFAOYSA-N trimethyl-[oxo(trimethylsilylperoxy)silyl]peroxysilane Chemical compound C[Si](C)(C)OO[Si](=O)OO[Si](C)(C)C UUJLHYCIMQOUKC-UHFFFAOYSA-N 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 229940005605 valeric acid Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229940117958 vinyl acetate Drugs 0.000 description 2
- 229920001567 vinyl ester resin Polymers 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- DVWJFTGEISXVSH-CWVFEVJCSA-N (1R,3S,5S,7Z,11R,12S,13Z,15Z,17Z,19Z,21R,23S,24R,25S)-21-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-12-ethyl-1,3,5,25-tetrahydroxy-11-methyl-9-oxo-10,27-dioxabicyclo[21.3.1]heptacosa-7,13,15,17,19-pentaene-24-carboxylic acid Chemical compound CC[C@H]1\C=C/C=C\C=C/C=C\[C@@H](C[C@@H]2O[C@@](O)(C[C@H](O)[C@H]2C(O)=O)C[C@@H](O)C[C@@H](O)C\C=C/C(=O)O[C@@H]1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O DVWJFTGEISXVSH-CWVFEVJCSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- PDHSAQOQVUXZGQ-JKSUJKDBSA-N (2r,3s)-2-(3,4-dihydroxyphenyl)-3-methoxy-3,4-dihydro-2h-chromene-5,7-diol Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2OC)=CC=C(O)C(O)=C1 PDHSAQOQVUXZGQ-JKSUJKDBSA-N 0.000 description 1
- KWBUARAINLGYMG-JGMIRXPNSA-N (2r,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(1r,2r,3s,4r,6s)-4,6-diamino-2-[(2s,3r,4s,5r)-4-[(2r,3r,4r,5s,6s)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO KWBUARAINLGYMG-JGMIRXPNSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- GYNQVPIDAQTZOY-ROUUACIJSA-N (2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](N)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 GYNQVPIDAQTZOY-ROUUACIJSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- ZEUUPKVZFKBXPW-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N ZEUUPKVZFKBXPW-TWDWGCDDSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- PAFJZWHXMSQJKV-UQZRNVAESA-N (3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol;octadecanoic acid Chemical compound OC[C@@H](O)C1OC[C@H](O)[C@H]1O.OC[C@@H](O)C1OC[C@H](O)[C@H]1O.OC[C@@H](O)C1OC[C@H](O)[C@H]1O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O PAFJZWHXMSQJKV-UQZRNVAESA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical class COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 description 1
- OKQBXIRUGKXBKP-AGQBKMEESA-N (3s,8s,9s,10r,13s,14s,16r,17r)-10,13-dimethyl-17-[(1s)-1-[(3s)-3-methyl-1,2,3,4-tetrahydropyridin-6-yl]ethyl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,16-diol Chemical compound C1([C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)CC[C@H](O)CC5=CC[C@H]4[C@@H]3C[C@H]2O)C)C)=CC[C@H](C)CN1 OKQBXIRUGKXBKP-AGQBKMEESA-N 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- VXPSARQTYDZXAO-CCHMMTNSSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O VXPSARQTYDZXAO-CCHMMTNSSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- YCIHPQHVWDULOY-FMZCEJRJSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O YCIHPQHVWDULOY-FMZCEJRJSA-N 0.000 description 1
- QYAPHLRPFNSDNH-MRFRVZCGSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O QYAPHLRPFNSDNH-MRFRVZCGSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- ZPFAVCIQZKRBGF-UHFFFAOYSA-N 1,3,2-dioxathiolane 2,2-dioxide Chemical compound O=S1(=O)OCCO1 ZPFAVCIQZKRBGF-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- MMEXPSCGRYPZKY-UHFFFAOYSA-N 1-(3-bromoindazol-2-yl)ethanone Chemical compound C1=CC=CC2=C(Br)N(C(=O)C)N=C21 MMEXPSCGRYPZKY-UHFFFAOYSA-N 0.000 description 1
- KODLUXHSIZOKTG-UHFFFAOYSA-N 1-aminobutan-2-ol Chemical class CCC(O)CN KODLUXHSIZOKTG-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GUPMCMZMDAGSPF-UHFFFAOYSA-N 1-phenylbuta-1,3-dienylbenzene Chemical compound C=1C=CC=CC=1[C](C=C[CH2])C1=CC=CC=C1 GUPMCMZMDAGSPF-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- UOFOXWQPZJNTDZ-UHFFFAOYSA-N 18-methylnonadecan-2-ol Chemical compound C(CCCCCCCCCCCCCCC(C)C)C(C)O UOFOXWQPZJNTDZ-UHFFFAOYSA-N 0.000 description 1
- FGPJTMCJNPRZGF-UHFFFAOYSA-N 2',4-Dihydroxychalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=CC=CC=C1O FGPJTMCJNPRZGF-UHFFFAOYSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- XPKVYKWWLONHDF-UHFFFAOYSA-N 2,3-dihydroxy-3-(2-hydroxyphenyl)prop-2-enoic acid Chemical class OC(=O)C(O)=C(O)C1=CC=CC=C1O XPKVYKWWLONHDF-UHFFFAOYSA-N 0.000 description 1
- DRBARRGCABOUIE-UHFFFAOYSA-N 2,3-dihydroxy-3-phenylprop-2-enoic acid Chemical compound OC(=O)C(O)=C(O)C1=CC=CC=C1 DRBARRGCABOUIE-UHFFFAOYSA-N 0.000 description 1
- WZPLEIAOQJXZJX-UHFFFAOYSA-N 2,3-dihydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C(O)=CC2=C1 WZPLEIAOQJXZJX-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- XJMNWALRJHPRBS-UHFFFAOYSA-N 2,3-dihydroxypropyl-[3-(docosanoylamino)propyl]-dimethylazanium;chloride Chemical group [Cl-].CCCCCCCCCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)CO XJMNWALRJHPRBS-UHFFFAOYSA-N 0.000 description 1
- ZXDDPOHVAMWLBH-UHFFFAOYSA-N 2,4-Dihydroxybenzophenone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 ZXDDPOHVAMWLBH-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- KLIVRBFRQSOGQI-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzothiepin-3-yl)acetic acid Chemical compound S1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 KLIVRBFRQSOGQI-UHFFFAOYSA-N 0.000 description 1
- PYIHCGFQQSKYBO-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzoxepin-3-yl)acetic acid Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 PYIHCGFQQSKYBO-UHFFFAOYSA-N 0.000 description 1
- PSHADDQTSCEAHY-UHFFFAOYSA-N 2-(2-methylpropyl)benzoic acid Chemical compound CC(C)CC1=CC=CC=C1C(O)=O PSHADDQTSCEAHY-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- SHGLJXBLXNNCTE-UHFFFAOYSA-N 2-(4-hydroxyphenyl)chromen-4-one Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=CC=CC=C2O1 SHGLJXBLXNNCTE-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- FKMHSNTVILORFA-UHFFFAOYSA-N 2-[2-(2-dodecoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCO FKMHSNTVILORFA-UHFFFAOYSA-N 0.000 description 1
- UOFCAQWHTQFNHS-UHFFFAOYSA-N 2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCO UOFCAQWHTQFNHS-UHFFFAOYSA-N 0.000 description 1
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
- HSEXOZXVUZVSDZ-UHFFFAOYSA-N 2-[2-ethylhexyl(methyl)amino]benzoic acid Chemical class CCCCC(CC)CN(C)C1=CC=CC=C1C(O)=O HSEXOZXVUZVSDZ-UHFFFAOYSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- WGDADRBTCPGSDG-UHFFFAOYSA-N 2-[[4,5-bis(4-chlorophenyl)-1,3-oxazol-2-yl]sulfanyl]propanoic acid Chemical compound O1C(SC(C)C(O)=O)=NC(C=2C=CC(Cl)=CC=2)=C1C1=CC=C(Cl)C=C1 WGDADRBTCPGSDG-UHFFFAOYSA-N 0.000 description 1
- ZDPCIXZONVNODH-UHFFFAOYSA-N 2-acetyloxybenzoic acid;n-(4-hydroxyphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(O)C=C1.CC(=O)OC1=CC=CC=C1C(O)=O ZDPCIXZONVNODH-UHFFFAOYSA-N 0.000 description 1
- JPPZWICGMJJBIH-JEDNCBNOSA-N 2-aminoacetic acid;(2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CC1=CNC=N1 JPPZWICGMJJBIH-JEDNCBNOSA-N 0.000 description 1
- OBWBSSIUKXEALB-UHFFFAOYSA-N 2-aminoethanol;2-hydroxypropanamide Chemical compound NCCO.CC(O)C(N)=O OBWBSSIUKXEALB-UHFFFAOYSA-N 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 1
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- JCTNVNANPZAULC-UHFFFAOYSA-N 2-methylbenzo[e][1,3]benzoxazole Chemical compound C1=CC=C2C(N=C(O3)C)=C3C=CC2=C1 JCTNVNANPZAULC-UHFFFAOYSA-N 0.000 description 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 1
- FIISKTXZUZBTRC-UHFFFAOYSA-N 2-phenyl-1,3-benzoxazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2O1 FIISKTXZUZBTRC-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- GQTFHSAAODFMHB-UHFFFAOYSA-N 2-prop-2-enoyloxyethanesulfonic acid Chemical compound OS(=O)(=O)CCOC(=O)C=C GQTFHSAAODFMHB-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HMKKFLSUPRUBOO-IUPFWZBJSA-N 3,4-dihydroxy-5-[3,4,5-tris[[(z)-octadec-9-enoyl]oxy]benzoyl]oxybenzoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1=C(OC(=O)CCCCCCC\C=C/CCCCCCCC)C(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(O)=O)O)=C1 HMKKFLSUPRUBOO-IUPFWZBJSA-N 0.000 description 1
- TUATYNXRYJTQTQ-BVRBKCERSA-N 3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-amino-11-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-a Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1 TUATYNXRYJTQTQ-BVRBKCERSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical class C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- IXOCGRPBILEGOX-UHFFFAOYSA-N 3-[3-(dodecanoylamino)propyl-dimethylazaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O IXOCGRPBILEGOX-UHFFFAOYSA-N 0.000 description 1
- BLNXQXNMBAGIHY-UHFFFAOYSA-N 3-hydroxy-6-phenylbenzene-1,2-disulfonic acid Chemical class OS(=O)(=O)C1=C(S(O)(=O)=O)C(O)=CC=C1C1=CC=CC=C1 BLNXQXNMBAGIHY-UHFFFAOYSA-N 0.000 description 1
- USWINTIHFQKJTR-UHFFFAOYSA-N 3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C(O)=CC2=C1 USWINTIHFQKJTR-UHFFFAOYSA-N 0.000 description 1
- QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 description 1
- NJLKZOZYTRRDBO-UHFFFAOYSA-N 3-iodopropyl n-butylcarbamate Chemical compound CCCCNC(=O)OCCCI NJLKZOZYTRRDBO-UHFFFAOYSA-N 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- FQMIAEWUVYWVNB-UHFFFAOYSA-N 3-prop-2-enoyloxybutyl prop-2-enoate Chemical compound C=CC(=O)OC(C)CCOC(=O)C=C FQMIAEWUVYWVNB-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- XUGISPSHIFXEHZ-UHFFFAOYSA-N 3beta-acetoxy-cholest-5-ene Natural products C1C=C2CC(OC(C)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XUGISPSHIFXEHZ-UHFFFAOYSA-N 0.000 description 1
- IHHWIRIIIZBIDV-UHFFFAOYSA-N 4,5-dihydroxy-3-phenylchromen-2-one Chemical compound OC=1C=2C(O)=CC=CC=2OC(=O)C=1C1=CC=CC=C1 IHHWIRIIIZBIDV-UHFFFAOYSA-N 0.000 description 1
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- LNYTUARMNSFFBE-UHFFFAOYSA-N 4-(diethylazaniumyl)benzoate Chemical compound CCN(CC)C1=CC=C(C(O)=O)C=C1 LNYTUARMNSFFBE-UHFFFAOYSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 1
- MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical class C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 1
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- PWWCDTYUYPOAIU-DHZHZOJOSA-N 4-hydroxychalcone Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=CC=C1 PWWCDTYUYPOAIU-DHZHZOJOSA-N 0.000 description 1
- OWBBAPRUYLEWRR-UHFFFAOYSA-N 4-hydroxycoumarin Chemical compound C1=CC=C2OC(O)=CC(=O)C2=C1 OWBBAPRUYLEWRR-UHFFFAOYSA-N 0.000 description 1
- FRRYMYQANNFABF-UHFFFAOYSA-N 4-oxo-6-propan-2-ylchromene-3-carbaldehyde Chemical compound O1C=C(C=O)C(=O)C2=CC(C(C)C)=CC=C21 FRRYMYQANNFABF-UHFFFAOYSA-N 0.000 description 1
- FSMYWBQIMDSGQP-UHFFFAOYSA-N 4-oxochromene-3-carbaldehyde Chemical compound C1=CC=C2C(=O)C(C=O)=COC2=C1 FSMYWBQIMDSGQP-UHFFFAOYSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- DANYIYRPLHHOCZ-UHFFFAOYSA-N 5,7-dihydroxy-4'-methoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 DANYIYRPLHHOCZ-UHFFFAOYSA-N 0.000 description 1
- KVOJTUXGYQVLAJ-UHFFFAOYSA-N 6,7-dihydroxy-4-methylcoumarin Chemical compound C1=C(O)C(O)=CC2=C1OC(=O)C=C2C KVOJTUXGYQVLAJ-UHFFFAOYSA-N 0.000 description 1
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
- IRUHWRSITUYICV-UHFFFAOYSA-N 6-hydroxy-4-methylchromen-2-one Chemical compound C1=CC(O)=CC2=C1OC(=O)C=C2C IRUHWRSITUYICV-UHFFFAOYSA-N 0.000 description 1
- HRRVLSKRYVIEPR-UHFFFAOYSA-N 6-hydroxy-5-nitroso-1H-pyrimidine-2,4-dione Chemical compound OC1=NC(O)=C(N=O)C(O)=N1 HRRVLSKRYVIEPR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 description 1
- ATEFPOUAMCWAQS-UHFFFAOYSA-N 7,8-dihydroxycoumarin Chemical compound C1=CC(=O)OC2=C(O)C(O)=CC=C21 ATEFPOUAMCWAQS-UHFFFAOYSA-N 0.000 description 1
- CFNMUZCFSDMZPQ-GHXNOFRVSA-N 7-[(z)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]chromen-2-one Chemical compound C=1C=C2C=CC(=O)OC2=CC=1OC/C=C(/C)CC1OC(=O)C(C)=C1 CFNMUZCFSDMZPQ-GHXNOFRVSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- HCKFPALGXKOOBK-NRYMJLQJSA-N 7332-27-6 Chemical compound C1([C@]2(O[C@]3([C@@]4(C)C[C@H](O)[C@]5(F)[C@@]6(C)C=CC(=O)C=C6CC[C@H]5[C@@H]4C[C@H]3O2)C(=O)CO)C)=CC=CC=C1 HCKFPALGXKOOBK-NRYMJLQJSA-N 0.000 description 1
- PCFGFYKGPMQDBX-FEKONODYSA-N 78355-50-7 Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 PCFGFYKGPMQDBX-FEKONODYSA-N 0.000 description 1
- 150000004325 8-hydroxyquinolines Chemical class 0.000 description 1
- KGKQNDQDVZQTAG-UHFFFAOYSA-N 8-methylnonyl 2,2-dimethylpropanoate Chemical compound CC(C)CCCCCCCOC(=O)C(C)(C)C KGKQNDQDVZQTAG-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000124001 Alcyonacea Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- MEGPDNMTLZGDEI-UHFFFAOYSA-N C(C)(=O)O.O1C=CC=C1.C(C)C1CC=CC=C1 Chemical compound C(C)(=O)O.O1C=CC=C1.C(C)C1CC=CC=C1 MEGPDNMTLZGDEI-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- ZMVWAGRWCPMCMY-UHFFFAOYSA-N C=CC(=O)OCCOP(=O)=O Chemical compound C=CC(=O)OCCOP(=O)=O ZMVWAGRWCPMCMY-UHFFFAOYSA-N 0.000 description 1
- ONJPCDHZCFGTSI-NJYHNNHUSA-N CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC(C)C)[C@H]1OC[C@H](O)[C@H]1O Chemical group CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC(C)C)[C@H]1OC[C@H](O)[C@H]1O ONJPCDHZCFGTSI-NJYHNNHUSA-N 0.000 description 1
- ACIWFNLWOKCXLD-ZHACJKMWSA-N CCCCCC(CC)(CC)C(\C(O)=O)=C\C(O)=O Chemical compound CCCCCC(CC)(CC)C(\C(O)=O)=C\C(O)=O ACIWFNLWOKCXLD-ZHACJKMWSA-N 0.000 description 1
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 1
- ONAIRGOTKJCYEY-XXDXYRHBSA-N CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 Chemical class CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ONAIRGOTKJCYEY-XXDXYRHBSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 229940122644 Chymotrypsin inhibitor Drugs 0.000 description 1
- 101710137926 Chymotrypsin inhibitor Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 235000010205 Cola acuminata Nutrition 0.000 description 1
- 235000015438 Cola nitida Nutrition 0.000 description 1
- 241000159174 Commiphora Species 0.000 description 1
- 240000003890 Commiphora wightii Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001174 Diethylhydroxylamine Polymers 0.000 description 1
- 241000497464 Dilar Species 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 239000004716 Ethylene/acrylic acid copolymer Substances 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- IUKIDFVOUHZRAK-QWRGUYRKSA-N Gly-Lys-His Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IUKIDFVOUHZRAK-QWRGUYRKSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical compound C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 description 1
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- DLVOSEUFIRPIRM-KAQKJVHQSA-N Hydrocortisone cypionate Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCC1CCCC1 DLVOSEUFIRPIRM-KAQKJVHQSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 240000007171 Imperata cylindrica Species 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- ROAIXOJGRFKICW-UHFFFAOYSA-N Methenamine hippurate Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CNC(=O)C1=CC=CC=C1 ROAIXOJGRFKICW-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000865461 Mitracarpus Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- GWDZTYHUUCKCAK-HWDFJVPCSA-N N[C@@H](CCCCN)C(=O)O.N1[C@@H](CCC1)C(=O)O.N[C@@H](CCC(N)=O)C(=O)O.C(CCCCCCCCCCCCCCC)NCC(=O)O Chemical compound N[C@@H](CCCCN)C(=O)O.N1[C@@H](CCC1)C(=O)O.N[C@@H](CCC(N)=O)C(=O)O.C(CCCCCCCCCCCCCCC)NCC(=O)O GWDZTYHUUCKCAK-HWDFJVPCSA-N 0.000 description 1
- RHUARSYGAJSCHM-HKWFEGLRSA-N N[C@@H](CCCNC(N)=N)C(=O)O.C(CCCCCCCCCCCCCCC)N1[C@@H](CCC1)C(=O)O Chemical compound N[C@@H](CCCNC(N)=N)C(=O)O.C(CCCCCCCCCCCCCCC)N1[C@@H](CCC1)C(=O)O RHUARSYGAJSCHM-HKWFEGLRSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930182473 O-glycoside Natural products 0.000 description 1
- 150000008444 O-glycosides Chemical class 0.000 description 1
- PHWQMRYVXCIETH-UHFFFAOYSA-N O1C(=CC(=O)C2=CC=CC=C12)C1=CC=CC=C1.OC1=C(C2=CC=CC=C2C=C1)O Chemical compound O1C(=CC(=O)C2=CC=CC=C12)C1=CC=CC=C1.OC1=C(C2=CC=CC=C2C=C1)O PHWQMRYVXCIETH-UHFFFAOYSA-N 0.000 description 1
- NICZGOYWNQLONP-FNHCRJELSA-N OC1CC[C@H](N1)C(=O)O.OC1CC[C@H](N1)C(=O)O Chemical compound OC1CC[C@H](N1)C(=O)O.OC1CC[C@H](N1)C(=O)O NICZGOYWNQLONP-FNHCRJELSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000019944 Olestra Nutrition 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- PAHWROPPWOVREG-UHFFFAOYSA-N P(=O)(O)(O)O.C(CCCCCCCCCCCCCCC)[K] Chemical compound P(=O)(O)(O)O.C(CCCCCCCCCCCCCCC)[K] PAHWROPPWOVREG-UHFFFAOYSA-N 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 235000016787 Piper methysticum Nutrition 0.000 description 1
- 240000005546 Piper methysticum Species 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- 102100026531 Prelamin-A/C Human genes 0.000 description 1
- 241001208007 Procas Species 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical class C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 1
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241001103643 Rubia Species 0.000 description 1
- 240000009235 Rubia cordifolia Species 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 241001077909 Sigesbeckia Species 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- JMSRDKIFVZVAMX-UHFFFAOYSA-N UNPD65971 Natural products OC1CC2C3CC=C4CC(O)CCC4(C)C3CCC2(C)C1C(C)C1=NCC(C)CC1 JMSRDKIFVZVAMX-UHFFFAOYSA-N 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Natural products O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- AQKOHYMKBUOXEB-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-(16-methylheptadecanoyloxy)oxolan-2-yl]-2-(16-methylheptadecanoyloxy)ethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC(C)C)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCC(C)C AQKOHYMKBUOXEB-RYNSOKOISA-N 0.000 description 1
- TTZKGYULRVDFJJ-GIVMLJSASA-N [(2r)-2-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-[(z)-octadec-9-enoyl]oxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1O TTZKGYULRVDFJJ-GIVMLJSASA-N 0.000 description 1
- HLLPKVARTYKIJB-MCQPFKOBSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O1 HLLPKVARTYKIJB-MCQPFKOBSA-N 0.000 description 1
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 1
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
- XMEDXTRRSJHOLZ-KRWDZBQOSA-N [(6as)-9-acetyloxy-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-2-yl] acetate Chemical compound CN1CCC2=CC(OC(C)=O)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC(C)=O)=C1 XMEDXTRRSJHOLZ-KRWDZBQOSA-N 0.000 description 1
- SCMSRHIBVBIECI-UHFFFAOYSA-N [2-hydroxy-4-(2-hydroxyethoxy)phenyl]-phenylmethanone Chemical compound OC1=CC(OCCO)=CC=C1C(=O)C1=CC=CC=C1 SCMSRHIBVBIECI-UHFFFAOYSA-N 0.000 description 1
- YLVWGZFPAPRBTR-UHFFFAOYSA-N [Br-].C(CCCCCCCCCCCCCCCCC)(=O)[NH3+] Chemical compound [Br-].C(CCCCCCCCCCCCCCCCC)(=O)[NH3+] YLVWGZFPAPRBTR-UHFFFAOYSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- CBWUNQZJGJFJLZ-UHFFFAOYSA-N [Cl].Cl Chemical compound [Cl].Cl CBWUNQZJGJFJLZ-UHFFFAOYSA-N 0.000 description 1
- HXELGNKCCDGMMN-UHFFFAOYSA-N [F].[Cl] Chemical compound [F].[Cl] HXELGNKCCDGMMN-UHFFFAOYSA-N 0.000 description 1
- SZQVPFAWVOAHPI-UHFFFAOYSA-N [O-]P([O-])([O-])=O.CCC[NH2+]CCC.CCC[NH2+]CCC.CCC[NH2+]CCC Chemical compound [O-]P([O-])([O-])=O.CCC[NH2+]CCC.CCC[NH2+]CCC.CCC[NH2+]CCC SZQVPFAWVOAHPI-UHFFFAOYSA-N 0.000 description 1
- CSDGRCWFCBMJOM-UHFFFAOYSA-N [Zn].SC1=NC=CC=C1.[O] Chemical compound [Zn].SC1=NC=CC=C1.[O] CSDGRCWFCBMJOM-UHFFFAOYSA-N 0.000 description 1
- NBVZMBLJRHUOJR-UHFFFAOYSA-N [amino-[4-[6-[4-[amino(azaniumylidene)methyl]phenoxy]hexoxy]phenyl]methylidene]azanium;2-hydroxyethanesulfonate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 NBVZMBLJRHUOJR-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- JYOXZYGMNJFYKV-UHFFFAOYSA-N acetic acid propanoic acid Chemical compound CC(O)=O.CC(O)=O.CCC(O)=O.CCC(O)=O JYOXZYGMNJFYKV-UHFFFAOYSA-N 0.000 description 1
- 229940014843 acetyl dipeptide-1 cetyl ester Drugs 0.000 description 1
- 108010074988 acetyltyrosyl-arginine cetyl ester Proteins 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229960004663 alminoprofen Drugs 0.000 description 1
- FPHLBGOJWPEVME-UHFFFAOYSA-N alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229950003408 amcinafide Drugs 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960001656 amikacin sulfate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940064734 aminobenzoate Drugs 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 229940098323 ammonium cocoyl isethionate Drugs 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000012874 anionic emulsifier Substances 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- MDUBPQGQPBQGGN-UHFFFAOYSA-N azanium;2-methylpropanoate Chemical compound [NH4+].CC(C)C([O-])=O MDUBPQGQPBQGGN-UHFFFAOYSA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 238000005284 basis set Methods 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 1
- 229960004277 benorilate Drugs 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 229940047187 benzoresorcinol Drugs 0.000 description 1
- VXIXUWQIVKSKSA-UHFFFAOYSA-N benzotetronic acid Natural products C1=CC=CC2=C1OC(=O)C=C2O VXIXUWQIVKSKSA-UHFFFAOYSA-N 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- GCTPMLUUWLLESL-UHFFFAOYSA-N benzyl prop-2-enoate Chemical compound C=CC(=O)OCC1=CC=CC=C1 GCTPMLUUWLLESL-UHFFFAOYSA-N 0.000 description 1
- 229910001423 beryllium ion Inorganic materials 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- WXNRYSGJLQFHBR-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O WXNRYSGJLQFHBR-UHFFFAOYSA-N 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 229960002968 capreomycin sulfate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229940073639 ceteareth-6 Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
- XUGISPSHIFXEHZ-VEVYEIKRSA-N cholesteryl acetate Chemical compound C1C=C2C[C@@H](OC(C)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XUGISPSHIFXEHZ-VEVYEIKRSA-N 0.000 description 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
- 210000003764 chromatophore Anatomy 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- FCSHDIVRCWTZOX-DVTGEIKXSA-N clobetasol Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O FCSHDIVRCWTZOX-DVTGEIKXSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- FZCHYNWYXKICIO-FZNHGJLXSA-N cortisol 17-valerate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O FZCHYNWYXKICIO-FZNHGJLXSA-N 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- YBGKGTOOPNQOKH-UHFFFAOYSA-N daphnetin Natural products OC1=CC=CC2=C1OC(=O)C=C2O YBGKGTOOPNQOKH-UHFFFAOYSA-N 0.000 description 1
- HOIXTKAYCMNVMY-PVOAASPHSA-N daphnin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=CC(=O)O2)C2=C1O HOIXTKAYCMNVMY-PVOAASPHSA-N 0.000 description 1
- HOIXTKAYCMNVMY-UHFFFAOYSA-N daphnin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=CC(=O)O2)C2=C1O HOIXTKAYCMNVMY-UHFFFAOYSA-N 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001912 dicoumarol Drugs 0.000 description 1
- PFCBRXGBIQWFED-UHFFFAOYSA-N didodecyl(methyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCC[NH+](C)CCCCCCCCCCCC PFCBRXGBIQWFED-UHFFFAOYSA-N 0.000 description 1
- SWWQNNDPJXYCNJ-UHFFFAOYSA-N didodecylazanium;chloride Chemical compound Cl.CCCCCCCCCCCCNCCCCCCCCCCCC SWWQNNDPJXYCNJ-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- 229960004091 diflucortolone Drugs 0.000 description 1
- OGPWIDANBSLJPC-RFPWEZLHSA-N diflucortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O OGPWIDANBSLJPC-RFPWEZLHSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- RNMIVNUNMNQFRD-UHFFFAOYSA-N dihexadecylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[NH2+]CCCCCCCCCCCCCCCC RNMIVNUNMNQFRD-UHFFFAOYSA-N 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- HRKQOINLCJTGBK-UHFFFAOYSA-N dihydroxidosulfur Chemical compound OSO HRKQOINLCJTGBK-UHFFFAOYSA-N 0.000 description 1
- SIUKXCMDYPYCLH-UHFFFAOYSA-N dihydroxycinnamic acid Natural products OC(=O)C=CC1=CC=CC(O)=C1O SIUKXCMDYPYCLH-UHFFFAOYSA-N 0.000 description 1
- BZCOSCNPHJNQBP-OWOJBTEDSA-N dihydroxyfumaric acid Chemical compound OC(=O)C(\O)=C(/O)C(O)=O BZCOSCNPHJNQBP-OWOJBTEDSA-N 0.000 description 1
- VNSCGZILQCUFEA-UHFFFAOYSA-N dimethyl sulfate;n-methylmethanamine Chemical compound CNC.COS(=O)(=O)OC VNSCGZILQCUFEA-UHFFFAOYSA-N 0.000 description 1
- FNQKDNSLNBDGJV-UHFFFAOYSA-N dimethyl(octadecanoyl)azanium bromide Chemical compound [Br-].C(CCCCCCCCCCCCCCCCC)(=O)[NH+](C)C FNQKDNSLNBDGJV-UHFFFAOYSA-N 0.000 description 1
- CKYSZONHDJIUOC-UHFFFAOYSA-N dimethyl(octadecanoyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC(=O)[NH+](C)C CKYSZONHDJIUOC-UHFFFAOYSA-N 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- KGOGNDXXUVELIQ-UHFFFAOYSA-N dioctadecylazanium;chloride Chemical compound Cl.CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC KGOGNDXXUVELIQ-UHFFFAOYSA-N 0.000 description 1
- 229960004960 dioxybenzone Drugs 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940105576 disalcid Drugs 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- DLFDEDJIVYYWTB-UHFFFAOYSA-N dodecyl(dimethyl)azanium;bromide Chemical compound Br.CCCCCCCCCCCCN(C)C DLFDEDJIVYYWTB-UHFFFAOYSA-N 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- 229960000385 dyclonine Drugs 0.000 description 1
- HEAHZSUCFKFERC-UHFFFAOYSA-N ecamsule Chemical compound CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2=CC(C=C1)=CC=C1C=C1C(=O)C2(CS(O)(=O)=O)CCC1C2(C)C HEAHZSUCFKFERC-UHFFFAOYSA-N 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229960000655 ensulizole Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- TYQXKHPOXXXCTP-CSLYCKPJSA-N erythromycin A 2'-propanoate Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 TYQXKHPOXXXCTP-CSLYCKPJSA-N 0.000 description 1
- 229950001028 erythromycin propionate Drugs 0.000 description 1
- 229960004142 erythromycin stearate Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 229960001618 ethambutol hydrochloride Drugs 0.000 description 1
- TVFJAZCVMOXQRK-UHFFFAOYSA-N ethenyl 7,7-dimethyloctanoate Chemical compound CC(C)(C)CCCCCC(=O)OC=C TVFJAZCVMOXQRK-UHFFFAOYSA-N 0.000 description 1
- IAJNXBNRYMEYAZ-UHFFFAOYSA-N ethyl 2-cyano-3,3-diphenylprop-2-enoate Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC)C1=CC=CC=C1 IAJNXBNRYMEYAZ-UHFFFAOYSA-N 0.000 description 1
- ZANNOFHADGWOLI-UHFFFAOYSA-N ethyl 2-hydroxyacetate Chemical compound CCOC(=O)CO ZANNOFHADGWOLI-UHFFFAOYSA-N 0.000 description 1
- CBZHHQOZZQEZNJ-UHFFFAOYSA-N ethyl 4-[bis(2-hydroxypropyl)amino]benzoate Chemical compound CCOC(=O)C1=CC=C(N(CC(C)O)CC(C)O)C=C1 CBZHHQOZZQEZNJ-UHFFFAOYSA-N 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 229950006236 fenclofenac Drugs 0.000 description 1
- IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
- HAWWPSYXSLJRBO-UHFFFAOYSA-N fendosal Chemical compound C1=C(O)C(C(=O)O)=CC(N2C(=CC=3C4=CC=CC=C4CCC=32)C=2C=CC=CC=2)=C1 HAWWPSYXSLJRBO-UHFFFAOYSA-N 0.000 description 1
- 229950005416 fendosal Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 229960000489 feprazone Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229960001440 fluclorolone Drugs 0.000 description 1
- VTWKPILBIUBMDS-OTJLYDAYSA-N fluclorolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(Cl)[C@@H](Cl)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 VTWKPILBIUBMDS-OTJLYDAYSA-N 0.000 description 1
- NJNWEGFJCGYWQT-VSXGLTOVSA-N fluclorolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1Cl NJNWEGFJCGYWQT-VSXGLTOVSA-N 0.000 description 1
- 229940094766 flucloronide Drugs 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 1
- 229960003973 fluocortolone Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229940060037 fluorine Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960003590 fluperolone Drugs 0.000 description 1
- HHPZZKDXAFJLOH-QZIXMDIESA-N fluperolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](OC(C)=O)C)(O)[C@@]1(C)C[C@@H]2O HHPZZKDXAFJLOH-QZIXMDIESA-N 0.000 description 1
- 229960000618 fluprednisolone Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- CATSNJVOTSVZJV-UHFFFAOYSA-N heptan-2-one Chemical compound CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- LIIALPBMIOVAHH-UHFFFAOYSA-N herniarin Chemical compound C1=CC(=O)OC2=CC(OC)=CC=C21 LIIALPBMIOVAHH-UHFFFAOYSA-N 0.000 description 1
- JHGVLAHJJNKSAW-UHFFFAOYSA-N herniarin Natural products C1CC(=O)OC2=CC(OC)=CC=C21 JHGVLAHJJNKSAW-UHFFFAOYSA-N 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- XQSBLCWFZRTIEO-UHFFFAOYSA-N hexadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[NH3+] XQSBLCWFZRTIEO-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- SELIRUAKCBWGGE-UHFFFAOYSA-N hexadecanoic acid;octadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O SELIRUAKCBWGGE-UHFFFAOYSA-N 0.000 description 1
- JFHZXDZUXGBFAQ-KYJUHHDHSA-N hexadecyl (2s)-2-[[(2s)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(C)=O)CC1=CC=C(O)C=C1 JFHZXDZUXGBFAQ-KYJUHHDHSA-N 0.000 description 1
- URXQDXAVUYKSCK-UHFFFAOYSA-N hexadecyl(dimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[NH+](C)C URXQDXAVUYKSCK-UHFFFAOYSA-N 0.000 description 1
- UXNFIJPHRQEWRQ-UHFFFAOYSA-N hexamethylenetetramine mandelate salt Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)C(O)C1=CC=CC=C1 UXNFIJPHRQEWRQ-UHFFFAOYSA-N 0.000 description 1
- 229960001715 hexamidine isethionate Drugs 0.000 description 1
- TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical compound CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960005388 hexylcaine Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 229960003331 hydrocortisone cypionate Drugs 0.000 description 1
- 229960000631 hydrocortisone valerate Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229940054190 hydroxypropyl chitosan Drugs 0.000 description 1
- 229920013818 hydroxypropyl guar gum Polymers 0.000 description 1
- CFUQBFQTFMOZBK-QUCCMNQESA-N ibazocine Chemical compound C12=CC(O)=CC=C2C[C@H]2N(CC=C(C)C)CC[C@]1(C)C2(C)C CFUQBFQTFMOZBK-QUCCMNQESA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- JGIDSJGZGFYYNX-YUAHOQAQSA-N indian yellow Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=CC=C(OC=2C(=C(O)C=CC=2)C2=O)C2=C1 JGIDSJGZGFYYNX-YUAHOQAQSA-N 0.000 description 1
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940113096 isoceteth 20 Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
- 229950011455 isoxepac Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 229940063199 kenalog Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 229940057905 laureth-3 Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 125000005644 linolenyl group Chemical group 0.000 description 1
- 125000005645 linoleyl group Chemical group 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229940106885 marcaine Drugs 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 230000037306 mature skin Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001011 medrysone Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 229940051860 methacycline hydrochloride Drugs 0.000 description 1
- 229960004011 methenamine Drugs 0.000 description 1
- 229960003900 methenamine hippurate Drugs 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- QUGJCUCHMFJZMD-UHFFFAOYSA-N methyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[NH+](C)CCCCCCCCCCCCCCCCCC QUGJCUCHMFJZMD-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- ZLQJVGSVJRBUNL-UHFFFAOYSA-N methylumbelliferone Natural products C1=C(O)C=C2OC(=O)C(C)=CC2=C1 ZLQJVGSVJRBUNL-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical compound Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 1
- 229960002395 metronidazole hydrochloride Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- 229950006616 miroprofen Drugs 0.000 description 1
- OJGQFYYLKNCIJD-UHFFFAOYSA-N miroprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CN(C=CC=C2)C2=N1 OJGQFYYLKNCIJD-UHFFFAOYSA-N 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- VHDPPDRSCMVFAV-UHFFFAOYSA-N n,n-dimethylhexadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[NH+](C)C VHDPPDRSCMVFAV-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- UNAFTICPPXVTTN-UHFFFAOYSA-N n-dodecyldodecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCC[NH2+]CCCCCCCCCCCC UNAFTICPPXVTTN-UHFFFAOYSA-N 0.000 description 1
- FIUPANZFULRRRQ-UHFFFAOYSA-N n-hexadecyl-n-methylhexadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[NH+](C)CCCCCCCCCCCCCCCC FIUPANZFULRRRQ-UHFFFAOYSA-N 0.000 description 1
- ALQWDAJTEFASRJ-UHFFFAOYSA-N n-hexadecylhexadecan-1-amine;hydrochloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[NH2+]CCCCCCCCCCCCCCCC ALQWDAJTEFASRJ-UHFFFAOYSA-N 0.000 description 1
- FFJMLWSZNCJCSZ-UHFFFAOYSA-N n-methylmethanamine;hydrobromide Chemical compound Br.CNC FFJMLWSZNCJCSZ-UHFFFAOYSA-N 0.000 description 1
- KTAFYYQZWVSKCK-UHFFFAOYSA-N n-methylmethanamine;nitric acid Chemical compound CNC.O[N+]([O-])=O KTAFYYQZWVSKCK-UHFFFAOYSA-N 0.000 description 1
- ZLDPNFYTUDQDMJ-UHFFFAOYSA-N n-octadecyloctadecan-1-amine;hydrobromide Chemical compound Br.CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC ZLDPNFYTUDQDMJ-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- 229960004832 netilmicin sulfate Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229960004738 nicotinyl alcohol Drugs 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- RNTRDTWDTOZSEV-UHFFFAOYSA-N norphytene Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=C RNTRDTWDTOZSEV-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229950002083 octabenzone Drugs 0.000 description 1
- YBGZDTIWKVFICR-UHFFFAOYSA-N octinoxate Chemical compound CCCCC(CC)COC(=O)C=CC1=CC=C(OC)C=C1 YBGZDTIWKVFICR-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- YAGMLECKUBJRNO-UHFFFAOYSA-N octyl 4-(dimethylamino)benzoate Chemical compound CCCCCCCCOC(=O)C1=CC=C(N(C)C)C=C1 YAGMLECKUBJRNO-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229950005708 oxepinac Drugs 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- YNXCGLKMOXLBOD-UHFFFAOYSA-N oxolan-2-ylmethyl prop-2-enoate Chemical class C=CC(=O)OCC1CCCO1 YNXCGLKMOXLBOD-UHFFFAOYSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 108010027628 palmitoyl-lysyl-threonyl-threonyl-lysyl-serine Proteins 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 229960005065 paromomycin sulfate Drugs 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940096994 peg-10 glyceryl stearate Drugs 0.000 description 1
- 229940072880 peg-10 stearate Drugs 0.000 description 1
- 229940077414 peg-12 stearate Drugs 0.000 description 1
- 229940119517 peg-6 stearate Drugs 0.000 description 1
- 108010069653 peptide E (adrenal medulla) Proteins 0.000 description 1
- 229940072417 peroxidase Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 235000020742 piper methysticum extract Nutrition 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001921 poly-methyl-phenyl-siloxane Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229940100518 polyglyceryl-4 isostearate Drugs 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 150000007519 polyprotic acids Polymers 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- YLSUMFQEBHBMQB-OOFFSTKBSA-M potassium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihydrox Chemical compound [K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O YLSUMFQEBHBMQB-OOFFSTKBSA-M 0.000 description 1
- KPFSGNRRZMYZPH-UHFFFAOYSA-M potassium;2-chloroacetate Chemical group [K+].[O-]C(=O)CCl KPFSGNRRZMYZPH-UHFFFAOYSA-M 0.000 description 1
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- YNZOICUNEVJUEJ-UHFFFAOYSA-N propane-1,2,3-triol Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO YNZOICUNEVJUEJ-UHFFFAOYSA-N 0.000 description 1
- MBHCWRKFAXKMRT-UHFFFAOYSA-N propanoic acid;1-tetradecoxytetradecane Chemical compound CCC(O)=O.CCCCCCCCCCCCCCOCCCCCCCCCCCCCC MBHCWRKFAXKMRT-UHFFFAOYSA-N 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000020746 red clover extract Nutrition 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical group CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- CBXWGGFGZDVPNV-UHFFFAOYSA-N so4-so4 Chemical compound OS(O)(=O)=O.OS(O)(=O)=O CBXWGGFGZDVPNV-UHFFFAOYSA-N 0.000 description 1
- 125000004436 sodium atom Chemical group 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229940079776 sodium cocoyl isethionate Drugs 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940045998 sodium isethionate Drugs 0.000 description 1
- 229940048106 sodium lauroyl isethionate Drugs 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical group [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 description 1
- 229940048109 sodium methyl cocoyl taurate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- IZWPGJFSBABFGL-GMFCBQQYSA-M sodium;2-[methyl-[(z)-octadec-9-enoyl]amino]ethanesulfonate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)N(C)CCS([O-])(=O)=O IZWPGJFSBABFGL-GMFCBQQYSA-M 0.000 description 1
- HYHAWELIVMOSBT-UHFFFAOYSA-M sodium;2-aminopentadecanoate Chemical compound [Na+].CCCCCCCCCCCCCC(N)C([O-])=O HYHAWELIVMOSBT-UHFFFAOYSA-M 0.000 description 1
- NHEFSTXHZRGAIH-UHFFFAOYSA-M sodium;2-bromopropanoate Chemical compound [Na+].CC(Br)C([O-])=O NHEFSTXHZRGAIH-UHFFFAOYSA-M 0.000 description 1
- BRMSVEGRHOZCAM-UHFFFAOYSA-M sodium;2-dodecanoyloxyethanesulfonate Chemical compound [Na+].CCCCCCCCCCCC(=O)OCCS([O-])(=O)=O BRMSVEGRHOZCAM-UHFFFAOYSA-M 0.000 description 1
- LADXKQRVAFSPTR-UHFFFAOYSA-M sodium;2-hydroxyethanesulfonate Chemical compound [Na+].OCCS([O-])(=O)=O LADXKQRVAFSPTR-UHFFFAOYSA-M 0.000 description 1
- LEEHDJJMXGSXDH-UHFFFAOYSA-M sodium;2-octadecanoyloxyethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OCCS([O-])(=O)=O LEEHDJJMXGSXDH-UHFFFAOYSA-M 0.000 description 1
- IWMMSZLFZZPTJY-UHFFFAOYSA-M sodium;3-(dodecylamino)propane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCNCCCS([O-])(=O)=O IWMMSZLFZZPTJY-UHFFFAOYSA-M 0.000 description 1
- XGRLSUFHELJJAB-JGSYTFBMSA-M sodium;[(2r)-2-hydroxy-3-[(z)-octadec-9-enoyl]oxypropyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)([O-])=O XGRLSUFHELJJAB-JGSYTFBMSA-M 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229950003429 sorbitan palmitate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940010735 steareth-12 Drugs 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical class NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- SJMYWORNLPSJQO-UHFFFAOYSA-N tert-butyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(C)(C)C SJMYWORNLPSJQO-UHFFFAOYSA-N 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 229930183279 tetramycin Natural products 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 229950002345 tiopinac Drugs 0.000 description 1
- 229950006150 tioxaprofen Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960004477 tobramycin sulfate Drugs 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229950000919 tribuzone Drugs 0.000 description 1
- OFVFGKQCUDMLLP-UHFFFAOYSA-N tribuzone Chemical compound O=C1C(CCC(=O)C(C)(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 OFVFGKQCUDMLLP-UHFFFAOYSA-N 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- ZLOOSHUZSLIYGX-UHFFFAOYSA-M triethyl(3-prop-2-enoyloxypropyl)azanium;bromide Chemical compound [Br-].CC[N+](CC)(CC)CCCOC(=O)C=C ZLOOSHUZSLIYGX-UHFFFAOYSA-M 0.000 description 1
- 229940078279 trilisate Drugs 0.000 description 1
- AJURYMCOXVKKFB-UHFFFAOYSA-M trimethyl(3-prop-2-enoyloxypropyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCOC(=O)C=C AJURYMCOXVKKFB-UHFFFAOYSA-M 0.000 description 1
- ZXKBZSUZLCNLAQ-UHFFFAOYSA-M trimethyl(octadecanoyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC(=O)[N+](C)(C)C ZXKBZSUZLCNLAQ-UHFFFAOYSA-M 0.000 description 1
- AISMNBXOJRHCIA-UHFFFAOYSA-N trimethylazanium;bromide Chemical class Br.CN(C)C AISMNBXOJRHCIA-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 108010012567 tyrosyl-glycyl-glycyl-phenylalanyl Proteins 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical group 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 150000003739 xylenols Chemical class 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- 229960003414 zomepirac Drugs 0.000 description 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
含有三肽(tripeptides)和四肽(tetrapeptides)的个人护理和化妆药物配方对治疗皱纹、伸张痕和黑斑圈等可见的老化迹象是有用的。
Description
技术领域
本发明涉及化妆品和个人护理品。
背景技术
变老的第一个迹象通常是反映在人体的皮肤上:干燥、细小的线纹和皱纹、老年斑,红斑,皮肤松弛和没有活力。迟钝和掉头发也是众所周知的征象。市场上有许多护肤和护发产品,可供消费者处理或防止这些由外因应力源造成的皮肤状况。这些外因源包括但不限于:大气污染、机械应力、与家居用品或其它化学药品接触、日晒(老化)和晒伤等。此外当然还包括内因应力引起的如粉刺,伙食影响和一般的进行性老化。
皮肤经常暴露于这些外因环境之中,结果便出现可见的皮肤老化和受损的迹象,例如皱纹和干燥、变薄和其它组织学变化。由于皮肤老化,蛋白质合成便减少,蛋白质水解便增加,导致皮肤屏障、连接组织和结合力的全面分裂。
许多化合物据说都能改善皮肤外观和生理学状况,包括减少细线纹、皱纹及或其它与老化或受光损伤有关的征象。世界市场上有许多处方。但人们总是希望处方得到不断的改善。
人们建议用类维生素A,α和β-羟基酸,类黄酮和异黄酮来治疗痤疮和皱纹,加快细胞更新,消除菏尔蒙不平衡现象。这些治疗方法并不是没有问题的,例如不稳定性(类维生素A,类黄酮),骚痒(类维生素A,羟酸)和可能的副作用(植物黄酮类-phytoflavones)。
2000年7月27日公布SEDERMA公司、国际专利申请号为WO00/43,417的专利文献披露了使用某些肽(peptides)和衍生物作为化妆品或药物处方,供调节被削弱的免疫功能和皮肤发炎之用。这些肽和衍生物为2~5个氨基酸长度。据说它们能将IL-6和IL-8的组织浓度减少至接近年轻组织的水平。此种肽包括N-棕榈酰-脯氨酸-精氨酸(N-Palmitoyl-Pro-Arg),N-棕榈酰-苏氨酸-赖氨酸-脯氨酸-精氨酸N-Palmitoyl-Thr-Lys-Pro-Arg(序列识别号:1),精氨酸-赖氨酸-脯氨酸-精氨酸Arg-Lys-Pro-Arg(序列识别号:2)和N-棕榈酰-甘氨酸-谷氨酰胺-脯氨酸-精氨酸N-Palmitoyl-Gly-Gln-Pro-Arg(序列识别号:3)。根据WO00/43,417,各种肽是可以组合的,但此参考文献中并未特别提及一种四肽和三肽的组合。见美国专利US6,620,419和US6,492,326,它们披露了某些含有四肽和其它物质的化妆品和个人护理品。
SEDERMA公司还销售一种治疗眼袋的产品,商标为EYELISS。这种产品成分中就含有一种上述的N-Palmitoyl-Gly-Gln-Pro-Arg(序列识别号:3)与二肽(dipeptide)Val-色氨酸(Val-Trp)的混合物。但这种二肽没有显着的胶原激发作用,与单独使用四肽时相比,此组合在这种特性上并不见有任何改进。亦见Daicel Chem,Ind.Ltd.公司的专利JP07/324097和JP 08/311098,以及“化工文摘(C.A.)”1996年5月6日第19期第124卷(摘要号261765)中Kawamoto Takafumi等的文章。
发明内容
令人惊异地,现已发现,含有某些四肽的配方,特别是链序列为甘氨酸-谷氨酰胺-脯氨酸-精氨酸Gly-Gln-Pro-Arg(序列识别号:3),它的类似物和衍生物(统称为“rigin-四肽”)与一种或多种三肽结合,特别是与链序列为甘氨酸-组氨酸-赖氨酸(Gly-His-Lys)的三肽及类似物和衍生物(统称为“GHK-三肽”)结合时,并任选地与一种或多种其它成份(可包括载体)组合后,可在某些情形下减轻上述一种或多种症状。
亦已发现,如下的四肽在与某些三肽结合使用时更具优势:带1个脂肪族组侧链的至少1个氨基酸,带至少1个有NH2-侧链的至少1个的氨基酸;最好有两个氨基酸,此氨基酸至少有1个含阳离子胺(NH3 +,NH2 +等等-在pH6.0时带正电的基本氨基酸)侧链;以及它们的酰基衍生物(统称为“ALAMCAT-四肽”)。
与上面所说的rigin基四肽不同,这些ALAMCAT-四肽不一定是以rigin、rigin类似物或rigin衍生物为基。但是,某些rigin基的四肽可能落入这种定义范围,就象某些 ALAMCAT-四肽是落入rigin基肽的定义范围那样。
按照本发明指出的方向,优先使用的三肽包括至少一个组氨酸基His(此处称为“组氨酸-三肽”)。与上述GHK-三肽不同,这些组氨酸基的三肽和它的类似物或衍生物基不一定以甘氨酸-组氨酸-赖氨酸Gly-His-Lys的三肽序列链接它的类似物或衍生物基。但某些以组氨酸为基的三肽则可能落入此定义范围,就象某些GHK-三肽落入组氨酸为基的肽之定义范围那样。这些ALAMCAT-四肽和组氨酸基三肽可以相同的数量、比例使用,可与相同的其它成份混合,而且使用方法相同(减少老化征象等),因为此种混合物含有rigin基的四肽和GHK基的三肽。的确,按照本发明指出的方向,如上所述,将ALAMCAT-四肽与组氨酸基三肽,或将rigin基的四肽与GHK-三肽组合是有可能的;ALAMCAT-四肽与GHK-三肽,rigin基四肽与组氨酸基三肽组合也是可以预期的。因此,尽管本发明将常常引用四肽和它与某些三肽的混合物来描述,如未特别说明,这些描述亦可同样适用于上述所有情形。
特别是,已经发现,四肽(rigin基四肽,ALAMCAT-四肽,或它们的混合物)与三肽(组氨酸基三肽,GHK-三肽或它们的混合物)的某些组合能提供至少此处所述的优点和质量、以及从常规化验所发现的其它优点。这些优点可包括但不限于,在某些情形下和对于某些优先组合,能改善可见的皮肤老化征象,包括细线纹、皱纹、毛孔增大、粗糙、干燥及其它皮肤组织缺陷如牵张痕(怀孕、创伤或其它影响造成),由皮肤变薄、血液循环不足和组织松弛造成的眼袋和眼下的黑斑圈。某些这种处方以确实被发现对组织的再生有好处。按照本发明,四肽和三肽的某些组合能引起某些有利的生物分子的产生,例如但不限于皮肤细胞内的胶原I、纤维结合蛋白、胶原IV和透明质酸。在某些例子中,此结合能刺激活质分字的产生,而单独使用四肽或三肽时则不能有此效果。在其它例子中,这种组合能引起活质分子的生产量比单独加入肽时更大。按照本发明的某些优先方面,产生的确实是增效的组合。
一方面,本发明涉及一种关于(皮肤)表面用药的配方,这些处方含有四肽与三肽混合物,并可任选地与其它皮肤护理活性剂或可能含有皮肤病学上可接受的载体之成分配伍,首选为包含1个复合了组氨酸His-的“ALAMCAT-四肽”混合物和包含1个复 合了GHK-三肽的“rigin-四肽”混合物。本发明推荐N-棕榈酰-甘氨酸-谷氨酰胺-脯氨酸-赖氨酸[N-Palmitoyl-Gly-Gln-Pro-Arg(序列识别号:3)],推荐的三肽是那些基于赖氨酸链序列的甘氨酸-组氨酸-赖氨酸Gly-His-Lys,类似物和它的酰基-衍生物(N-acyl-derivatives)成分正如N-棕榈酰-甘氨酸-组氨酸-赖氨酸(N-Palmitoyl-Gly-His-Arg)。
另一方面,本发明也涉及如何利用上述配方来制造化妆品、个人护理品、表面用制剂或减少皮肤可见的老化迹象的药物。这种药物施用在人体皮肤而达到治疗的需要。
另外,本发明也是关于如何使用本处方来改善人体皮肤情形以及外貌的方法,有效防止和/或减少可见的老化迹象。这些方法通常是按需要将本处方合成物按合适的数量和次数施用在皮肤表面。本发明在防止和延迟衰退或改善皮肤的状况等方面亦作了考虑。
具体实施方式
此处引述的所有刊物已全文收在参考文献内。
本发明的化妆品处方含有四肽,特别是rigin基三肽和/或ALAMCAT-四肽。如非上下文有说明或另有明确说明,这些东西都统称为四肽。本发明的化妆品处方亦含有某些组氨酸基三肽和/或GHK-三肽。如非上下文有说明或另有明确说明,这些东西都统称为三肽。一种或多种外加成分,包括一种或多种皮肤病学上可接受的载体亦宜用在这些处方中。
此处″多种皮肤病学上可接受″这一词表示该处方的成分适于用在皮肤上而没有毒性、不兼容性、不稳定性、过敏反应之类的危险。所用″皮肤老化″,″表面使用″之类的所有名词,其意义是与它们通常广泛使用在开发,试验和推销化妆品和个人护理品时一样。在本发明中,“化妆品处方”或简单地说“处方”一词指的是可用于化妆目的、卫生目的或作为输送一种或多种成分的基础之配方。这些配方也可能同时用于两种或两种以上的这些目的。例如,加药的去头皮洗发剂便具有药物学特性,可用作个人护理品以使头发干净。至少,这些处方含有三肽和四肽、它们的类似物或衍生物以及它们 的混合物。这些处方还可以含有其它成分,如皮肤病学上可接受的载体。
此处所说的″化妆品″包括但不限于唇膏,染眉毛油,口红,粉底,胭脂(blush),眼线膏,唇光膏,面和身体用粉,遮光剂和防晒剂,指甲油,喷发摩丝(mousse),喷剂,发胶(styling gel),指甲调节剂,不论其状态是膏,洗剂,凝胶,油膏,乳状液,胶体,溶液,悬浮液,密实,固体,铅笔状,喷剂配方,刷涂配方和其它类似物质。个人护理品包括但不限于,沐浴胶,洗发水,调节剂,洗乳,染发剂和染色剂,不用洗去的调节剂,遮光剂和防晒霜,唇膏,皮肤调节剂,头发喷剂,肥皂,身体擦剂,落屑剂,收敛剂,脱毛剂和永久性卷曲液,防头皮配方,防汗止汗处方,刮胡、刮前和刮后用品,润湿剂,除气味剂,冷霜,除气味剂,清洁剂,皮肤胶和洗剂,不论他们的形态是固体,粉状,液体,乳状,凝胶,药膏,洗液,乳化液,胶体,悬浮液或其它形式。在本发明中,药物制剂包括但不限于皮肤病学用的、包括皮肤表面用的和透入皮肤用的有效药物成分之载体。这些载体的形式可以是凝胶,贴片,霜,喷鼻剂,药膏,洗液,乳化液,胶体,溶液,悬浮液,粉剂,等等。
在本发明中,″三肽″一词指的是一种化合物,此种化合物的结构中带有一条不中断的3个氨基酸链区。此处用传统的左边以N结尾、右边以C结尾的三字母惯例来表示。在此名词述语表中,Gly是氨基乙酸,His为组氨酸,Lys是赖氨酸,Pro是脯氨酸,Gln是谷氨盐酸,Arg是精氨酸。在本发明中,″四肽″是一种化合物,它的结构中有四条不中断的氨基酸链。
这里所用的氨基酸一词,包括和总刮了所有天然形态的氨基酸,不论是光学上活性的D-或L-构造的、还是称为非天然的合成的和改性的氨基酸,例如高半胱氨酸,鸟氨酸,正亮氨酸和P-A颉氨酸。非天然氨基酸一览表见D.C.Roberts和F.Vellaccio写的四肽,卷5(1983),科学快报,第VI章。
本发明中的肽内的氨基酸可以是它们的天然L-结构,非天然D-结构或是外消旋混合物。
“皮肤老化迹象”包括但不限于所有外部可见的和可感触到的表现,以及因皮肤老化而致的其它微观和宏观结果。这种迹象可因内在因素或其它外部因素造成,例如时间 生物学老化和/或环境损害。这些迹象可因各种过程而致,包括但不限于组织例如皱纹和深而粗的皱纹那样的不连续,皮肤上的线纹,裂缝,肿块,毛孔粗大(例如与附属结构如汗腺管、脂肪腺或毛囊有关的孔)或不均匀或粗糙,失去弹性(功能皮肤弹性蛋白损失或无活性),下垂(包括眼区域和颔的虚胖,皮肤不结实,皮肤不紧,皮肤变形后不反弹,变色(包括眼下的圈),斑点,菜色,皮肤上的深色区例如老斑和雀斑,角质物,不正常的差别,角化过度,弹性组织变性,胶原破坏,以及其它角质层、皮肤,表皮和的皮肤脉管系统(例如毛细管扩张或蜘蛛状脉管),和皮下组织特别是紧邻皮肤的组织之组织性变化。
在本文中,皮肤状况的预防性调节包括延迟,减少和/或防止可见和/或可感触的皮肤不连续(例如可见的或可摸到的皮肤组织不规则)、包括皮肤老化迹象。
在本文中,用疗法来调节皮肤状况包括改善例如减少和/或消除皮肤上的不连续、包括皮肤老化的迹象。采用本发明的配方生产的某些产品,而且确实是这些配方的本身可以预防性的方式或疗法的方式调节皮肤的状况。本发明的某些产品和配方可以改善皮肤外观和/或手感。例如,本发明的优先配方,涂上后可立即改善皮肤的外观。一般地说,本发明的配方,如再加上某些特殊物质的,对改善皮肤外观将特别有用。
本发明的某些配方还有另外的优点,包括稳定性,无显着(消费者不能接受)的皮肤刺激,防发炎作用和美观。
本发明的某些优先配方可改善人皮肤的生理学状况和/或物理外观,尤其是能减少因日晒,荷尔蒙变化,擦伤,营养问题和其它类似原因而致的物理和皮肤老化迹象。这些配方可经常用来防止和/或治疗老化迹象,使使用者显得更年轻。
在详述后所作的结论中特别和明确地指出,通过下面的描述,相信本发明将被人们更好地了解,专利要求中对本发明已针对性地和明确地提出了要求。如上下文未做另外说明,“具有”和“包括”这两个词应理解为并未完全列举。
如未特别说明,本文所用的所有百分比和比率均为占总重量的比值,所有测量均在25℃时进行。
本发明的各处方可包括(未完全列举)主要是本发明的组分以及本处所说的其它 成分。此处所用的″主要包括″可包括外加的成分,但只在这种外加成分并不实质上改变所宣称的配方或方法之基本的或新的特性时才是这样。这种添加剂最好完全不加或仅加微量。但是,可以包括最大约10%重量的、要保持其效用(效用越大、影响越大)便会改变本发明的基本或新特性的物质。
四肽
本发明之化妆品配方至少含有一种安全和有效剂量的四肽。这些配方可以是一种或多种rigin-四肽,一种或多种ALAMCAT四肽或它们的混合物。这些四肽可以是天然的或者是合成的。
在本发明中,Rigin-四肽是基于甘氨酸-谷酰胺-脯氨酸-精氨酸Gly-Gln-Pro-Arg(序列识别号:3)结构(Rigin)并包括其类似物和衍生物。
Rigin是一种优先使用的四肽。本发明提出,有用的四肽Rigin类似物包括一种或多种四肽类似物,其链区有4个氨基酸被重组或重新布置和/或不多于两个氨基酸被取代(e.g.,Ala-Gln-Thr-Arg(序列识别号:4)。更宜用的是,链区内至少有一个氨基酸为脯氨酸-Pro或精氨酸-Arg的四肽,最宜用的是含有脯氨酸-Pro和精氨酸-Arg的四肽、即使它们的顺序和位置会有改变。此氨基酸取代物可来自本处所定义的任何氨基酸。特别宜优先使用的是rigin基的四肽,包括Xaa-Xbb-Arg-Xcc,Xaa-Xbb-Xcc-Pro,Xaa-Xbb-Pro-Arg。其内的Xaa-Xbb-Pro-Xcc,Xaa-Xbb-Xcc-Arg,Xaa,Xbb和Xcc可以相同或不同,可从以下选择,Xaa为Gly或可因此而取代的氨基酸,Xbb是Gln或可因此而取代的氨基酸,Xcc可以是Pro或Arg或可由它取代的氨基酸。最宜使用的取代Gly的氨基酸包括一条含有一个脂肪质的侧链,例如但不限于beta-Ala,Ala,Val,Leu,Pro,Sarcosine(Sar)和Ile。最宜用来取代Gln的氨基酸包括一个氨基酸组,此氨基酸组在中性pH值(pH6-7)时已显着地不带电,例如但不限于Asn,Lys,Orn,5-hydroxyproline,Citrulline和Canavanine。当Arg被取代时,最佳是由一个具有侧链的氨基酸、侧肩内含有在pH约为6时显着地带电荷的一个氮;例如但不限于Pro,Lys,His,Desmosine和Isodesmosine.
根据本发明,衍生物亦认为是属于rigin-四肽(所以包括更多类的四肽)。衍生物 包括这里所说的被取代的和被重新排列的rigin-四肽。这些衍生物包括特别是酰基衍生物,这些衍生物是四肽的其中一个或多个直链或支链、长链或短链、饱和或不饱链或由一个氢氧根,氨基,氨酰基硫酸盐组或硫化物组所取代,或未被取代但具有1~29个碳原子。N-acyl-衍生物包括各种酰基组,这种酰基组可以从以下酸衍生出来:乙酸acetic acid,癸酸capric acid,丹桂酸lauric acid,肉豆蔻酸myristic acid,辛酸octanoic acid,棕榈酸palmitic acid,硬脂酸stearic acid,山萮酸behenic acid,亚油酸linoleic acid,亚麻酸linolenic acid,硫辛酸lipoic acid,油酸oleic acid,异硬脂酸isostearic acid,反油酸elaidoic acid,2-ethylhexaneic酸,椰子油脂肪酸coconut oil fatty acid,牛油脂肪酸tallowfatty acid,硬化牛油脂肪酸hardened tallow fatty acid,棕榈仁油脂肪酸palm kernel oilfatty acid,羊毛脂脂肪酸lanolin fatty acid,等等。
更可取的例子是酰基acyl团包括一个乙酰基acetyl组,一个棕榈酰基palmitoyl组,一个肉豆蔻基myristyl组,一个油基elaidoyl组,一个生物素biotinyl基组和1个辛酰基octanoyl组。这些组是可以被取代的。如被取代,最好由含有氢氧基hydroxyl或硫sulphur的组取代,例如但不限于SO3H,SH or S-S。
ALAMCAT四肽是带有至少一个氨基酸的四肽,此氨基酸带有一个含有侧链的脂肪族组。这些氨基酸包括但不限于氨基乙酸Gly,2-氨基果糖酸beta-Ala,氨基果糖酸Ala,α-氨基异戊酸Val,异己氨酸Leu,肌氨酸Sar和异亮氨酸Ile。这些四肽也包括至少一个氨基酸,此氨基酸带有至少一个含NH2-的侧链。这些氨基酸带有一个侧链,此侧链带有一个胺组,在中性pH值(pH6~7)时此胺组是大体上不带电的,例如但不限于谷酰胺Gln,天冬酰胺Asn,赖氨酸Lys,Orn,5-羟基脯氨酸5-hydroxyproline,瓜氨酸Citrulline,刀豆氨酸Canavanine。这些ALAMCAT四肽也带有至少一个氨基酸,此氨基酸至少含有一个侧链、侧链至少含有一个阳离子胺(主要种类是带电的,如NH3 +,NH2 + 等-基本氨基酸,在pH约为6时带正电)。这些氨基酸包括但不限于脯氨酸Pro,精氨酸Arg,赖氨酸Lys,组氨酸His,锁链赖氨素Desmosine和异锁链赖氨素Isodesmosine。其余的氨基酸可以是任何氨基酸,但最好是含有一个alphatic组、下挂pendant氨基组或下挂氧离子组的氨基酸。
按照本发明,衍生物也被认为属于ALAMCAT四肽(因而有更广义地是属名上的四肽)。这些衍生物包括特别是酰基衍生物acyl-derivatives,即由一个或多个直链或支链、已取代或未取代的长链或短链、饱和或不饱和的、含有1~29个碳原子的酰基组所取代的四肽。可以使用的这种酰基组与rigin-四肽中的acyl组相同。优先的实现方案包括N-酰基酸-氨基乙酸-谷酰胺-脯氨酸-精氨酸肽N-acyl-Gly-Gln-Pro-Arg(序列识别号:3),最优先使用的是N-棕榈酰-氨基乙酸-谷酰胺-脯氨酸-精氨酸N-palmitoyl-Gly-Gln-Pro-Arg(序列识别号:3)。
优先使用的、市场上可买到的四肽包括RIGIN,EYELISS and MATRIXYLRELOADED,MATRIXYL 3000,它们含有50~500ppm的棕榈酰-氨基乙酸-谷酰胺-脯氨酸-精氨酸(序列识别号:3),以及其它成分例如可从法国SEDERMA买到的肽,查尔酮chalcones和一种赋形剂。这些物质便可用来生产本发明的配方,只要向它们加入这里所说的其中至少一种肽便可。
本发明中所说的四肽,用量宜为0.1ppm(0.0001%w/w,此处称为″百分重量″或″重量%″,或简称为重量)至约5000ppm(0.5%w/w),较好是约0.5ppm至约500ppm(0.05%w/w),最好是约1ppm至约100ppm,按配方重量计算。
三肽
本发明的化妆品配方最好含有一种安全而有效数量的三肽。此处所用的三肽包括一个或多个组氨酸-三肽,一个或多个GHK-三肽和/或它们的混合物。这些物质当然是与这里所说的四肽混合。这种三肽可以是天然的或合成的。
按照本发明的一个方面,宜选用的三肽是基于甘氨酸-组氨酸-赖氨酸(Gly-His-Lys)结构,其类似物和衍生物的,它们统称为GHK-三肽。按本发明的这一方面,宜选用的三肽确实具有此种氨基酸链式。按照本发明,宜选用的三肽包括这样的类似物,即其内的3个氨基酸中有一个或更多个在链区中被重组或重新排列(例如Gly-Lys-His),和/或不多于两个氨基酸被取代(例如Hid-Ala-Orn)。但是,最好是取代氨基乙酸的氨基酸带有一个脂肪族侧链,例如但不限于2-氨基果糖酸beta-Ala,氨基果糖酸Ala,α-氨基异戊酸Val,异己氨酸Leu,脯氨酸Pro,肌氨酸Sar和异亮氨酸Ile。最宜用的是氨基果糖酸Ala, 异己氨酸Leu和异亮氨酸Ile。最适宜用来取代赖氨酸Lys或组氨酸His的氨基酸包括,有一个侧链、侧链上主要有1个在pH值约为6时带电的氮的氨基酸。例如但不限于脯氨酸Pro,赖氨酸Lys,精氨酸Arg,组氨酸His,锁链赖氨素Desmosine和异锁链赖氨素Isodesmosine,。赖氨酸最好由Orn,Arg或瓜氨酸Citrulline取代。
衍生物亦被认为是包括在三肽内(所以亦属广义上的三肽)。按本发明,GHK-三肽的衍生物包括这里所说的被取代和被重新排列的三肽之衍生物。这些衍生物包括特别是:酰基衍生物acyl-derivatives,即由饱和或不饱和一条或多条直链或支链,长或短链所取代的三肽,而这些链则由一个氢氧根hydroxy,氨基amino,氨酰基acyl amino,硫酸盐sulfate或硫化物sulfide组所取代或未被取代。这些三肽可从醋酸acetic acid,癸酸capric acid,丹桂酸lauric acid,肉豆蔻酸myristic acid,辛酸octanoic acid,棕榈酸palmiticacid,硬脂酸stearic acid,山萮酸behenic acid,亚油酸linoleic acid,亚麻酸linolenic acid,硫辛酸lipoic acid,油酸oleic acid,异硬脂酸isostearic acid,反油酸elaidoic acid,2-ethylhexaneic酸,椰子油脂肪酸coconut oil fatty acid,牛油脂肪酸tallow fatty acid,硬化牛油脂肪酸hardened tallow fatty acid,棕榈仁油脂肪酸palm kernel oil fatty acid,羊毛脂脂肪酸lanolin fatty acid等衍生出来。宜用的酰基组的例子包括一个乙酰基acetyl组,一个棕榈酰基palmitoyl组,一个油酸基elaidoyl组,一个肉豆蔻基myristyl组,一个生物素基biotinyl组和一个辛酸基octanoyl组。这些物质可以是被取代了的或未被取代的。如要被取代,最好是由含有氢氧基hydroxyl或硫sulphur的组所取代,例如但不限于SO3H,SH或S-S。
在本发明中,组氨酸His-三肽包括至少一个组氨酸。在链式中的其它两个氨基酸可以相同或不同。因而可以预期但无限制,它们是His-Xaa-Xaa,His-Xaa-Xbb,His-Xbb-Xaa,Xbb-His-Xbb,Xbb-His-Xaa,Xaa-His-Xbb,Xaa-Xaa-His,Xaa-Xbb-His,Xbb-Xaa-His andXbb-Xbb-His,此处Xaa和Xbb是两个不同的氨基酸,虽然其中一个可以是组氨酸His。较好是至少一个其它氨基酸为氨基乙酸Gly,2-氨基果糖酸beta-Ala,氨基果糖酸Ala,α-氨基异戊酸Val,异己氨酸Leu,脯氨酸Pro,肌氨酸Sarcosine(Sar)或异亮氨酸Ile。较好是至少一个其它氨基酸为脯氨酸Pro,赖氨酸Lys,精氨酸Arg,组氨酸His,锁链赖氨 素Desmosine和异锁链赖氨素Isodesmosine。最好的是,赖氨酸由Orn,Arg或Citrulline替代。
在本发明中,衍生物也被认为是属于组氨酸-基三肽(因而也是从属更广义的三肽)。这些衍生物包括,特别是acyl-衍生物,此衍生物是三肽,已由一个或多个有直链或支链、长或短链、饱和或不饱和的、已被取代或未被取代的、具有1~29个碳原子的acyl组所取代。可以使用的acyl组和GHK-三肽所用的相同。
在本发明中,特别优先的实现方案三肽包括N-酰基酸-甘氨酸-组氨酸-赖氨酸(N-Acyl-Gly-His-Lys)和最好是N-棕榈酰-氨基乙酸-组氨酸-赖氨酸(N-Palmitoyl-Gly-His-Lys)。市场上可买到的、优先使用的含三肽和三肽衍生物的配方包括SEDERMA公司的Biopeptide-CL,SEDERMA公司的 和SEDERMA公司的 。
本发明中的三肽的用量宜由至少0.10ppm至约10,000ppm,较好是在0,50ppm至约1,000ppm之间,更好是在1ppm至约500ppm之间,最好是在1ppm至约200ppm之间。和四肽的情形一样,这种用量也是按%w/w计算。因而100,000ppm是化妆品配方重量的约10%。
在本发明的一个优先方面,是一种配方,此配方可以只包括是一种混合物;此混合物有至少1个分子,分子内有1条含有4个氨基酸的链区;至少两个氨基酸是选自氨基乙酸Gly,谷酰胺Gln,脯氨酸Pro和精氨酸Arg;至少1个氨基酸为精氨酸Arg或脯氨酸Pro;至少1个分子内有1条3个氨基酸的链区,而至少1个氨基酸为组氨酸His。可以是氨基酸中至少有1个被acyl组所取代。更优先的是这种混合物可与至少1种外加成分组合。这些混合物可与此处所述的任何外加成分一此处所说的数量组合。确实,这些分子的数量及其相对比例可与此处所述的三肽和四肽的情形相同。
较好的是,含有4个氨基酸链区的分子内同时有脯氨酸和精氨酸,更好的是这些带有3或4个氨基酸链区的分子中至少有1个带有1个由acyl组取代的氨基酸。此acyl组最好是与至少1个氨基酸的N-终端连接,而且为直链或支链、长或短链、饱和或不饱和的酰基组。此种组可以从醋酸acetic acid,癸酸capric acid,丹桂酸lauric acid,肉豆蔻酸 myristic acid,辛酸octanoic acid,棕榈酸palmitic acid,硬脂酸stearic acid,山萮酸behenic acid,亚油酸linoleic acid,亚麻酸linolenic acid,硫辛酸lipoic acid,油酸oleic acid,异硬脂酸isostearic acid,反油酸elaidoic acid,2-ethylhexaneic acid,椰子油脂肪酸coconutoil fatty acid,牛油脂肪酸tallow fatty acid,硬化牛油脂肪酸hardened tallow fatty acid,棕榈仁油脂肪酸palm kernel oil fatty acid,羊毛脂脂肪酸lanolin fatty acid或它们的混合物衍生出来。这些组可以是已被取代或未被取代的。如已被取代,最好是被含有羟基或硫的组所取代,例如但不限于SO3H,SH或S-S。
四肽与三肽的比例,或确切地说是带4个氨基酸的分子与带3个氨基酸的分子之间的比例可以在100∶1至1∶100之间;更好的是约50∶1至1∶50之间,最好的是在10∶1至1∶10之间。最好的是,四肽与三肽的比例为3∶1至约1∶3之间。这种比例为重量比(%w/w-例如每千克最终配方内的纯肽毫克数)。在特别优先的实现方案中,以配方总重量之百万分数计算,三肽的用量比四肽大。
已意外地发现,与用其它小肽单独地或组合地生产出的产品相比,三肽与四肽以及它们的衍生物的有选择组合可提供重要的优点。例如SEDERMA公司出售的、N-棕榈酰-氨基乙酸-谷酰胺-脯氨酸-精氨酸(序列识别号:3)浓度为500ppm的溶液。如表1所示,在浓度为2,5ppm时,此种肽显示出较小的超出基线的胶原I合成刺激作用(+19%)。三肽,在浓度为5ppm即两倍于四肽时,造成的增加量更小。但如这两种肽以相同的量组合时,在刺激胶原I合成方面能造成重大增加(+63%)。此增加量是这些肽之预期添加剂效果的两倍以上。
在胶原I合成方面,在浓度为3.64ppm时,四肽产生的增加量为(+65%)。在7.3ppm时,合成量有所减少。如将这种数量的两种肽组合,结果为+265%。在此浓度时,从纤维结合蛋白,胶原IV和透明质酸方面还发现有意外的优良效果。
表1:在溶剂(0.08%DMSO in DMEM):3×10E-4%抗坏血酸方面的变化百分比
Collagen I | Fibronectin | Collagen IV | Hyaluronic Acid | ||
TGF-β | 10<sup>E</sup>-6% | +91%<sup>*</sup> | +176% | +4% | +43% |
Pal KTTKS (序列识别号:5) | 1ppm 2ppm 4ppm 8ppm | +8% +30% +48% +93% | +24% +20 +74% +100% | +6% +12% +15% +22% | +3% +26% +28% +31% |
Pal GQPR (序列识别号:3) | 0.5ppm 1.5ppm 2.5ppm 3.64ppm | +4% -1% +19% +65% | +1% +15% +35% +56% | +5% -8% -5% -14% | -4% +9% -13% -1% |
Pal GHK | 1ppm 3ppm 5ppm 7.3ppm | +9% -11% +11% -9% | +8% +2% -15% +13% | +5% -4% +6% -9% | +3% +11% 0% -1% |
Combination 1 | 1+0.5 3+1.5 5+2.5 7.3+3.64 | +33% +67% +63% +256% | +1% +41% +44% +147% | -4% -10% -5% +20% | +9% +11% +27% +92% |
Acetyl-YGG | 1ppm 3ppm 5ppm | -2% +5% -11% | n.t. | n.t. | n.t. |
Pal-YGGF(序 列识别号:6) | 1ppm 3ppm 5ppm | +5% -6% +4% | n.t. | n.t. | n.t. |
Combination 2 | 1+0.5 3+1.5 5+2.5 | -7% -5% -13% | n.t. | n.t. | n.t. |
Oleoyl-RGD | 1ppm 3ppm | +5% -3% | n.t. | n.t. | n.t. |
Oleoyl-RGDS (序列识别号:7) | 1ppm 3ppm | -7% -2% | n.t. | n.t. | n.t. |
Combination 3 | 1+0.5 3+1.5 | -12% -15% | n.t. | n.t. | n.t. |
*超出基线的增长百分数
为取得表1的数据,在DMEM内将正常的人皮肤纤维原细胞放入24块培养皿(well-plate)内以10%胎儿腓肠血清(″FCS″)培养24小时,然后漂洗干净。然后让细胞在无FCS的、含有抗坏血酸维生素C的中度DMEM内接受要试验的产品。让细胞与产品接触3小时,然后去处上清液并加以冷冻。每次试验都有一种无溶剂的负对照物,一种对照溶剂和一种正对照物(10-60/oTransforming Growth Factor-(TGF-β))。每种测定进行3次。可进行与试验无关的几次重复。有关分子的化验由Elisa(胶原I和IV;Fibronectine)或用颜色计法进行(hyaluronic acid)。在此实验条件下,单独用三肽时基本上没有效果。四肽则有刺激效应,这至少是申请人以前所不知道的。但最有意义的是测定结果,即两者的组合不仅比人们所希望的、基于加入三肽和四肽的情形要好,而且比商业上成功的、SEDERMA出售的五肽MATRIXYL(Pal-KTTKS)(序列识别号:5)更有效。表1还表明,不是所有肽和/或四肽、或组合都能导致观察到的效应。不同性质的三肽和四肽链区(YGG是enkephaline的一个碎片,YGGF也是,YGGF=Tyr-Gly-Gly-Phe(序列识别号:6);RGD=Arg-Gly-Asp,是fibronectin的一个碎片,RGDS=Arg-Gly-Asp-Ser)(序列识别号:7)并未表现出胶原I刺激作用。因为毒性问题,更高浓度的试验未进行,其它生物分子亦未化验(n.t.=未试验),因为在胶原I刺激作用方面缺少初始响应,而初始响应是一个重要参数。
此外,按照本发明的某些方面,四肽与三肽的优先组合已显示出强大的抗皱纹效果和在牵张痕方面的好处(预防和治疗)。
外加成分Additional Ingredients
除三肽和四肽,它们的类似物和/或衍生物外,本发明的各种配方可包括其它和外加成分,这些成分可以是有效的、有功能的、常规地用在化妆品、个人护理品或表面/经皮使用的药品或其它药品内。当然,决定是否加入外加成分和选择具体的外加成分取决于具体用途和产品配方。而且,″有效″成分和″无效″成分的划分是人为的,取决于具体用途和产品形式。一种物质在某一用途或产品内是″有效″成分,但在另一种产品内可能是″功能性″的,反之亦然。一种特定成分在一种配方中可提供直接性,在另一配方内有助于经皮用途,但在第三中配方中却仅提供合适的粘性。这些外加成分中, 哪一种是功能性的,哪一种是有效的,要经过辩论才能明确。但是,不论辩论结果如何,这种物质终究是一种外加成分。
因而,本发明的各种配方可包括一种或多种对配方的目的、有好处的外加成分。这些外加成分可包括一种或多种物质,例如清洗剂,头发调节剂,皮肤调节剂,头发定型剂,防头皮剂,头发助长剂,香水,遮光剂和防晒剂,颜料,加湿剂,成膜剂,染发剂,化装剂,洗涤剂,药品,加厚剂,乳化剂湿润剂,润肤剂,防腐剂,除臭剂,皮肤病学上可接受的载体和表面活性剂。
本发明的各种配方通常都含有至少一种外加成分。本发明的各种配方也可含有多种外加成分。有一种优先实现方案,其配方是要与人的角质组织接触的,各外加成分便应适于用在角质组织上。也就是说,加于配方内之后,他们适于与人的角质组织(头发,指甲,皮肤,嘴唇)接触而无不应有合理的医学判断范围内的毒性,不兼容性,不稳定性,过敏反应,等等。CTFA化妆品成分手册第9版(2002)描述了各种非限制性化装品和通常用于皮肤护理品工业的药物成分,这些成分适用于作为本发明的配方之外加成分。这些外加成分类别的非限制性的例子包括:研磨料,吸收剂,美学成分如香料、颜料、染色/着色剂、芳香油、皮肤感觉剂、收敛剂等(例如丁香油、薄荷醇、樟脑、桉油、丁子香酚、孟基乳酸盐、金缕梅溜出液),抗粉刺剂,抗结块剂,防沫剂,抗菌剂(例如iodopropyl butylcarbamate),抗氧化剂,粘合剂,缓冲剂,填充剂,螯合剂,化学添加剂,着色剂,换装用收敛剂,化装用生物杀灭剂,变性剂,药物收敛剂,外用止痛剂,成膜剂或材料等,用来帮助配方的成膜特性和直接性的聚合物(例如eicosene和乙烯基吡咯烷酮的共聚物)乳浊剂,pH调节剂,推进剂,还原剂,螯合剂,皮肤漂白和光亮剂(例如对苯二酚,曲酸,抗坏血酸维生素C,磷酸抗坏血酸镁,抗坏血酸基葡糖胺),皮肤调节剂(例如保湿剂,包括附属品和包藏剂),皮肤抚慰剂和/或康复剂(例如泛酰醇及其衍生物乙烷基,泛酰醇,泛酸及其衍生物,尿囊素,没药醇),皮肤治疗剂,稠化剂,维生素及其衍生物。其它皮肤护理和头发护理有效成分与三肽/四肽混合物组合时特别有用,它们可以在SEDERMA商业文献中和网址 www.sederma.fr<http://www.sederma.fr>上找到(此处全部收入)。
但是,在本发明的任何实现实现方案中,此处可用的外加成分可按它们提供的好处或他们的基本作用方式来分类。不过,这一点应理解为此处有用的外加成分在某些情形下可提供不止一种优点或通过不止一种方式起作用。因此,此处的分类只是为了方便,并不意在将外加成分限制于特定用途或所列出的用途。
金合欢醇Farnesol
本发明的表面用处方可含有安全和有效数量的金合欢醇。金合欢醇是一种天然物质,据信在鲨烯和甾醇特别是胆固醇的生物合成中可作为先驱和/或媒介使用。金合欢醇还可用于蛋白质改性和调节(例如蛋白质的法呢基化),而且有一种对法呢醛有响应的细胞核接受器。从化学上说,法呢醛是[2E,6E]-3,7,11-trimethyl-2,6,10-dodecatrien-1-ol,此处说的法呢醛包括法呢醛的异构体和互变体。 法呢醛可在市场上买到,例如以法呢醛(各种异构体的混合物,新泽西州10 Gordon Drive的Dragoco公司生产)名字出售的法呢醛和转移法呢醇(Sigma Chemical Company公司,P.O.Box 14508,St.Louis,Mo)。
如在本发明的处方中使用法呢醛,法呢醛的含量,按处方的百分重量计且适宜性越往后越高时,用量为:约0.001%至约50%,约0.01%至约20%,约0.1%至约15%,约0.1%至约10%,约0.5%至约5%,约1%至约5%。
Phytantriol
本发明的表面用处方可含有安全和有效数量的Phytantriol。Phytantriol是化学物质3,7,11,15,tetramethylhexadecane-1,2,3,-triol的通俗名字。可从BASF(1609 BiddleAvenue,Wyandotte,密执安州)买到。例如,Phytantriol可用作蜘蛛状脉管/红斑点(blotchiness)修理剂,黑斑圈/肿眼修理剂,菜色修理剂,松垂修理剂,止痒剂,皮肤增厚剂,毛孔缩小剂,油/光泽减少剂,发炎后色素沉积过多修理剂,伤痕处理剂,抗臀腿脂肪组剂,和调节皮肤组织、包括皱纹和细线。
在本发明的各种处方中,以适宜性递增计,按占处方重量的百分数,phytantriol的用量为:约0.001%至约50%,约0.01%至约20%,约0.1%至约15%,约0.2%至约10%,约0.5%至约10%,约1%至约5%。
剥离活性剂Desquamation Actives
本发明的处方内可加入安全和有效数量的剥离活性剂,按占处方重量的百分数,以适宜性递增计,加入量为:约0.1%至约10%,约0.2%至约5%,约0.5%至约4%。剥离活性剂能增进本发明在改善皮肤外观上的优点。例如,剥离活性剂坑改善皮肤组织(例如光滑度)。适用于本处的一种剥离活性剂系统含有硫氢基化合物和两性离子表面活性剂,此系统在Bissett的美国专利号5,681,852中有说明,此处列在参考文献中。另一种剥离活性剂系统含有水杨酸和两性离子表面活性剂,在授予Bissett的美国专利号5,652,228中有说明,此处收集在参考文献内。这种用途的两性离子表面活性剂在此处亦可用作剥离剂,特别宜用的是十六烷基甜菜碱。
酶,酶抑制剂和酶活化剂(辅酶)Enzymes,Enzyme Inhibitors and Enzymeactivators(Coenzymes)
本发明的配方可含有安全和有效数量的一种或多种酶,酶抑制剂和酶活化剂(辅酶)。.酶的例子有:脂肪酶,蛋白酶,过氧化氢酶,过氧化物-歧化酶,淀粉酶,葡萄糖苷酸酶,过氧化物酶,特别是谷胱甘肽过氧化物酶或乳过氧化物酶,神经酰胺,透明质酸酶。所有这些酶都可通过提取或发酵生物技术工艺获得。酶抑制剂的例子有胰蛋白酶抑制剂,Bowmann Birk抑制剂,糜蛋白酶抑制剂,含或不含丹宁酸的植物性药材提取物,类黄酮,抑制酶的活性的栎精。酶制剂可以在例如称为VENUCEANE的、法国SEDERMA提出的产品内找到(2002年8月28日的专利WO 02/066668)。酶活化剂和辅酶包括辅酶A,辅酶Q10(泛醌,甘草酸,黄莲素,柯因。
植物性药材提取物和海生生物提取物Botanical Extracts and Marine Extracts
本发明的配方可含有安全和有效数量的一种或多种植物或海生资源提取物。这些提取物可以是通过标准的提取工艺获得,可以是粉状,糊状,膏状,油状或液体状(即溶液),较好的是陆生或海生植物例如海草、海藻、微藻的hydroglycolic提取物。这些植物和海生提取物用于化装品时其特性已为人熟知,可以与三/四肽组合,对为本专利的目的很有利:镇痛和防发炎,酶抑制,湿润,抗皱纹,荷尔蒙替代,抗氧化剂,润肤剂,皮脂调节(seboregulating),防脱发,促进毛发生长,防脂肪组,皮肤康复,使 皮肤变白,脂肪分解,使皮肤变褐色,抗微生物等。
防粉刺剂Anti-Acne Actives
本发明的配方可含有安全和有效数量的一种或多种防粉刺活性剂。有用的防粉刺活性剂包括间苯二酚,硫黄,水杨酸,过氧化苯酰,红霉素,锌等。合适的抗粉刺活性剂的例子在1997年3月4日McAtee等人的美国专利5,607,980号有详细的叙述。特别有用的是与称为″ac.net″的抗粉刺成分的各种组合,他们是由SEDERMA提供的,在2003年4月10日的WO 03/028692 A2中有描述。
防皱纹/防萎缩活性剂Anti-Wrinkle Actives/Anti-Atrophy Actives
本发明的配方可含有安全和有效数量的一种或多种防皱纹活性剂或防萎缩活性剂。适用于本发明的配方之防皱纹活性剂/防萎缩活性剂包括含硫的D和L氨基酸及其衍生物和盐,特别是三-甲基乙酰衍生物。这种盐的优先例子是三-甲基乙酰-左旋半胱氨酸;硫醇类,例如乙胺硫醇,醇酸(例如,α-醇酸如乳酸和乙二醇酸或2-羟基酸如水杨酸和水杨酸衍生物如辛酰基衍生物),phytic酸,硫辛酸;lysophosphatidic酸,皮肤剥落剂(例如,石炭酸之类); 维生素B3化合物和树脂样的,它们能增强本发明在改善角质组织外观方面、特别是在调节角质组织状况例如皮肤状况方面的优点。特别有用的是与SEDERMA、称为Dermolectine和Sterocare的抗皱纹剂的组合,后者在1999年4月22日的WO99/18927中有描述。
a)维生素B3化合物Vitamin B3 Compounds
本发明的配方可含有安全和有效数量的维生素B3化合物。如尚待批准的1997年4月11日归档的美国申请序号08/834,010(相当于1997年10月30日出版的国际申请号WO97/39733 A1)所述,维生素B3化合物对调节皮肤状况特别有用。
如本发明的配方中有维生素B3化合物,按适宜性顺序由低至高,维生素B3化合物的百分重量含量最好是约0.01%至约50%,约0.1%至约10%,约1%至约5%,约2%至约5%。
此处的″维生素B3化合物″指的是具有以下分子式的化合物:
此处R为-CONH2(即烟酰胺),-COOH(即烟碱酸)或-CH2OH(即nicotinyl alcohol);它们的衍生物;和上述任何一种物质的盐。
维生素B3化合物的衍生物的例子包括各种烟碱酸酯,包括烟碱酸的非血管扩张性酯(例如烟酸盐),acids烟碱基氨基酸,羧酸类的烟醇酯,烟酸三-甲基氧化物和烟酰胺三-甲基氧化物。
合适的维生素B3化合物在本行业中已为人熟知,可以从许多来源买到,例如Sigma化学公司(St.Louis,Mo.);ICN生物医学公司(Irvin,Calif.)和Aldrich化学公司(Milwaukee,Wis.)。
所加入的维生素化合物可以是足够纯的物质,或通过合适的物理和/或化学离析从天然来源(例如植物)获得的提取物。
b)类维生素A Retinoids
本发明的配方也可以含有类维生素A。此处,″类维生素A″包括所有天然和/或合成的、在皮肤内具有类维生素A的生物学特性之维生素A类似物或似维生素A的化合物,以及几何异构体和这些化合物的立体异构体。类维生素A较好是维生素A,维生素A酯(例如维生素A的C2-C22烃基酯,包括棕榈酸视黄酯,视黄基乙酸酯,视黄基丙酸),视黄醛和(或)视黄醛酸(包括全透过视黄酸和/或13-cis-视黄酸),更好的是非retinoic酸的类维生素A。这些化合物在本行业中已为人熟知,可以从许多来源买到,例如Sigma化学公司(St.Louis,Mo.)和Boerhinger Mannheim(Indianapolis,Ind.)。本处可用的其它retinoids在1987年6月30日批准给Parish等人的美国专利4,677,120号;1989年12月5日批准给Parish等人的美国专利4,885,311号;1991年9月17日批准给Purcell等人的美国专利5,049,584号;1992年6月23日批准给Purcell等人的美国专利5,124,356号;和1992年9月22日批准给Purcell等人的美国专利号Reissue 34,075已有描述。其它合适的类维 生素A有tocopheryl-retinoate[视黄酸维生素酯(横或顺式),adapalene{6-[3-(1-adamantyl)-4-甲氧苯基]-2-萘甲酸},和tazarotene(乙醇6-[2-(4,4-dimethylthiochroman-6-yl)-乙炔基]烟酸盐)。优先的类维生素A有维生素A,棕榈酸视黄酯,乙酸视黄基,丙酸视黄基,视黄醛和他们的组合物。
.所加入的类维生素A可以是足够纯的物质,或通过合适的物理和/或化学离析从天然来源(例如植物)获得的提取物。类维生素A最好是足够纯的或最好是十分纯的.
本发明的配方可含有安全和有效数量的类维生素A,以使所得的配方能安全而有效地调节角蛋白组织状况,较好的是调节可见和/或可感触到的皮肤老化迹象,再好的是调节皮肤组织随老化而出现的可见和/或可感触到的不连续现象。按适宜性由低到高,本配方的类维生素A的含量为约0.005%至约2%,约0.01%至约2%。Retinal的用量宜为约0.01%至约0.15%;retinol酯的用量宜为0.01%至2%(例如约1%);retinol酸的用量宜为月0.01%至约0.25%;tocopheryl-retinoate,adapalene,和tazarotene的用量宜为约0.01%至2%
如本发明的配方同时含有类维生素A和维生素B3化合物,类维生素A的用量最好如上述,维生素B3化合物的用量宜为约0.1%至约10%,更宜的是约2%至约5%。
羟基酸Hydroxy Acids
本发明的配方可含有安全而有效数量的羟基酸。对本发明的配方,宜用的羟基酸有salicylic酸和salicylic酸衍生物。按适宜性由低到高,本配方的salicylic酸用量宜为约0.01%至约50%,约0.1%至约20%,约0.1%至约10%,约0.5%至约5%,约0.5%至约2%。
肽Peptides
外加的肽,包括但不限于二-,三-,五-和六肽以及它们的衍生物,可以以安全而有效的数量加入本发明的配方内。此处,肽指的是天然和合成的肽。这里可以使用的还有天然的和市场上可买到的含肽的配方。
此处适用的二肽包括Carnosine(beta-Ala-组氨酸)。适用的三肽包括精氨酸-赖氨酸-精氨酸,组氨酸-氨基乙酸-氨基乙酸。宜用的四肽和它们的衍生物包括可从法国Sederma买到的N-棕榈酰-氨基乙酸-赖氨酸-组氨酸;Peptide CK(精氨酸-赖氨酸-精氨 酸);Peptide CK+(ac-精氨酸-赖氨酸-精氨酸-NH2);和Sigma(St.Louis,Mo.)公司作为lamin出售的组氨酸-氨基乙酸-氨基乙酸铜衍生物。此处适用的四肽包括肽E和精氨酸-Ser-精氨酸-赖氨酸(序列识别号:8)。适用本处的其它肽包括但不限于Tyr-精氨酸,Val-Trp,天冬酰胺-Phe,Asp-Phe,N-Palmitoyl-beta-Ala-组氨酸,N-醋酸-Tyr-精氨酸--hexadecylester,和它们的衍生物;赖氨酸-Phe-赖氨酸,N-Elaidoyl-赖氨酸-Phe-赖氨酸和它的conservative substitution类似物;N-Acetyl-精氨酸--赖氨酸-精氨酸-NH2,和它的衍生物。适用的五肽和六肽包括但不限于N-棕榈酰-赖氨酸-苏氨酸-苏氨酸-赖氨酸-Ser(序列识别号:5),带X Met或Leu的N-棕榈酰-Tyr-氨基乙酸-氨基乙酸-Phe-X(序列识别号:9)或它们的混合物;N-棕榈酰-Val-氨基乙酸-Val-Ala-Pro--氨基乙酸(序列识别号:10)和它的衍生物。宜用的二肽衍生物为N-Acetyl-Tyr-精氨酸--hexadecylester(法国SEDRMA的产品 ).宜用的三肽及其衍生物包括N-棕榈酰-氨基乙酸-赖氨酸-组氨酸(法国SEDERMA公司的Pal-GKH),Peptide CK(精氨酸-赖氨酸-精氨酸),和Lipospondin(N-Elaidoyl-赖氨酸-Phe-赖氨酸)及其conservative substitutionanalogs,Peptide CK+(N-Acetyl-精氨酸-赖氨酸-精氨酸-NH2).。适用的五肽还包括法国SEDERMA公司出售的,商标为 的N-棕榈酰-赖氨酸-苏氨酸-苏氨酸-赖氨酸-Ser(序列识别号:5)。六肽,例如2003年5月12日SEDERMA提出的法国专利申请号FR 0305707所披露的六肽,也可以使用。
用在本配方内时,外加的肽的用量,按适宜性递增计,从约1×10-6%至约10%,约1×10-6%至约0.1%,约1×10-5%至约0.01%。在某些含有peptide 的方案中,这种肽的含量,按占配方的百分重量计,宜为约0.1%至约5%。在含肽的配方之其它方案中,使用了 ,此种配方所含之 按占配方之百分重量计,宜为约0.1%至约10%。
抗氧化剂/根清除剂(Anti-Oxidants/Radical Scavengers)
本发明的配方可含有安全和有效数量的抗氧化剂/根清除剂或氧化剂/还原剂。在提供紫外线辐射保护方面和防止其它环境因素的损害方面,抗氧化剂/根清除剂或氧化剂/还原剂特别有用,紫外线能使脱落增加或角质层内的组织改变;这些化合物还可 用于头发干燥和其它化装用途。
本发明的配方中可以加入安全而有效数量的抗氧化剂/根清除剂或氧化剂/还原剂,其含量宜为配方重量的约0.1%至约10%,更适宜的是约1%to about 5%。可以使用的抗氧化剂/根清除剂有:例如维生素酸(维生素C)及其盐类,脂肪酸的抗坏血酸酯,抗坏血酸衍生物(例如,磷酸抗坏血酸镁,磷酸抗坏血酸钠,山梨酸抗坏血酸),维生素(维生素E),山梨酸维生素,乙酸维生素,其它维生素,丁基羟基苯甲酸酯及其盐类,过氧化物包括过氧化氢,过硼酸盐,thioglycolates,过硫酸盐,6-羟(基)2,5,7,8-tetramethylchroman-2-羧酸(可以买到,商标为 ),镓酸及其酰基酯尤其是propyl gallate,尿酸及其盐类和酰基酯,sorbic acid及其盐类,硫辛酸,胺类(例如N,N-diethylhydroxylamine,二甲锍氨酸胍),巯基化合物(例如谷胱甘肽),二羟延胡索酸及其盐类,甜菜碱,精氨酸,去甲二氢愈创木酸,生物类黄酮,酸性黄,赖氨酸,1-蛋氨酸,脯氨酸,过氧化物歧化酶,水飞蓟素,茶提取物,葡萄皮/籽提取物,黑色素,和迷迭香提取物。宜用的抗氧化剂/根清除剂从山梨酸维生素和维生素的其它酯,最好是山梨酸维生素中选择。例如,(皮肤)表面用配方使用山梨酸维生素且适用于本发明的情形在1989年7月11日授给Donald L.Bissett,Rodney D.Bush和Ranjit Chatterjee的美国专利US 4,847,071已有描述。
螯合剂Chelators
本发明的配方也可含有安全和有效数量的螯合剂。这里说的螯合剂指的是一种活性剂,此种活性剂能通过形成络合物来清除金属离子,使金属离子不容易参与催化化学反应。螯合剂的加入对提供保护、防止紫外线辐射造成皮肤鳞屑过多或组织变化特别有用,并能防止其它环境因素造成皮肤损伤。螯合剂的例子有乙二胺四乙酸,氮川三乙酸,去铁敏,hydroxamic酸和它们的盐类,phytic酸,肌醇六磷酸,gluconic酸和它的盐类,乳铁蛋白。
本发明的配方也可含有安全和有效数量的螯合剂,按适用性递增计,加入量为配方重量的约0.1%至约10%,约1%to about 5%。可用于本发明的螯合剂例子,在1996年1月30日授给Bissett等人的美国专利5,487,884号中,在1995年10月31日出版的Bush等 人着的国际刊物No.91/16035,和1995年10月31日出版的、Bush着的国际刊物91/16034号中都有描述。宜用于本发明的的螯合剂有deferoxamine,hydroxamic酸,gluconic酸,phytic酸,和它们的衍生物。
类黄酮Flavonoids
本发明的配方可含或不含类黄酮化合物。类黄酮在美国专利5,686,082和5,686,367号中有大量的说明,两者均收集在本文的参考文献中。适用于本发明的类黄酮有由未替代的氢黄酮类中选出的氢黄酮,单基取代后的氢黄酮以及它们的混合物;从未取代的查耳酮、单基取代后的查耳酮、二基取代后的查耳酮、三基取代后的查耳酮,以及它们的混合物;从未取代的查耳酮、单基取代后的查耳酮、二基取代后的查耳酮中选出的查耳酮,以及它们的混合物;一种或多种异黄酮;从未取代的香豆素选出、单基取代后的、二基取代后的香豆素,以及它们的混合物;从未取代的色酮中选出的色酮,单基取代后的色酮,二基取代后的色酮,以及它们的混合物;一种或多种双羟香豆素;它们的异构体(例如cis/trans异构体);以及他们的混合物。此处,″已取代″的意思是各种类黄酮,其内的一个或多个氢原子已被独立地由羟基,C1-C8 alkyl,C1-C4alkoxyl,O-glycoside之类或这些取代基的混合物所取代。
适用的类黄酮的例子有但不限于:未取代的类黄酮,单-羟基类黄酮(例如2′-羟基黄烷酮,6-羟基黄烷酮,7-羟基黄烷酮,等等)单-烃氧基黄烷酮(例如,5-甲氧基黄烷酮,6-甲氧基黄烷酮,7-甲氧基黄烷酮,4′-甲氧基黄烷酮,等),未取代的查耳酮(特别是未取代的转移查耳酮),单-羟基查耳酮(例如2′-羟基查耳酮,4′-羟基查耳酮,等),二-羟基查耳酮(例如2′羟基查耳酮,4-羟基查耳酮,2′,4′-羟基查耳酮,2,2′-羟基查耳酮,2′,3-羟基查耳酮,2′,5′-羟基查耳酮,等),和3-羟基查耳酮(例如2′,3′,4′-三羟基查耳酮,4,2′,4′-三羟基查耳酮,2,2′,4′-三羟基查耳酮,等),未取代的黄酮,7,2′-二羟黄酮,3′,4′-二羟萘黄酮,4′-羟基黄酮,5,6-苯黄酮,萘黄酮,未取代的异黄酮,黄豆苷原(7,4′-二羟异黄酮),5,7-二羟-4′-甲氧基异黄酮,大豆异黄酮(从大豆中提取的一种混合物),未取代的香豆素,4-羟基香豆素,7-羟基香豆素,6-羟基-4-甲基香豆素,未取代的色酮,3-甲酰色酮,3-甲酰-6-异丙基色酮,为取代的双羟香豆素,未取代的,未取代的二氢色原酮,和它们的混 合物。
宜用于此处的有未取代的黄烷酮,未取代的查尔酮,2′,4-二羟查尔酮,和它们的混合物。更宜用的是未取代的黄烷酮,未取代的查尔酮(特别是trans异构体),和它们的混合物。
它们可以是合成物质或来自天然物质(例如植物)的提取物。天然物质还可进一步被衍生(例如从天然来源提取后再调制的酯或醚衍生物)。此处可用的类黄酮化合物来源较多,可从市场上买到,例如Indofine化学公司(新泽西州Somerville),Steraloids公司(Wilton,N.H.),和Aldrich化学公司(威士康星州Milwaukee)。
上述类黄酮化合物的混合物也可以使用。
以适宜性递增计,这里所说的类黄酮化合物在本发明中的浓度宜为约0.01%至约20%,0.1%至约10%,0.5%至约5%。
抗发炎剂Anti-Inflammatory Agents
本发明的配方也可加入安全和有效数量的抗发炎剂,按适宜性递增计,其用量宜为约0.1%至约10%,约0.5%至约5%。抗发炎剂能增强本配方对皮肤外观的好处,例如有助于使皮肤的色调或颜色更均匀和更好。在本配方中抗发炎剂的用量取决于所用的抗发炎剂,因为这种剂在效用上差别较大。
可以使用的甾族抗发炎剂,包括但不限于皮质类固醇如氢化可的松,hydroxyltriamcinolone,α甲基地塞米松,磷酸地塞米松,二丙酸氯地米松,戊酸clobetasol,desonide,desoxymethasone,醋酸脱氧皮质酮,地塞米松,dichlorisone,二醋酸diflorasone,戊酸diflucortolone,fluadrenolone,丙酮化fluclorolone,氟氢可的松,三甲基乙酸flumethasone,丙酮化fluosinolone,氟轻松醋酸酯,flucortine butylesters,氟考龙,醋酸fluprednidene(fluprednylidene),fluradrenolone,氯氟松,醋酸氢化可的松,丁酸氢化可的松,甲强龙,丙酮化去炎松,可的松,11-脱氧可的松,flucetonide,氟氢可的松,二醋酸difluorosone,fluradrenolone,氟氢可的松,二醋酸diflurosone,丙酮化fluradrenolone,medrysone,amcinafel,amcinafide,培他米松及作为余量的其酯类,氯强的松,醋酸chlorprednisone,clocortelone,clescinolone,dichlorisone,diflurprednate, flucloronide,flunisolide,fluoromethalone,氟培龙,氟氢化泼尼松,皮质甾醇戊酸盐,皮质甾醇cyclopentylpropionate,氢可的松-21-二乙氨基醋酸酯,meprednisone,泼拉米松,氢化尼松,泼尼松,二丙酸氯地米松,氟羟脱氢皮醇,和它们的混合物。宜用的甾族抗发炎剂为氢化可的松。
可用于本配方的第二类抗发炎剂包括非甾族抗发炎剂。这类化合物已为包括行业中的专家所熟知。非甾族抗发炎剂的化学结构,合成法,副作用等的详情见各种标准文献,例如Anti-inflammatory and Anti-Rheumatic Drugs,K.D.Rainsford,Vol.I-III,CRCPress,Boca Raton,(1985),和Anti-inflammatory Agents,Chemistry and Pharmacology,1,R.A.Scherrer,et al.,Academic Press,New York(1974)。
可用于本配方的具体非甾族抗发炎剂包括但不限于:
1)oxicams,例如吡罗昔康,异恶噻酰胺,tenoxicam,sudoxicam,和CP-14,304;
2)水杨酸盐,例如阿斯匹林,disalcid,扑炎痛,trilisate,safapryn,solprin,二氟苯水杨酸,fendosal
3)醋酸衍生物,例如diclofenac,芬氯酸,消炎痛,sulindac,甲苯酰吡酸,isoxepac,乙基二氢苯呋喃乙酸,二氢氧二苯并硫杂,acematacin,fentiazac,氯苯酰二甲基吡咯乙酸,clindanac,oxepinac,felbinac,和ketorolac;
4)fenamates,例如mefenamic,meclofenamic,flufenamic,niflumic,和tolfenamic酸;
5)propionic酸衍生物,例如异丁苯丙酸,甲氧萘丙酸,benoxaprofen,flurbiprofen,ketoprofen,fenoprofen,fenbufen,indopropfen,pirprofen,carprofen,oxaprozin,pranoprofen,miroprofen,tioxaprofen,suprofen,alminoprofen,和tiaprofenic;
6)pyrazoles,例如苯基丁氮酮,羟基保泰松,feprazone,azapropazone,和trimethazone.
这些非甾族抗发炎剂,它们的皮肤病学上可接受的盐类和酯类也可以使用。例如,etofenamate即一种flufenamic酸的衍生物特别适于表面使用。在非甾族抗发炎剂中宜用的有ibuprofen,naproxen,flufenamic酸,etofenamate,阿斯匹林,mefenamic酸, meclofenamic酸,piroxicam和felbinac;异丁苯酸,甲氧萘丙酸,ketoprofen,etofenamate,阿斯匹林和flufenamic酸则更适宜。
最后,所谓″天然的″抗发炎剂在本发明的各种方法中是有用的。这种剂可以是以合适的物理或化学离析法从天然来源(例如植物,菌,微生物的副产品)中获得的提取物,或可以用合成法制备。例如,可以使用的有蜡大戟蜡,红没药醇(例如α-红没药醇),aloe vera,plant sterols(例如,phytosterol),Manjistha(从genus Rubia类植物特别是Rubia Cordifolia中提取),和Guggal(从Commiphora,类植物特别是Commiphora Mukul中提取),kola extract,chamomile,red clover extract,Piper methysticum extract(SEDERMA的Kava Kava,2000年3月的FR2 771 002和WO99/25369中透露),Bacopamonieri extract(SEDERMA的Bacocalmine,在1999年8月19日的WO 99/40897)和seawhip提取物。
这里可以使用的外加抗发炎剂包括欧亚甘草(Licorice)(the plant genus/speciesGlycyrrhiza glabra种/类植物)族化合物、包括glycyrrhetic酸,glycyrrhizic酸,和它们的衍生物(例如,盐和酯).上述化合物的合适盐类包括金属和铵盐。合适的酯类有这些酸的C2-C24饱和或不饱和酯,宜用的是C10-C24更宜用的是C16-C24。上述物质的具体例子有可溶于油的欧亚甘草提取物,glycyrrhizic和glycyrrhetic酸本身,monoammonium glycyrrhizinate,monopotassium glycyrrhizinate,dipotassiumglycyrrhizinate,1-2-萘酚-氢琥珀酸甘草次酸,硬脂酰glycyrrhetinate,和3-stearyloxy-甘草次酸,以及二钠3-succinyloxy-2-萘酚-氨基乙酸cyrrhetinate.硬脂酰glycyrrhetinate,优先使用的是1-2-萘酚-氢琥珀酸甘草次酸,硬脂酰glycyrrhetinate,3-stearyloxy-甘草次酸,分子中有两个钠原子的3-succinyloxy-2-萘酚-glycyrrhetinate.硬脂酰glycyrrhetinate。
抗脂肪团剂Anti-Cellulite Agents
本发明的配方也可含有安全和有效数量的抗脂肪团剂。合适的抗脂肪团剂可包括但不限于xanthine化合物(例如,咖啡因,茶碱,可可碱,和氨茶碱)。特别有用的是与称为Vexel的脂肪团/减肥剂(1992年2月31日的FR 2 654 619),Coaxel(1992年7月30日的FR 2 694 195),Cyclolipase(1995年4月21日的FR 2 733 149),Pleurimincyl and Lipocare(1998年10月8日的WO 98/43607)和Unislim(2003年5月20日的FR 0306063)的组合物,这些药剂均为SEDERMA提供。
表面用麻醉剂Topical Anesthetics
本发明的配方还可含有安全和有效数量的表面麻醉剂。表面麻醉药的例子有苯坐卡因,利多卡因,丁哌卡因,盐酸氯普鲁卡,因奴白卡因,etidocaine,嘧哌凡卡因,丁卡因,达克罗宁,海克卡因,普鲁卡因,可卡因,克他命,普拉莫星,苯酚,和药物学上可接受的它们的盐类。
皮肤变褐活性剂Tanning Actives
本发明的配方也可含有安全和有效数量的皮肤变褐活性剂。如含有作为人造变褐活性剂,按适宜性递增计,二羟基丙酮占配方重量为约0.1%至约20%,约2%至约7%,约3%至约6%。二羟基丙酮亦称为DHA或1,3-二羟-丙酮,为白色至较白的晶体粉末。此物质的化学式为C3H6O3,具有如下的化学结构。
此化合物的外观可以是单体和二聚物的混合物,在固体晶体状态时以二聚物为主。加热或熔化时,二聚物分解,产生单体。此种二聚物形式至单体形式的的转换在水溶液中也会出现。二羟基丙酮在酸性pH值时更稳定。见The Merck Index,Tenth Edition,entry 3167,p.463(1983)(Merck索引,第10版,第3167条,第463页(1983)),和″Dihydroxyacetone for Cosmetics,″E.Merck Technical Bulletin(E.Merck技术公告),03-304 110,319 897,180 588.特别有用的是与称为Tyr-ol and Tyr-exel的皮肤变褐剂的组合,此剂由SEDERMA提供并在1993年3月15日的Fr 2 702 766和2003年3月6日的WO03/017966 A2中有说明。
皮肤光亮剂Skin Lightening Agents
本发明的配方中可含有皮肤光亮剂。如有,按适宜性递增计,配方的皮肤光亮剂 含量为约0.1%至约10%,约0.2%to about 5%,约0.5%to about 2%,按占配方的重量计。合适的皮肤光亮剂包括行业中熟知的光亮剂,包括曲酸,熊果苷,抗坏血酸维生素C和它们的衍生物(例如磷酸抗坏血酸镁或磷酸抗坏血酸钠),和各种提取物(例如桑葚提取物,胎盘提取物)。此处适用的皮肤光亮剂还包括Hillebrand发表的PCT刊物95/34280号中所说的那些,此刊物相当于1995年6月12日提出的PCT专利申请U.S.Ser.No.95/07432号;和待批准的、Kvalnes,Mitchell A.DeLong,Barton J.Bradbury,Curtis B.Motley和John D.Carter提出的专利申请U.S.application Ser.No.08/390,152号,此申请相当于95/8/9出版的专利申请PCT Publication Ser.No.95/23780。特别有用的是与称为Melaclear,Etioline,Melaslow和Lumiskin的组合,这些药物均由SEDERMMA提供,在1995年3月28日的FR 2 732 215,1996年8月2日的WO 98/05299和2002年8月30日的PCT/FR 03/02400中分别有说明。
皮肤光滑和皮肤康复活性剂Skin Soothing and Skin Healing Actives
本发明的配方可含有皮肤光滑或皮肤康复活性剂。此处适用的皮肤光滑或皮肤康复活性剂有panthenoic酸衍生物(包括泛酰醇,dexpanthenol,ethyl panthenol),aloevera,尿囊素,bisabolol,和dipotassium glycyrrhizinate。本配方中可加入安全而有效数量的皮肤光滑或皮肤康复活性剂,按适宜性递增计,加入量站配方重量的百分数为:约0.1%至约30%,约0.5%至约20%,约0.5%至约10%。特别有用的是与称为Calmosensine和Bacocalmine的皮肤光滑和皮肤康复活性剂的组合,此皮肤光滑和皮肤康复活性剂由SEDERMA提供,在1998年2月26日的WO98/07744和1999年8月19日的WO 99/40897中分别有说明。.
红没药醇bisabolol
本发明的表面用配方还可含有安全而有效数量的红没药醇。没药醇是天然的未饱和单环萜酒精的首要成分,具有如下结构:
它是甘菊提取物/油的首要成分。没药醇可以合成(d,1-alpha-isomer or(+/-)-alpha-isomer)的或天然的,可以基本上纯的化合物或各种化合物的混合物(例如从甘菊等的天然来源获得的提取物)的形式使用。α型的没药醇(α-没药醇)已用于各种化妆品,作为皮肤调节剂或光亮剂。这里,没药醇包括甘菊提取物或油以及它们的任何单体和异构体。适用的没药醇化合物有可从Dragoco公司(新泽西州Totowa)买到的天然材料,产品名字叫做alpha-bisabolol natural,和可从Fluka公司(Milwaukee,Wis.)买到的称为alpha-bisabolol合成物质。
在本发明的配方中,以占配方的百分重量计,按适宜性递增计,bisabolol的含量宜为约0.001%至约50%,约0.01%至约20%,0.01%至约15%,约0.1%至约10%,约0.1%to about 5%。
抗菌和抗真菌活性剂Antimicrobial and Antifungal Actives
本发明的表面用配方还可含有抗菌和抗真菌活性剂。这种活性剂能破坏微生物或防止微生物繁殖或防止微生物的致病作用。本配方中可加入安全而有效数量的抗菌和抗真菌活性剂,按占本配方的百分比重量计,按适宜性递增计,为约0.001%至约10%,约0.01%至约5%,约0.05%至约2%。特别有用的是与称为OSMOCIDE的成分结合,此成分由SEDERMA公司提供,在1997年2月20日的WO97/05856中有说明。
抗菌和抗真菌活性剂的例子有:-1乳胺药,2-羟基喹啉,ciprofloxacin,norfloxacin,四环素,红霉素,氨基羟丁基卡那霉素A,2,4,4′-三氯-2′-羟基二苯醚,3,4,4′-trichlorobanilide,苯氧乙醇,含苯氧基丙醇,phenoxyisopropanol,强力霉素,缠霉素,洗必太,金霉素,土霉素,氯林肯霉素,乙胺丁醇,hexamidine羟乙基磺酸盐,灭滴灵,异硫化羟酸,庆大霉素,卡那霉素,lineomycin,甲烯土霉素,乌洛托品,二 甲胺四环素,新霉素,netilmicin,巴龙霉素,链霉素,托普霉素,咪康唑,盐酸四环素,红霉素,锌红霉素,无味红霉素,红霉素硬脂酸酯,氨基羟丁基卡那霉素A硫酸盐,强力霉素氢氯化物,缠霉素硫酸盐,洗必太葡糖酸盐,洗必太氢氯化物,金霉素氢氯化物,盐酸土霉素,氯林肯霉素氢氯化物,乙胺丁醇氢氯化物,灭滴灵氢氯化物,异硫化羟酸氢氯化物,庆大霉素硫酸盐,硫酸卡那霉素,lineomycin氢氯化物,甲烯土霉素氢氯化物,乌洛托品马尿酸盐,杏仁酸乌洛托品,二甲胺四环素氢氯化物,新霉素硫酸盐,netilmicin硫酸盐,硫酸巴龙霉素,链霉素硫酸盐,硫酸妥布霉素,咪康唑氢氯化物,ketaconazole,amanfadine氢氯化物,amanfadine硫酸盐,octopirox,parachlorometa二甲苯酚,制霉菌素,发癣退,氧巯基吡啶锌和氯三苯甲咪唑.
此处,首先使用的这些活性剂的例子有:从水杨酸中选出的活性剂,过氧化苯甲酰,3-羟基苯甲酸,乙醇酸,乳酸,4-羟基苯甲酸,乙酰水杨酸,2-hydroxybutanoic酸,2-hydroxypentanoic酸,2-hydroxyhexanoic酸,维生素A酸,转移维生素A酸,视黄醇,植酸,三-甲基氨丙磺酸乙酰左旋的半胱氨酸,硫辛酸,壬二酸,花生四烯酸,过氧化苯甲酰,四环素,布洛芬,naproxen,皮质甾醇,acetominophen,间苯二酚,苯氧乙醇,phenoxypropanol,phenoxyisopropanol,2,4,4′-三氯-2′-羟基二苯醚,3,4,4′-三氯碳酰替苯胺,octopirox,盐酸利多卡因,氯三苯甲咪唑,咪康唑,ketoconazole,neocycin硫酸盐,和它们的混合物。
防晒活性剂Sunscreen Actives
皮肤暴露于紫外线时,回造成过多的鳞屑和角质层组织变化。所以,本发明的配方也可含有或不含遮光活性剂。这里说的″遮光活性剂″包括各种遮光活性剂和物理防晒霜。适用的遮光活性剂可以是有机或无机的。
此处有用的无机遮光活性剂包括以下金属氧化物;平均粒度为15nm至100nm的二氧化钛,平均粒度为约15nm至约150nm的氧化锌,平均粒度为约15nm至约150nm的氧化锆,平均粒度为约15nm至约100nm的氧化铁,以及它们的混合物。如用在本配方中,按适宜性递增计,无机遮光活占配方的重量百分数为约0.1%至约20%,约1%至约5%。
此出可用的遮光活性剂种类很多。Sagarin等人在Cosmetics Science and Technology(1972)第VIII章第189页以后的叙述中披露了各种盒式的活性剂。合适的具体活性剂包括,例如:p-aminobenzoic酸,它的衍生物(乙醇,异丁基,甘油酯;p-dime-thylaminobenzoic酸);氨基苯甲酸盐(即正氨基苯酸盐;甲基,薄荷基,苯基,苯甲基,苯乙基,里哪基,松油基,和环己烯基酯);水杨酸盐(戊基,苯基,辛基,苯甲基,薄荷基,甘油基,和di-pro-pyleneglycol酯);苯乙烯酸衍生物(薄荷基和苯甲基酯,a-phenyl cinnamonitrile;丁基丙酮酸肉桂酰);dihydroxycinnamic酸阏生物(扇形酮,methylumbelliferone,methylaceto-扇形酮);trihydroxy-cinnamic酸衍生物(七叶亭,methylesculetin,daphnetin,和配糖物,七叶亭和daphnin);碳氢化合物(diphenylbutadiene,stilbene);二亚苄基丙酮和d亚苄基乙酰苯;naphtholsulfonates(2-naphthol-3,6-disulfonic酸和2-naphthol-6,8-disulfonic酸的钠盐);di-hydroxynaphthoic酸及其盐类;o-和p-hydroxybiphenyldisulfonates;香豆素衍生物(7-hydroxy,7-methyl,3-phenyl);二唑(2-acetyl-3-bromoindazole,phenyl benzoxazole,methyl naphthoxazole,various aryl benzothiazoles);奎宁盐(bisulfate,sulfate,chloride,oleate,and tannate);喹啉衍生物(8-hydroxyquinoline salts,2-phenylquinoline);hydroxy-或methoxy-取代的苯甲酮;uric and violuric酸;丹宁酸及其衍生物(例如,hexaethylether);(butyl carbotol)(6-propyl piperonyl)醚;对苯二酚;苯甲酮(oxybenzene,sulisobenzone,dioxybenzone,benzoresorcinol,2,2′,4,4′-tetrahydroxybenzophenone,,2′-dihydroxy-4,4′-dimethoxybenzophenone,octabenzone;4-isopropyldibenzoylmethane;butylmethoxydibenzoylmethane;etocrylene;octocrylene;[3-(4′-methylbenzylidene boman-2-one),terephthalylidenedicamphor sulfonic acid和4-isopropyl-di-benzoylmethane.
其中,优先使用的有2-ethylhexyl-p-methoxycinnamate(市场上可买到的叫PARSOLMCX),4,4′-t-丁基甲氧基联苯甲酰-甲烷(市场上可买到的叫PARSOL 1789),2-羟(基)-4-甲氧基二苯甲酮,对氨基苯甲酸,digalloyltrioleate,2-二羟-4-甲氧基二苯甲酮,ethyl-4-(bis(hydroxy-propyl))aminobenzoate,2-ethylhexyl-2-cyano-3,3-diphenylacrylate,2-ethylhexyl-salicylate,glyceryl-p-aminobenzoate,3,3,5-tri-methylcyclohexylsalicylate, methylanthranilate,p-dimethyl-aminobenzoic acid或aminobenzoate,2-ethylhexyl-p-dimethyl-amino-benzoate,2-phenylbenzimidazole-5-sulfonic acid,2-(p-dimethylaminophenyl)-5-sulfonicbenzoxazoic acid,octocrylene和这些化合物的混合物。
优先使用的还有aNogueira等人的美国专利6,190,645号所描述和要求的配方和组合,特别是在col.3,lns.4-23中所披露的遮光剂与cinnamido alkyl amine cationicquaternary盐的组合,此种盐例如Croda公司(7Century Road,Parsippany,New Jersey)制造的、商标为INCROQUAT-UV-283的cinnamidopropyl trimethyl ammonium chloride。专利6,190,645的这些部分已收集在参考文献内。在本大名的配方中优先使用的有机遮光剂有2-ethylhexyl-p-methoxycinnamate,butylmethoxydibenzoyl-methane,2-hydroxy-4-methoxybenzo-phenone,2-phenylbenzimidazole-5-sulfonic acid,octyldimethyl-p-aminobenzoicacid,octocrylene和它们的混合物。
在本配方中也特别有用的遮光活性剂有,例如在1990年6月26日授予Sabatelli的美国专利4,937,370号中披露的遮光活性剂,和1991年3月12日授予Sabatelli和Spirnak的美国专利4,999,186号中披露的遮光活性剂。所披露的这些中披露的遮光活性剂,在单分子的形式时。具有两个明显的chromophore moieties(载色体半族),此半族呈现出不同的紫外线辐射吸收光谱。其中一个半族主要在UVB辐射范围内吸收,另一个则在UVA辐射范围内强烈地吸收。
这些遮光剂中,优先使用的是2,4-dihydroxybenzophenone的4-N,N-(2-ethylhexyl)methyl-aminobenzoic酸酯;带4-hydroxydibenzoylmethane的N,N-di-(2-ethylhexyl)-4-aminobenzoic酸酯;带4-hydroxydibenzoylmethane的4-N,N-(2-ethylhexyl)methyl-aminobenzoic酸酯;的4-N,N-(2-ethylhexyl)methyl-aminobenzoic酸酯;4-(2-hydroxyethoxy)dibenzoylmethane的4-N,N-(2-ethylhexyl)-methylaminobenzoic酸酯;2-hydroxy-4-(2-hydroxyethoxy)benzophenone的N,N-di-(2-ethylhexyl)-4-aminobenzoic酸酯;4-(2-hydroxyethoxy)dibenzoylmethane的N,N-di-(2-ethylhexyl)-4-aminobenzoic酸酯。和它们的混合物。
特别适宜使用的遮光活性剂包括4,4′-t-butylmethoxydibenzoylmethane,2-ethylhexyl- p-methoxycinnamate,phenyl benzimidazole sulfonic acid,和octocrylene.使用了安全和有效数量的有机遮光活性剂,典型用量为配方重量的约1%至约20%,更典型的是约2%至约10%。准确用量依所选的遮光剂和要求的日晒保护系数(SPF)而异。
微粒材料Particulate Material
本发明的配方可含有微粒材料,最好是金属氧化物。这些微粒材料可带或不带涂层,充或不充(药)。充(药)的粒子在Ha等人的美国专利5,997,887号中有披露,此处入供参考。此处可用的微粒材料包括:氯氧化铋,氧化铁,云母,用硫酸钡和TiO2处理过的云母,和硅石,尼龙,聚乙烯,滑石,苯乙烯,乙烯/丙烯酸共聚物,绢云母,氧化铝,硅树脂,硫酸钡,碳酸钙,醋酸纤维素,二氧化钛,polymethyl methacrylate,和它们的混合物。
无机微粒材料,例如TiO2,ZnO或ZrO2来源很多,可在市场上买到。适用的一种微粒材料例子含有可从美国换装品公司买到的材料(TRONOX TiO2系列,SAT-TCR837,一种金红石TiO2).本配方中,微粒材料的含量。以适宜性递增计,为约.01%至约2%,约0.05%至约1.5%,约0.1%至约1%,以占配方的百分重量计算。
调节剂Conditioning Agents
本发明可含选自湿润剂,加湿剂或皮肤调节剂的一种调节剂。可使用的此种材料有多种,按适宜性递增计,其用量占配方重量的百分数为:约0.01%至约20%,约0.1%至约10%,约0.5%至约7%。这类材料包括但不限于:胍,尿素;乙醇酸和乙醇酸盐(例如铵和四烷基铵);水杨酸;乳酸和乳酸盐(例如,铵和四烷基铵);各种形式的aloe vera(例如aloe vera胶);多羟基酒精如山梨醇,甘露醇,木糖醇,赤藻糖醇,丙三醇,hexanetriol,丁三醇,propylene glycol,butylene glycol,hexylene glycol之类;polyethyleneglycols;各种糖(例如melibiose)和淀粉;糖和淀粉衍生物(例如alkoxylated葡萄糖,果糖,葡糖胺);hyaluronic酸;lactamide monoethanolamine;acetamidemonoethanolamine;泛酰醇;尿囊素;和它们的混合物。这里有用的还有1990年12月11日授予Orr等人的美国专利4,976,953号内描述的propoxylated glycerols。
有用的还有各种C1-C30单酯和糖的聚酯及有关材料。这些酯是从糖或polyolmoiety和一种或多种carboxylic acid moieties衍生出来的。这些酯材料在以下专利中有所描述:1997年1月25日授予Jandacek的美国专利2,831,854号和4,005,196号;1977年1月25日授予Jandacek的美国专利4,005,195号;1994年4月26日授予Letton等人的美国专利5,306,516号;Apr.26,1994授予Letton等人的美国专利5,306,515号;1994年4月26日,授予Letton等人的美国专利5,305,514号;1989年1月10日授予等人的美国专利4,797,300号;1976年6月15日授予Rizzi等人的美国专利3,963,699号;1985年5月21日,授予Volpenhein的美国专利4,518,772号;和and198 5年5月21日授予Volpenhein的美国专利4,517,360号.
调节剂最好是选自尿素,胍,蔗糖聚酯,泛酰醇,dexpanthenol,尿囊素,和它们的组合。
结构剂Structuring Agents
本发明的配方,特别是它的乳化液,可含有结构剂。结构剂特别宜用于本发明的、油在水中的乳化液。不受理论的限制,人们相信结构剂有助于配方的流变学特性,对排放的稳定性有利。例如,结构剂能帮助形成液态晶体凝胶网络结构。结构剂还可起乳化剂和表面活性剂的作用。本发明的优先配方的一种或多种结构剂含量为,以适宜性递增计,约0.1%至于约20%,约0.1%至约10%,约0.5%至约9%。
优先使用的结构剂是HLB约1到8、熔点至少为45℃的结构剂。合适的结构剂是选自饱和的C14 to C30脂肪族醇、饱和C16至C30脂肪族醇的结构剂,含约1至5模尔ethylene oxide者,饱和C16至C30二醇,饱和C16至C30 monoglycerol醚,饱和C16 至C30羟基脂放酸,C14至C30 hydroxylated和nonhydroxylated饱和脂肪酸,C14至C30饱和ethoxylated脂肪酸,含约1到约5模尔ethylene oxide diols的胺和醇,含至少40%monoglyceride的C14至C30饱和glyceryl mono esters,含约1至约3个alkyl组和约2到3个饱和甘油单位的C14 to C30饱和polyglycerol esters,C14至C30甘油基醚,带约1至5模尔ethylene oxide的C14至C30山梨聚糖单/二酯,C14 to C30饱和methylglucoside酯,C14 to C30饱和蔗糖单/二酯,带约1至约5模尔ethylene oxide的C14 to C30 饱和ethoxylated methyl glucoside esters,带平均为1至2个葡萄糖单位的、熔点至少约45℃的C14 to C30饱和polyglucosides和它们的混合物。
本发明中优先使用的结构剂选自硬脂酸,棕梠酸,cetyl alcohol,behenyl alcohol,硬脂酸,棕梠酸,平均含有约1至5个ethylene oxide单位的stearyl alcoho的polyethyleneglycol ether,平均含有约1至5个ethylene oxide单位cetyl alcohol的polyethylene glycolether,和它们的混合物。本发明更优先使用的结构剂选自stearyl alcohol,cetyl alcohol,behenyl alcohol,平均含约两个ethylene oxide单位stearyl alcohol(steareth-2)的polyethylene glycol ether,平均含约两个ethylene oxide单位cetyl alcohol的polyethyleneglycol ether,以及它们的混合物。
稠化剂(包括增稠剂和胶凝剂)Thickening Agent(including thickeners and gellig agents
本发明的配方可含一种或多种增稠剂,按适宜性递增计,含量为约0.1%至约5%,约0.1%至约4%,约0.25%至约3%,按占配方重量的百分数计。
非限制性稠化剂包括从以下选出的稠化剂:
a)羧基酸聚合物Carboxylic Acid Polymers
这种聚合物为交联化合物,含有1个或多个从丙烯酸衍生的单体,已取代的丙烯酸酸,和这些丙烯酸的盐和酯,以及已取代的丙烯酸,交联剂则含两个或多个碳-碳双键、是从polyhydric alcohol衍生出来的。本发明可用的聚合物在1992年2月11日授予acrylicacids等人的Haffey美国专利5,087,445号、1985年4月5日授予Huang等人的美国专利4,509,949号、1957年6月2日授予Brown的美国专利2,798,053号、和2002年第9版,CTFA国际化装品成分词典中有详细的描述。
市场上可买到的可用于本配方的carboxylic acid polymers例子包括carbomers,是丙烯酸与蔗糖或pentaerytritol交联而成的一种均聚物。可买到的适用的carboxylic acidpolymers例子包括carbomers,它们是丙烯酸均聚物,与蔗糖或pentaerytritol的allylethers交联。可买到的carbomers是 900系列,由B.F.Goodrich公司生产(例如 954).此外,其它适用的carboxylic酸聚合剂包括 10(B.F.Godrich公司生产)和带一个或多个丙烯酸单体,methacrylic acid,或它们一个或多条短 链(例如C1-4 alcohol)酯的C10-30 alkyl acrylates共聚物,其交联剂是蔗糖或pentaerytritol的一种allyl ether。这些共聚物称为acrylates/C10-C30 alkyl acrylate crosspolymers,可买到的是 1342, 1382,Pemulen TR-1,和Pemulen TR-2,由B.F.Goodrich生产。换句话说,本配方可以使用的carboxylic acid polymer增稠剂例子是从carbomers,acrylates/C10-C30 alkyl acrylate crosspolymers,和它们的混合物选择的。
b)交联聚丙烯酸脂聚合物Crosslinked Polyacrylate Polymers
本发明的配方可含有可作为增稠剂或胶凝剂用的交联聚丙烯酸脂聚合物polyacrylate polymers,包括阳离子cationic和非离子nonioic聚合物,通常阳离子表面活性剂cationics更适宜。适用的胶联非离子聚丙烯酸脂聚合物和交联阳离子聚丙烯酸脂聚合物的例子在以下专利中描述的例子:1992年3月31日授予Hawe等人的美国专利5,100,660号,1989年7月18日授予Heard的美国专利4,849,484号,1989年5月30日授予Farrar等人的美国专利4,835,206号,1986年12月9日授予Glover等人的美国专利4,628,078号,1986年7月8日授予等人的美国专利4,599,379号,和1987年7月15日出版的授予Farrar等人的EP 228,868。
c)聚丙烯酰胺聚合物Polyacrylamide Polymers
本发明的配方可任选地含有聚丙烯1酰胺聚合物,尤其是非离子聚丙烯1酰胺聚合物,包括已取代或未取代的有分枝或无分枝聚合物。这些聚丙烯1酰胺聚合物中更优先使用的是称为CTFA的非离子聚合物,由Seppic Corporation公司(Fairfield,N.J.)生产。本配方可使用的其它polyacrylamide polymers包括acrylamides和已由acrylic acids取代的acrylamides的多块共聚物。可买到的这些多块共聚物的例子包括Hypan SR150H,SS500V,SS500W,SSSA100H,由Lipo Chemicals公司生产(Paterson,N.J.).。
已制造好的凝胶体Ready-made gels
本配方还可含有稠化和结构化凝胶,其例子是United Guardian公司(230MarcusBlvd,Hauppauge NY 11788)生产的,称为 的产品系列。这些凝胶有湿润,粘性化,稳定化特性,可用浓度范围为1到99%之间,最好成绩是5到15%之间。
d)多聚糖Polysaccharides
可用于本配方的polysaccharides很多。″Polysaccharides″指使的是含一条重复糖(即carbohydrate)单位骨干的胶凝剂。非限制性例子是各种polysaccharide胶凝剂,包括从以下选出的胶凝剂:纤维素,羧甲基羟乙基纤维素,醋酸-丙酸织维素羧化物,羟乙基纤维素,羟乙基乙基纤维素,hydroxypropylcellulose,羟丙基甲基纤维素,甲基羟乙基纤维素,微晶纤维素,钠纤维素硫酸酯,和他们的混合物。此处也可以用的是alkyl取代的纤维素。在这些聚合物中,纤维素聚合物的hydroxy组由hydroxyalkylated(preferably hydroxyethylated or hydroxypropylated)取代、形成hydroxyalkylated纤维素,此纤维素再由C10-C30直链或支链组通过醚键进一步改性。通常,这些聚合物是带hydroxyalkyl-纤维素的C10-C30直链或支链alcohols的醚。此出可用的alkyl组包括从以下选出的例子:stearyl,isostearyl,lauryl,myristyl,cetyl,isocetyl,cocoyl(即从椰子油醇衍生出的alkyl组),palmityl,oleyl,linoleyl,linolenyl,ricinoleyl,behenyl,和它们的混合物。在这些alkyl hydroxyalkyl cellulose ethers中优先使用的有CTFA命名的cetylhydroxyethylcellulose,属cetyl alcohol和hydroxyethylcellulose的醚。此材料由Aqualon公司(Wilmington,Del.)生产,商标为 CS Plus。
其它有用的polysaccharides包括scleroglucans,是一种(1-3)linked glucose单位的线性链,每3个单位带一个(1-6)联接的glucose,市场上可买到的例子是ClearogelTM CS11,由Michel Mercier Products公司(Mountainside,N.J.).生产。
e)胶质Gums
其它可用的稠化和胶凝剂包括主要由天然来源得来的各种物质。这些胶凝剂胶的非限制性的例子包括阿拉伯树胶,琼脂,褐藻胶,alginic酸,藻酸铵,胶淀粉,藻酸钙,calcium carrageenan,肉碱,角叉胶,糊精,白明胶,洁冷胶,瓜尔胶,瓜尔豆氯化物,汉克特石,玻尿酸,含水硅石,hydroxypropyl脱乙酰壳多糖,羟丙基瓜尔胶,刺梧桐树胶,海草,刺槐豆胶,纳豆树胶,藻酸钾,钾角叉菜胶,丙撑二醇藻蛋白酸盐,菌核树胶,钠羧甲基右旋糖酐,钠角叉菜胶,黄芪胶,黄原胶,和它们的混合物。
本发明的优先配方包括一种稠化剂,此稠化剂是选自羧基酸聚合物,交联聚丙烯酸脂聚合物,聚丙烯1酰胺聚合物,和他们的混合物,更适宜的是选自羧基酸聚合物,聚 丙烯酰胺聚合物,和他们的混合物。
皮肤病学上接受的载体Dermatologically-Acceptable Carrier
本发明的配方可用于各种化妆品和/或个人护理品,例如皮肤护理,头发护理,指甲护理,面部和身体护理和遮光配方。这种产品包括洗液,凝胶体,喷剂等,洗手液,沐浴配方,晒黑油,anti-perspirant配方,香水和,冷霜,头发遮光剂配方,刮胡膏,除臭剂,表面用药膏,皮肤湿润剂,洗面奶,清洗霜,皮肤胶,洗发精,头发调节剂,清洁剂,家用清洁剂,化装产品,唇用产品,染眉毛油,和染发剂。因此,除上面引述的护肤,护发肽和其它活性剂外,本发明中所描述的化装品配方可常常含有外加成分作为皮肤病学上可接受的载体。载体的形式和四肽与任何外加活性剂和载体结合后的最终产物可以是任何形式:液体,胶体,霜,水-油或油-水乳化液,以及硅树脂乳化液,泡沫,和固体;它们可以透明或不透明;可以配制成水剂和非水剂,包括但不限于表面用制剂。
为以任何这种物理方式实现本发明,其它物质、药剂和化合物,虽然不一定必要,但还是有用的,例如调节剂、结构祭和稠化剂。这些化合物有时也有辅助作用,有时是外加成分的作用。这种作用都不会将它们排除处本发明之外,因为他们是与四肽/三肽混合物和衍生物结合使用的。.
皮肤病学上可接受的载体的性质,最终产品的性质和制备方法在此处无须详细叙述。在可获得的文献中有许多例子,如Larry R.Robinson等人2000年4月19日提出的、2000年10月26日发表的PCT申请号WO 00/62743,或更广泛的、在Milady着的、JohnWiley & Sons出版(2001年1月23日)的Standard Textbook of Cosmetology 2000(DelmarLearning出版),或Hans Mollet,Arnold Grubenmann和Helen Payne着的、XXXX出版的Formulation Technology:Emulsions,Suspensions,Solid Forms,或在 CliffordWilliams Schmitt着的,1996年7月由Dordrecht市Kluwer Academic出版社出版的Chemistry and Technology of the Cosmetics and Toiletries Industry中的例子,现都收集于本文中。Fiedler着的、Edition Cantor Verlag Aulendorf(出版社)2002年出版的Encyclopedia of Excipients,第5版对开发化妆品载体的熟练配方师也是有用的指南。这 里所说的所有成分可以以某种方法组合,形成一种皮肤病学上可以接受的载体和/或本发明的化妆品配方的一种外加成分。在多数情形下,外加成分将将包括一种皮肤病学上可接受的载体,载体单独使用或与其它外加成分结合使用。外加成分的用量,按适宜性递增计,可由约99.5%至约99.99999%,约99.9%至约99.9999%,约99.99%至约99.999%,以占配方重量的百分比计。简单地说,是配方中的余量。如载体(单独使用,或与水或复合物的共溶剂)是有用的,可占配方的整个余量。
载体的形式很多。例如,各种乳化液载体,有用的包括但不限于油--水,水-油,水-油-水,和油-水-硅乳化液。
优先用的载体含有一种乳化液、例如油-水乳化液,水-油乳化液,和油-水-硅乳化液。熟练的专家将会明白,规定的组分将分布在水或油/硅相内,依配方内该组分的水溶性/分散性而定。特别优先使用的是油-水乳化液。
按本发明,乳化液一般含有上述一种溶液和一种脂或油。脂和油可从动物,植物或石油中获得,可以是天然或合成的(例如人造的)。优先使用的乳化液还含有一种湿润剂,例如甘油。按占载体的重量计算,乳化液宜含有约0.01%至约10%、更宜的是约0.1%至约5%的乳化剂,乳化剂可以是离子性的,阴离子性的,阳离子性的。合适的乳化剂已有披露,例如1973年8月28日D授予ickert等人的美国专利3,755,560号,1983年12与20日授予Dixon等人的美国专利4,421,769号,和McCutcheon着的Detergents and Emulsifiers,North American Edition,第317-324页(1986)。
乳化液还可含有抗泡沫剂,以便涂在角质组织上时减少起泡。抗泡沫剂包括高分子硅树脂和本行业人士熟知的其它物质。
适用乳化液的粘度范围很广,粘度依所要求的产品形式而定。按适宜性递增计,优先使用的低粘性乳化液,厘其粘度约为50 centistoke或更低,10 centistokes或更低,5 centistokes或更低。
优先使用的水-硅树脂乳化液和油-水乳化液在下文中有详细的描述。
A)水-硅树脂乳化液Water-in-silicone Emulsion
水-硅树脂乳化液含有连续的硅树脂相和已分散的水相。
(1)连续硅树脂相Continuous Silicone Phase
本发明有限使用的水-硅树脂乳化液含有约1%至约60%,约5%至约40%,约10%至约20%重量的连续硅树脂相。此连续硅树脂相作为外部相存在、包容或包围在上述连续硅树脂相的外面。
此连续硅树脂相含有聚硅氧烷油。配制了优先使用的水-硅树脂乳化液系统以为类维生素A提供氧化性上稳定的媒介物。这些优先使用的乳化液的连续硅树脂相含有约50%至约99.9%重量的organopolysiloxane油,和少于50%重量的非硅脂油。在特别优先的方案中,按适宜性递增和占连续硅树脂相的重量百分比计,连续硅树脂相的polyorganosiloxane油含量为至少50%,约60%至于约99.9%,约70%至约99.9%,约80%至约99.9%,以及达50%,非硅油含量少于40%,少于30%,少于20%,少于10%,少于2%,与相当的含低浓度polyorganosiloxane油的水-油乳化液相比,这些优先乳化液系统给类维生素A提供了长期的、更高的氧化稳定性。连续硅树脂相内的非硅脂油的浓度被减少或完全避免,以进一步改善配方内的类维生素A的氧化稳定性。此种水-硅脂乳化液在1997年6月19日出版的PCT申请号WO 97/21423中有描述。
本配方内使用的organopolysiloxane油可以是挥发性的,或挥发性与非挥发性硅油的混合物。本文中,″非挥发性″指的是在环境条件下为液态切闪点(在大气压力下)高于约100℃的情形。″挥发性″指的是所有其它硅油。适用的organopolysiloxanes可从不同挥发性和粘度的各种硅油中选择。合适的organopolysiloxane油包括polyalkylsiloxanes,cyclic polyalkylsiloxanes,和polyalkylarylsiloxanes.
使用于本配方的Polyalkylsiloxanes包括约25℃时粘度为约0.5至约1,000,000centistokes的polyalkylsiloxanes。这种polyalkylsiloxanes的一般化学式为R3SiO[R2SiO]xSiR3,此处R为含有1个到30个碳原子的alkyl组组(R宜为最好是methyl或ethyl,较好是methyl;混合的alkyl组也可用在同一分子内),x为0到约10000的整数、用以达到要求的、0到10,000,000的分子量。I可买到的polyalkylsiloxanes包括:polydimethylsiloxanes、亦成为dimethicones,其例子包括General Electric公司的 系列,和Dow Corning公司的 200系列。适用的polydimethylsiloxanes具 体例子包括 200液,其粘度为0.65centistokes,沸点为100℃.;Dow 225液,其粘度为l0centistokes,沸点高于200℃.;和 200液,其粘度分别为f50,350和12,500centistokes,沸点高于200℃。合适的dimethicones之化学式为(CH3)3SiO[(CH3)2SiO]x[CH3RSiO]ySi(CH3)3,此处R为直链或支链的alkyl,具有由两个至约30个碳原子;x和y为1或大于1的整数,以达到要求的可大于10,000,000的分子量。这种alkyl-取代dimethicones的例子包括cetyl dimethicone和lauryldimethicone。
使用于本配方的环状polyalkylsiloxanes,其化学式为[SiR2-O]n,此处R为alkyl组组(R宜为methyl或ethyl,最好成绩为methyl),n为3到8、较好是3到7、最好是4到6的整数)。如R为methyl,这些物质通常称为cyclomethicones。可买到的cyclomethicones有 244液、其粘度为2.5centistokes、沸点约为172℃.,主要含cyclomethicone tetramer(即n=4); 344液,其粘度为2.5centistokes,沸点约为178℃.,主要含cyclomethicone pentamer(即n=5);Dow 245液,其粘度为4.2centistokes,沸点约为205℃.,主要含cyclomethiconetetramer and pentamer(即n=4和5)的混合物,以及 345液,其粘度为4.5centistokes,沸点约为217℃,主要含cyclomethicone tetramer,pentamer,和hexamer(即n=4,5,和6)的混合物。
可用的还有trimethylsiloxysilicate,之类的物质。这是一种聚合物质,其化学式相当于[(CH2)3SiO1/2]x[SiO2]y,此处x为约1到约500的整数,y为约1到约500的整数。可以买到的trimethylsiloxysilicate是与dimethicone的混合物,例如 593液体。Dimethiconols也可用于本配方。这些化合物的分子式为R3SiO[R2SiO]xSiR2OH andHOR2SiO[R2SiO]xSiR2OH,此出R为alkyl组组(R宜为methyl或ethyl,最好为methyl),x为0到约500的整数,用以达到要求的分子量。可买到的dimethiconols通常为与dimethicone or cyclomethicone (例如 1401,1402,和1403液fluids)的混合物。
Polyalkylaryl siloxanes亦适用于本配方。25℃时粘度为约15到约65 centistokes的 polymethylphenyl siloxanes尤其有用。
这里优先使用的是选自polyalkylsiloxanes的organopolysiloxa nes,alkyl substituteddimethicones,cyclomethicones,trimethylsiloxysilicates,dimethiconols,polyalkylarylsiloxanes,和它们的混合物。更优先的是polyalkylsiloxanes和cyclomethicones.在各种polyalkylsiloxanes中,优先的是dimethicones。
如上所述,连续硅相可含1种或多种非硅油。非硅油在连续硅相中的浓度宜低或完全没有,以进一步提高配方内的来维生素A的氧化稳定性。适用的非硅油,在约1个大气压下其熔点约为25℃或更低。适于用在连续硅相内的非硅油是为化学行业所熟知的、表面用个人护理品内所用的非硅油,其形式为水-油乳化液,例如矿物油,植物油,合成油,半合成油等等。
(2)分散水相Dispersed Aqueous Phase
本发明的表面用配方含有约30%至约90%,较好是约50%至约85%,最好是约70%至约80%的分散水相。在乳化技术上,″分散相″一词已为行业专家所熟知,意思是该相以小粒子或小滴存在、悬浮于连续相内并为连续相所包围。分散相也称为内部相或不连续相。分散水相是小水粒或小滴的分散,小水粒或小滴悬浮在上述连续硅相内并为其包围。
水相可以是水,或水与一种或多种水溶性或可分散成分的组合。这种成分的非限制性例子包括增稠剂,酸,碱,盐,螯合掩蔽剂,胶,水溶性或可分散醇和多羟基化合物,缓冲剂,防腐剂,遮光剂,染色剂,等等。
本发明的表面用配方,在其分散水相内将一般含有约25%至约90%,较好是约40%至80%,最好是约60%至约80%的水,以配方重量计。
(3)将水相分散用的乳化剂Emulsifier for Dispersing the Aqueous Phase
本发明的水-硅油乳化液宜含有乳化液。在一个优先方案中,配方含有占其重量约0.1%至约10%,较好的是约0.5%至约7.5%,最好是约1%至约5%的乳化剂。此乳化剂能帮助水相在连续硅相内分散和悬浮。
为形成优先的水-硅乳化液,有很多种乳化剂可以使用。已知的或常规的乳化剂可 以用在本配方内,只要所选的乳化剂在化学上和物理上与本发明的配方兼容并能提供要求的分散特性便可。合适的乳化剂包括表面用个人护理品专家门所知的不含硅的乳化剂,以及它们的混合物。这些乳化剂的pH值宜小于约14,较宜的是约4到14,更宜的是约4到14。HLB值超出这些范围的乳化剂可与其它乳化剂结合使用,以让该组合的有效加权平均HLB值落入这些范围内。.
硅乳化剂宜使用。此处可用的硅乳化剂很多。这些乳化剂通常是有机地改性的organopolysiloxanes,专家门亦称之为硅表面活化剂。有用的硅乳化剂包括dimethiconecopolyols。U这些物质为polydimethyl siloxanes,已改性为带有polyether侧链例如氧化polyethylene链,氧化polypropylene链,这些链的混合,和带有从ethylene oxide和propylene oxide衍生的polyether链。其它例子有alkyl-modified dimethicone copolyols,即含C2-C30侧垂链的化合物。其它可用的dimethicone copolyols包括带有各种阳离子,阴离子,两性的和两性离子下垂半族的物质。
此出可用的dimethicone copolyol乳化剂具有以下一般结构:
此处,R为C1-C30直,分支,或环状alkyl,R2选自含以下物质的组:
此处,n为0至约10的整数;R3和R4选自包含H和C1-C6直或支链alkyl的组,使R3和R4不同时为同一数值;m,o,x和y选成使分子的总分子量为约200到约10,000,000之间,而m,o,x和y独立地选成0或大于0的整数,m和o不同时为0,z独立地选成1或大于1的整数。已认识到,这些.Copolyols的位置异构体是可以实现的。含R3和R4组组的R2半族之上述化学式并不是限制性的,只是为了方便才表示成这样。
虽然未严格地分类为dimethicone copolyols,硅表面活性剂在此处也有用,其结构在前面一段中已有描述,其中R2为:
-(CH2)n-O-R5,R5为阳离子性,阴离子性,两性或两性离子的半族。
作为非限制性例子,Dimethicone copolyols和可用作乳化剂的其它硅表面活性剂包括带pendant polyethylene oxide侧链的polydimethylsiloxane polyether copolymers,带pendant polypropylene oxide侧链的polydimethylsiloxane polyether copolymers,带pendant mixed polyethylene oxide和polypropylene oxide侧链的polydimethylsiloxanepolyether copolymers,带pendant mixed poly(ethylene)(propylene)oxide侧链的polydimethylsiloxane polyether copolymers,带pendant organobetaine侧链的polydimethylsiloxane polyether copolymers,带pendant carboxylate侧链的polydimethylsiloxane polyether copolymers,带pendant quaternary ammonium侧链的polydimethylsiloxane polyether copolymers;以及上述含C2-C3直、支或环状alkyl半族的共聚物之进一步改性物。可买到的此处可用的dimethicone copolyols是Dow Corning公 司出售的 190,193,Q2-5220,2501 Wax,2-5324液,和3225C(作为与cyclomethicone的混合物出售).可买到的Cetyl dimethicone copolyol是与polyglyceryl-41sostearate(and)hexyl laurate的混合物,商标为 WE-09(Goldschmidt公司出售).市场上可买到的Cetyl dimethicone copolyol夜可以是与hexyl laurate(and)poiyglyceryl-3 oleate(and)cetyl dimethicone的混合物,商标为 WS-08 (也是Goldschmidt公司出售的).作为其它非限制性例子,二甲聚硅氧烷环包括月桂酰二甲聚硅氧烷,二甲聚硅氧烷乙酸酯,二甲聚硅氧烷己二酸盐,二甲聚硅氧烷,二甲聚硅氧烷copolyol behenate,二甲聚硅氧烷丁基醚,二甲聚硅氧烷copolyol羟基硬脂酸盐,二甲聚硅氧烷copolyol isostearate,二甲聚硅氧烷copolyol月桂酸盐,二甲聚硅氧烷copolyol甲醚,二甲聚硅氧烷copolyol磷酸盐,和二甲聚硅氧烷硬脂酸盐,见国际化妆品成分词典(International Cosmetic Ingredient Dictionary),第5版,1993.
此处可用的dimethicone copolyol乳化剂在以下文献中已有描述:例如1990年10月2日授予Figueroa打.等人的美国专利4,960,764号;授予SanoGueira的,1989年8月30日出版的欧洲专利EP 330,369号;G.H.Dahms等人着的”New Formulation PossibilitiesOffered by Silicone Copolyols,”Cosmetlcs&Toiletries出版社,11O卷,91-100页,1995年3月;M.E.carlotti等人着的”Optimization of W/O-S Emulsions And study Of TheQuantitative Relationships Between Ester Structure And Emulsion Properties,”J.Dispersionsclence And Technology出版社,13(3)卷, 315.336页(1992);P.Hameyer着的”Comparative Technological Investigations of Organic and Organosilicone Emulsifiers inCosmetic Water-in-Oil Emulsion Preparations,”HAPPI 28(4),88-128页(1991);J.smid-Korbar等人着的”Emciency and usability of silicone surfactants in emulsions,”Provisional Communication International Joumal Of Cosmetic Science,12,pp.135-139(1990);和D.G.Krzysik等人着的”A New silicone Emulsifer For Water-in-Oil Systems,”Drug and Cosmetic Industry,Vol.146(4)pp.28-8l(April 1990).
在此处有用的不含硅乳化剂中,有各种非离子和阴离子性乳化剂,如糖酯和聚酯,烷氧基化糖酯sugar esters和聚酯,C1-C30 fatty alcohols的C1-C30脂肪酸酯,C1-C30 faty alcohols的C1-C30脂肪酸酯之烷氧基化衍生物,C1-C30 fatty alcohols的烷氧基化醚,C1-C30脂肪酸的polyglyceryl酯,polyols的C1-C30酯,polyols的C1-C30醚,alkylphosphates,polyoxyalkylene fatty ether phosphates,fatty acid amides,acyl lactylates,肥皂,以及它们地混合物。其它适用的乳化剂在文献中已有描述,如:McCutcheon着的Detergents and Emulsifiers,北美版(1986),Allured Publishing Corporation出版;1991年4月30日授予Ciotti等人的美国专利.5,011,681号;1983年12月20日授予Dixon等人的美国专利4,421,769号;1973年8月28日授予Dickert等人的美国专利3,755,560号。
这种不含硅乳化剂的非限制性例子包括:polyethylene glycol 20 sorbitanmonolaurate(Polysorbate 20),polyethylene glycol 5 soya sterol,Steareth-20,Ceteareth-20,PPG-2 methyl glucose ether distearate,Ceteth-10,Polysorbate 80,cetyl phosphate,potassium cetyl phosphate,diethanolamine cetyl phosphate,Polysorbate 60,glycerylstearate,PEG-100 stearate,polyoxyethylene 20 sorbitan trioleate(Polysorbate 85),sorbitanmonolaurate,polyoxyethylene 4 lauryl ether sodium stearate,polyglyceryl-4 isostearate,hexyl laurate,steareth-20,ceteareth-20,PPG-2 methyl glucose ether distearate,ceteth-10,diethanolamine cetyl phosphate,glyceryl stearate,PEG-100 stearate,以及他们的混合物。
B)油-水(油混于水的)乳化液Oil-in-Water Emulsions
其它优先使用的表面用载体包括油-水乳化液,具有连续水相和分散在其内的憎水、不溶于水的相(″油相″)。使用的油-水乳化液载体的例子见:1991年12月17日授予Turner,D.J.等人的美国专利5,073,371号,1991年12月17日授予Turner,D.J.等人的美国专利5,073,372号。特别优先的油-水乳化液,含有结构剂,亲水表面活性剂和水,将在下文详述。
(1)结构剂Structuring Agent
优先使用的油-水乳化液含有结构剂,以帮助形成液晶凝胶网络结构。不受理论的限制,我们相信,结构剂有助于给本配方提供流变学特性,对配方的稳定性有利。结构剂还有乳化剂或表面活性剂的作用。本发明的有限配方含有约0.5%至约20%,较好的是约1%至约10%,最好成绩是约1%至约5%的结构剂,以占配方重量的百分比 计。
本发明优先使用的结构剂包括:硬脂酸,棕梠酸,stearyl alcohol,cetyl alcohol,behenyl alcohol,硬脂酸,棕梠酸,具有平均约1到约21个ethylene oxide单位的stearylalcohol的polyethylene glycol醚,具有平均约1到约5个ethylene oxide单位的cetylalcohol的polyethylene glycol醚,以及它们的混合物。本发明较优先使用的结构剂选自stearyl alcohol,cetyl alcohol,behenyl alcohol,具有平均约两个ethylene oxide单位(steareth-2)的stearyl alcohol的polyethylene glycol醚,具有平均约21个ethyleneoxide单位(steareth-21)的stearyl alcohol的polyethylene glycol醚,具有平均约两个ethylene oxide单位的cetyl alcohol的polyethylene glycol ether,以及它们的混合物。更优先使用的机构剂选自硬脂酸,棕梠酸,stearyl alcohol,cetyl alcohol,behenyl alcohol,steareth-2,steareth-21,和它们的混合物。
(2)亲水表面活性剂Hydrophilic Surfactant
优先的油-水乳化液含约0.05%至约10%,好号是约1%至约3%的至少1种表面活性剂,表面活性剂能将憎水物质分散在水相中(表面用载体重量的百分数)。表面活性剂要足够亲水,以便分散在水中。
优先的亲水表面活性剂选自非离子表面活性剂。此出有用的非离子表面活性剂中,有广义地称为长链酒精冷凝产物的非离子表面活性剂,例如带糖或淀粉聚合物的C8-C30 alcohols,即glycosides。这些化合物的分子式为(S)n-O-R,S为糖半族,如葡萄糖,果糖,甘露糖,和半乳糖;n为整数,由约1到约100,is an integer of fromabout 1 to about 1000,R为C8-C30 alkyl组组。Alkyl组组可由之验生的长链alcohols的例子包括decyl alcohol,cetyl alcohol,stearyl alcohol,lauryl alcohol,myristyl alcohol,oleyl alcohol,等等。这些表面活性剂的优先例子包括那些表面活性剂,其S是葡萄糖半族,R是C8-C20 alkyl组组,n是约1到约9的整数。可买到的这些表面活性剂的例子包括decyl polyglucoside(牌子为APG 325 CS,Henkel公司生产),和lauryl polyglucoside(牌子为APG 600 CS和625 CS,Henkel公司生产)。
其它有用的非离子表面活性剂是带脂肪酸的alkylene oxides之冷凝物(即脂肪酸的 alkylene oxide esters)。这些物质的一般分子式为RCO(X)nOH,此处R为C10-C30 alkyl组组,X为-OCH2CH2-(即来自ethylene glycol或氧化物)或-OCH2CH(CH3)-(即来自propylene glycol或氧化物),n为约6到约200的整数。其它非离子表面活性剂为带2模尔脂肪酸(即脂肪酸的alkylene oxide diesters)的alkyleneoxides之冷凝物。这些物质的分子式一般为RCO(X)nOOCR,R为a C10-C30 alkyl组组,X为-OCH2CH2-(即来自ethylene glycol或氧化物)或-OCH2CH(CH3)-(即来自propylene glycol或氧化物),n为约6到约100的整数。其它非离子表面活性剂是带fatty alcohols的alkylene oxides之冷凝物(即alkylene oxide ethers或fattyalcohols)。这些物质的一般分子式为R(X)nOR′,R为C10-C30 alkyl组组,X为-OCH2CH2-(即来自ethylene glycol或氧化物)或-OCH2CH(CH3)-(即来自propylene glycol或氧化物),n为约6到约100的整数,R′为H或a C10-C30 alkyl组组。再其它的非离子表面活性剂是同时带脂肪酸和fatty alcohols的alkylene oxides之冷凝物[即此处的polyalkylene oxide部分在一端被一个脂肪酸所酯化,另一端为一个fatyalcohol所醚化(即通过醚键联结)]。这些物质的一般分子式为RCO(X)nOR′,R and R′为C10-C30 alkyl组组,X为-OCH2CH2-(即来自ethylene glycol或氧化物)或-OCH2CH(CH3)-(来自propylene glycol或氧化物),n为约5到约100的整数。这些来自alkylene oxide的非离子表面活性剂,其例子包括ceteth-6,ceteth-10,ceteth-12,ceteareth-6,ceteareth-10,ceteareth-12,steareth-6,steareth-10,steareth-12,steareth-21,PEG-6 stearate,PEG-10 stearate,PEG-100 stearate,PEG-12 stearate,PEG-20 glycerylstearate,PEG-80 glyceryl tallowate,PEG-10 glyceryl stearate,PEG-30 glyceryl cocoate,PEG-80 glyceryl cocoate,PEG-200 glyceryl tallowate,PEG-8 dilaurate,PEG-10 distearate,和它们的混合物。
有用的其它非离子表面活性剂还有,与以下分子式相应的polyhydroxy fatty acid amide表面活性剂:
此处,R1为H,C1-C4 alkyl,2-hydroxyethyl,2-hydroxy-propyl,preferably C1-C4 alkyl,较宜的是methyl或ethyl,最好的是methyl;R2为C5-C31 alkyl或alkenyl,较宜的是C7-C19 alkyl或alkenyl,更宜的是C9-C17 alkyl或alkenyl,最好的是C11-C15 alkyl或alkenyl;Z为polhydroxyhydrocarbyl半族,具有线性hydrocarbyl链,链上带至少3个直接与链连结的hydroxyls,或它们的一个alkoxylated衍生物(最好是ethoxylated或propoxylated)。Z宜为糖半族,选自含有以下物质的组组:glucose,fructose,maltose,lactose,galactose,mannose,xylose,及其混合物.特别优先的、相应于上述结构的表面活性剂是coconut alkyl N-methyl glucoside amide(即,此处R2CO-半族来自椰子油脂肪酸)。制造含polyhydroxy fatty acid amides的配方之工艺在文献中有描述,例如Thomas Hedley & Co.,Ltd.公司1959年2月1 8日出版的英国专利规格809,060,1960年12月20日授予E.R.Wilson的美国专利2,965,576号;1955年3月25日授予Piggott的美国专利1,985,424号;1934年12月25日授予Piggott的美国专利1,985,424号。这些文献已全文收入参考文献内。
在非离子表面活性剂中,优先使用的是选自含的组:steareth-21,ceteareth-20,ceteareth-12,sucrose cocoate,steareth-100,PEG-100 stearate,和它们的混合物。
适用于此处的其它非离子表面活性剂包括sugar esters和polyesters,alkoxylatedsugar esters和polyesters,C1-C30fatty alcohols的C1-C30脂肪酸酯,C1-C30 fatty alcohols的C1-C30脂肪酸酯的alkoxylated衍生物,C1-C30 fatty alcohols的alkoxylated醚,C1-C30 脂肪酸的polyglyceryl酯,polyols的C1-C30酯,polyols的C1-C30醚,alkyl phosphates,polyoxyalkylene faty ether phosphates,fatty acid amides,acyl lactylates,和它们的混合物。作为非限制性例子,这些乳化剂包括:乙二醇20单月桂酸山梨醇酐酯(聚山梨酸酯20),聚乙二醇5黄豆固醇,steareth-20,Ceteareth 20,聚丙二醇-2甲基葡萄糖醚,ceteth-10,聚山梨酸酯80,十六基磷酸盐,十六基磷酸钾,十六基磷酸二乙醇胺,聚山梨酸酯60, 甘油基硬脂酸盐,聚氧乙烯20去水山梨糖醇三油酸酯(聚氧乙烯山梨醇脂肪酸酯85),单月桂酸山梨醇酐酯聚氧乙烯4十二烷基醚硬脂酸钠,己基月桂酸盐,聚丙二醇-2甲基葡萄糖醚,PEG-100硬脂酸盐,和它们的混合物。
此处有用的另一种组非离子表面活性剂为:基于山梨醇脂肪酸酯和脂肪酸糖酯混合物的脂肪酸酯掺合物,在每中情形下此脂肪酸均宜为C8-C24,较宜的是C10-C20。优先的脂肪酸酯乳化剂是一种掺合物,由sorbitan或sorbitol C16-C20脂肪酸酯与sucroseC10-C16脂肪酸酯、特别是去水山梨糖醇单硬脂酸酯和蔗糖组成。此乳化剂可从ICI买到,商标为Arlatone 2121。
此处可用的其它表面活性剂包括各种阳离子、阴离子、两性离子、和两性的表面活性剂,如行业内熟知的活性剂,下面将详细讨论。见例如McCutcheon着的Detergentsand Emulsifiers,北美版(1986),Allured Publishing Corporation出版;1991年4月30日授予Ciotti等人的美国专利5,011,681号;1983年12月20日授予Dixon等人的美国专利4,421,769号;1973年8月28日授予Dickert等人的美国专利3,755,560号;此4编参考文献已全文收入。此处有用的亲水表面活性剂含单一的表面活性剂,或各种合适的表面活性剂的组合。选用的表面活性剂(或多种表面活性剂)依配方和其它成分的pH值而定。
此处可用的还有阳离子表面活性剂,尤其是dialkyl quaternary ammonium化合物或″quats″。其例子见美国专利5,151,209号;美国专利5,151,210号;美国专利5,120,532号;美国专利4,387,090号;美国专利3,155,591号;美国专利3,929,678号;美国专利3,959,461号;McCutcheon′s Detergents & Emulsifiers,(北美版,1979),M.C.PublishingCo.公司出版;和Schwartz等人着的Surface Active Agents,Their Chemistry andTechnology,New York:Interscience出版社,1949;其描述已收入以供参考。此处有用的阳离子表面活性剂包括阳离子铵盐,例如具有以下分子式的铵盐:
此处,R1为带约12到30个碳原子的alkyl组组,或带约12到30个碳原子的1个aromatic、aryl或alkaryl组组;R2,R3,和R4为独立选自氢、具有约1到22个碳原子的1个alkyl组组或带有12到22个碳原子的aromatic,aryl或alkaryl组组;X为任何相容的阳离子,宜选自氯化物,溴化物,碘化物,醋酸盐,磷酸盐,硝酸盐,硫酸盐,methylsulfate,ethyl sulfate,tosylate,乳酸盐,柠檬酸盐,乙醇酸盐,和他们的混合物。此外,R1,R2,R3,和R4的alkyl组还可含有酯和/或醚键,或hydroxy或amino group取代物(例如alkyl组可含polyethylene glycol和polypropylene glycol半族)。
较适宜的是,R1为带约12到22个碳原子的alkyl组;R2选自H或带1到22个碳原子的alkyl组;R3和R4独立地选自H或带约1到3个碳原子的alkyl组;X为如上所述。
更适宜的是,R1为带约12到22个碳原子的alkyl组;R2,R3,和R4选自H或带约1到3个碳原子的alkyl组;X为如上所述。
或者,其它可用的阳离子乳化剂包括amino-amides,在上述结构中,它的R1是R5CONH-(CH2)n,R5为带约12到22个碳原子的alkyl组;n为约2到约6、较宜的是约2到约4、更宜的是约2到约3的整数。这些阳离子乳化剂的非限制性例子包括stearamidopropyl前列腺素-dimonium氯化物磷酸盐,behenamidopropyl前列腺素dimonium氯化物,stearamidopropyl ethyldimonium ethosulfate,stearamidopropyl二甲基(十四烷基乙酸酯)氯化铵,stearamidopropyl二甲基cetearyl铵甲苯磺酸盐,stearamidopropyl二甲氯化铵,stearamidopropyl二甲基乳酸铵,和他们的混合物。特别优先的是behenamidopropyl前列腺素dimonium氯化物。
季铵盐阳离子表面活性剂的非限制性例子包括选自以下物质的表面活性剂:氯化 铵,十六基溴化铵,十二烷基氯化铵,十二烷基溴化铵,硬脂酰氯化铵,硬脂酰溴化铵,十六基二甲氯化铵,十六基二甲基溴化铵,十二烷基二甲氯化铵,十二烷基二甲基溴化铵,硬脂酰二甲氯化铵,硬脂酰二甲基溴化铵,十六烷基三甲基氯化铵,十六浣基三甲基溴化铵,十二烷基三甲基氯化铵,十二烷基三甲基溴化铵,硬脂酰三甲基氯化铵,硬脂酰三甲基溴化铵,十二烷基二甲氯化铵,硬脂酰二甲基十六基ditallow二甲氯化铵,联十六烷基氯化铵,联十六烷基溴化铵,dilauryl氯化铵,dilauryl溴化铵,distearyl氯化铵,distearyl溴化铵,联十六烷基甲基氯化铵,联十六烷基甲基溴化铵,dilauryl甲基氯化铵,dilauryl甲基溴化铵,distearyl甲基氯化铵,distearyl甲基溴化铵,以及它们的混合物。另外的季铵盐包括:C12 to C30 alkyl碳链来自牛脂脂肪酸或椰子脂肪酸的季铵盐。牛脂指的是从牛脂脂肪酸(通常为hydrogenated牛脂脂肪酸)衍生的alkyl组,在C16 to C18范围内通常有alkyl链的混合物。″椰子″指的是从椰子脂肪酸衍生的alkyl组,在C12 to C14的范围内通常带有alkyl链的混合物。从牛脂和椰子衍生的季铵盐的例子包括:ditallow二甲氯化铵,ditallow二甲基铵硫酸二甲酯,二(氢化脂)二甲氯化铵,二(氢化脂)二甲基乙酸铵,ditallow二丙基磷酸铵,ditallow二甲基硝酸铵,二(coconutalkyl)二甲氯化铵,二(coconutalkyl)二甲基溴化铵,油脂氯化铵,椰子氯化铵,stearamidopropyl前列腺素-dimonium氯化物磷酸盐,stearamidopropyl ethyldimonium ethosulfate,stearamidopropyl二甲基(十四烷基乙酸酯)氯化铵,stearamidopropyl二甲基cetearyl铵甲苯磺酸盐,stearamidopropyl二甲氯化铵,stearamidopropyl二甲基乳酸铵,以及它们的混合物。带酯键的alkyl组之季铵化合物的例子是ditallowyl oxyethyl dimethyl ammoniumchloride.。
更优先的阳离子表面活性剂是选自以下物质的表面活性剂:behenamidopropyl前列腺素dimonium氯化物,dilauryl二甲氯化铵,distearyl二甲氯化铵,dimyristyl二甲氯化铵,dipalmityl二甲氯化铵,distearyl二甲氯化铵,stearamidopropyl前列腺素-dimonium氯化物磷酸盐,stearamidopropyl ethyldiammonium ethosulfate,stearamidopropyl二甲基(十四烷基乙酸酯)氯化铵,stearamidopropyl二甲基cetearyl铵甲苯磺酸盐,stearamidopropyl二甲氯化铵,stearamidopropyl二甲基乳酸铵,以及他们的混合物。 最优先的阳离子表面活性剂是选自以下物质的表面活性剂:behenamidopropyl前列腺素dimonium氯化物,dilauryl二甲氯化铵,distearyl二甲氯化铵,dimyristyl二甲氯化铵,dipalmityl二甲氯化铵,以及它们的混合物。
阳离子表面活性剂和结构剂的优先组合是behenamidopropyl PG dimonium chloride和/或behenyl alcohol,起比例宜加以优化并保持,以提高物理化学稳定性,特别是这种组合含有离子和/或高极溶剂时。对输送遮光剂如氧化锌和octyl methoxycinnamate,此组合特别有用。
阴离子表面活性剂在此处也有用。见例如1975年12月30日授予Laughlin等人的美国专利3,929,678号此处已全文收入供参考。阴离子表面活性剂的非限制性例子包括alkoyl isethionates,以及alkyl和alkyl ether sulfates。Alkoyl isethionates的分子式通常为RCO-OCH2CH2SO3M,此处R为带约10到约30个碳原子的alkyl或alkenyl,M为水溶性阳离子。如铵,钠,钾和triethanolamine。这种isethionates的非限制性例子包括从以下物质来的isethionates:选自ammonium cocoyl isethionate的alkoylisethionates,sodium cocoyl isethionate,sodium lauroyl isethionate,sodium stearoylisethionate,和它们的混合物。
Alkyl and alkyl ether sulfates的分自式通常分别为:ROSO3M和RO(C2H4O)xSO3M,,此处R为带有约10到约30个碳原子的alkyl或alkenyl,x为约1到约10,M为水溶性厌离子如铵,钠,钾和triethanolamine。另一类合适的阴离子表面活性剂是具有以下分子式的有机,硫酸反应产物的水溶性盐:
R-SO3-M
此处,R1为选自带直链或支链的该组,带约8到24、最好是约10到16个碳原子的饱和脂肪族羟根;M为阳离子。其它阴离子合成表面活性剂还有:称为succinamates那类表面活性剂,带约12到约24个碳原子的olefin sulfonates,和-alkyloxy alkanesulfonates。这些物质的例子是sodium lauryl sulfate和ammonium lauryl sulfate。
此处可用的其它阴离子材料有:脂肪酸肥皂(即alkali metal salts,例如纳盐或钾盐),通常带有约8到约24、最好是约10到约20个碳原子。制造肥皂用的脂肪酸可天然材料获得,例如来自植物或动物的甘油脂(例如棕榈油,椰子油,大豆油,蓖麻油,牛脂,猪油等)。脂肪酸可用合成法制备。肥皂在美国专利4,557,853号中有描述。
两性表面活性剂和两性离子表面活性剂在这里也有用。可用于本发明配方的两性表面活性剂和两性离子表面活性剂的例子有:广泛描述为脂肪族第二和第三胺的衍生物的表面活性剂,其脂烦族根可以是直链或支链,其中一个脂肪族取代基含有约8到约22个碳原(为C8-C18)、一个含有1个阴离子水溶性组,例如carboxy,sulfonate,sulfate,phosphate,or phosphonate。例子是alkyl imino acetates;分子式为RN[CH2]mCO2M]2 andRNH(CH2)mCO2M的iminodialkanoates和aminoalkanoates,此处m为1到4,R为C8-C22 alkyl or alkenyl,M为H,alkali metal,alkaline earth metal ammonium,或alkanolammonium。Imidazolinium and铵衍生物也包括在内。适用的两性表面活性剂的具体例子包括sodium 3-dodecyl-aminopropionate,sodium 3-dodecylaminopropanesulfonate;N-alkyltaurines,如美国专利2,658,072所说的、用sodium isethionate以达到dodecylamine的方法制备的活性剂,此专利已全文收入做参考;N-higher alkyl asparticacids如按美国专利2,438,091号所说的办法制备的活性剂,次专利已全文收入;以及美国专利2,528,378好所描述的、,商标为″Miranol″的产品,此专利已全文收入。有用的其它两性表面活性剂包括phosphates,例如coamidopropyl PG-dimonium chloridephosphate(商标为Monaquat PTC,Mona公司生产)。
此处有用的其它两性表面活性剂和两性离子表面活性剂包括甜菜碱。甜菜碱的例子包括higher alkyl甜菜碱,如coco dimethyl carboxymethyl甜菜碱,lauryl dimethylcarboxymethyl甜菜碱,lauryl dimethyl alphacarboxyethyl甜菜碱,cetyl dimethylcarboxymethyl甜菜碱,cetyl dimethyl甜菜碱(商标为Lonzaine 16SP,Lonza公司生产),lauryl bis-(2-hydroxyethyl)carboxymethyl甜菜碱,stearyl bis-(2-hydroxypropyl)carboxymethyl甜菜碱,oleyl dimethyl gamma-carboxypropyl甜菜碱,laurylbis-(2-hydroxypropyl)alpha-carboxyethyl甜菜碱,coco dimethyl sulfopropyl甜菜碱, stearyl dimethyl sulfopropyl甜菜碱,lauryl dimethyl sulfoethyl甜菜碱,laurylbis-(2-hydroxyethyl)sulfopropyl甜菜碱,以及amidobetaines和amidosulfobetaines(此处RCONH(CH2)3根附在甜菜碱的氮原子上),oleyl甜菜碱(商标为两性VelvetexOLB-50,Henkel公司生产),和cocamidopropyl甜菜碱(商标为Velvetex BK-35和BA-35,Henkel公司生产)。
其它有用的两性表面活性剂和两性离子表面活性剂包括sultaines和hydroxysultaines如cocamidopropyl hydroxysultaine(商标为Mirataine CBS,Rhone-Poulenc公司生产);以及分子式为RCON(CH3)CH2CH2CO2M的alkanoylsarcosinates,此处R为带约10到约20个碳原子的`alkyl或alkenyl,M为水溶性阳离子如铵,钠,钾和trialkanolamine(例如,triethanolamine),有限的例子为sodium lauroylsarcosinate。
当所用的表面活性剂为含季氮的化合物(″quat″)时,或按照本发明的优先方案、确实将quat物质用在配方或产品内时,可用阳离子的活性来衡量quat的实际用量。在quat方面,用阳离子活性来讨论是合适的。阳离子活性可通过几种方法测量,这些方法很容易为业内专家理解。一种方法是利用阴离子物质的标准溶液,如sodium laurylsulfate。将此物质加入含quat的溶液内,到quat的阳离子全部配位(终点)为止。终点可用电位计测量或用颜色指示器测量。
在典型的试验中要用sodium lauryl sulfate标准溶液进行quat样品的滴定,直到到达终点为止,样品通常溶解在溶剂内。如已全文收入此处的、待批准和共同授予的美国专利申请09/438,631号所说的那样,一旦达到终点,阳离子活性可按以下公式计算:
此处:mL=阴离子物质的毫升数
N=所用溶液的常态
MW=被化验的quat的当量分子量
S.wt.=样品重量,克
关于测量阳离子活性的其它资料,见:W.Schempp and H.T.Trau,Wochenblatt furPapierfabrikation 19,1981,pages 726-732,或J.P.Fischer and K.Lohr,Organic CoatingsScience Technology,Volume 8,pages 227-249,Marcel Dekker,Inc.April 1986),均已全文收入本处作参考。如想所用的quat原材料具有高的阳离子活性(至少约35%,最好是约50%),也可以设想用较低的阳离子活性,特别是总阳离子活性低于25%、低于10%、甚至低于5%的成品。
(3)水Water
优先的油-水乳化液含约25%至约98%、较好是约65%至95%、最好是约70%至90%的水,以占表面用载体的重量百分数计。
憎水相分散在连续水相内。The hydrophobic phase is dispersed in the continuousaqueous phase.憎水相可含水溶性或部分水溶性物质,如业内人士所知的那些,包括但不限于本处所就油-水乳化液所描述的硅酯,以及其它油和油脂例如上文就乳化液所描述的那些。
本发明的表面用配方,包括但不限于洗剂和霜,和含有皮肤病学上可接受的润肤剂。这种配方宜含约1%到约50%的润肤剂。此处所用的″润肤剂″指的是用来防止或减轻干燥的物质,以及用来保护皮肤的物质。已知的而且本处可用的润肤剂有很多种。作为参照而收入本文作为参考文献的Sagarin,Cosmetics Science and Technology,第2版,卷1,32-43页(1972)讲了适于作为润肤剂的许多物质作为例子。优先使用的润肤剂是甘油。甘油的用量宜为约0.001至约30%,较宜的是约0.01至约20%,最好的是约0.1至约10%,例如,5%。
合适的润肤剂的例子包括C8-C30 carboxylic酸的C8-C30 alkyl酯;C8-C30 carboxylic酸的C1-C6二醇单酯和二酯;C8-C30 carboxylic酸的甘油一酸酯,甘油二酯,和甘油三酸酯,C8-C30 carboxylic酸的cholesterol酯,胆固醇,和羟。这些物质的例子包括二异丙基己二酸盐,十四烷酸异丙酯,棕榈酸异丙酯,乙基己基棕榈酸,异癸 neopentanoate,c12-15醇类苯(甲)酸盐,diethylhexyl顺丁烯二酸,聚丙二醇-14丁基醚,聚丙二醇-2十四烷基醚丙酸,十六基蓖麻醇酸酯,硬脂酸胆甾醇,胆固醇isosterate,乙酸胆甾醇,希蒙德木油,可可脂,牛油树脂,羊毛脂,羊毛脂酯类,矿物油,石油冻,以及直链和支链的C16-C30羟。直链和支链fatty C8-C30 alcohols也有用,例如十八醇,isostearyl酒精,乙烯基酒精,鲸蜡醇,isocetyl酒精,以及它们的混合物。其它适用的润肤剂的例子包括美国专利US4,919,934好所披露的润肤剂,该专利已全文收入本文作参考。
其它合适的润肤剂是各种alkoxylated醚,二醚,酯,二酯,和trimesters(三酯?).。适用的alkoxylated醚的例子包括聚丙二醇-10丁基醚,聚丙二醇-11丁基醚,聚丙二醇-12丁基醚,聚丙二醇-13丁基醚,聚丙二醇-14丁基醚,聚丙二醇-15丁基醚,聚丙二醇-16丁基醚,聚丙二醇-17丁基醚,聚丙二醇-18丁基醚,聚丙二醇-19丁基醚,聚丙二醇-20丁基醚,聚丙二醇-22丁基醚,聚丙二醇-24丁基醚,聚丙二醇-30丁基醚,聚丙二醇-11硬脂酰醚,聚丙二醇-15硬脂酰醚,聚丙二醇-10油烯基醚,聚丙二醇-7十二烷基醚,聚丙二醇-30isocetyl醚,聚丙二醇-10甘油基醚,聚丙二醇-15甘油基醚,聚丙二醇-10丁二醇醚,聚丙二醇-15丁二醇醚,聚丙二醇-27甘油基醚,聚丙二醇-30十六基醚,聚丙二醇-28十六基醚,聚丙二醇-10十六基醚,聚丙二醇-10己二醇醚,聚丙二醇-15己二醇醚,聚丙二醇-10 1,2,6-hexanetriol醚,聚丙二醇-15 1,2,6-hexanetriol醚,以及它们的混合物。Alkoxylated二醚的例子包括聚丙二醇-10 1,4-丁二醇二醚,聚丙二醇-12 1,4-丁二醇二醚,聚丙二醇-14 1,4-丁二醇二醚,聚丙二醇-2丁二醇二醚,聚丙二醇-10 1,6-己二醇二醚,聚丙二醇-12 1,6-己二醇二醚,聚丙二醇-14己二醇二醚,聚丙二醇-20己二醇二醚,以及它们的混合物。优先使用的是:从含聚丙二醇-10 1,4-丁二醇二醚,聚丙二醇-12 1,4-丁二醇二醚,聚丙二醇-10 1,6-己二醇二醚,聚丙二醇-12己二醇二醚的组选出的alkoxylated二醚,以及它们的混合物。
适用的alkoxylated二酯和trimesters(三酯)的例子在美国专利5,382,377,5,455,025和5,597,555号中已讲到,这些专利是授予Croda Inc.公司的,此处已收入作参考。
使用的适用油脂包括c8-c20酒精monosorbitan酯类,c8-c20酒精山梨糖醇酐二酯类,c8-c20酒精山梨糖醇酐三酯物,c8-c20酒精蔗糖单酯,c8-c20酒精蔗糖二酯类,c8-c20酒精蔗糖三酯物,双着丝点的-c62-羟基c8-c20脂肪族醇酯类,特别适用的油脂的例子是山梨糖醇酐diisostearate,去水山梨糖醇二油酸酯,山梨糖醇酐distearate,山梨糖醇酐isostearate,去水山梨糖醇月桂酸酯,去水山梨糖醇单油酸酯,去水山梨糖醇单棕榈酸酯,山梨糖醇酐sesquioleate,山梨糖醇酐sesquistearate,去水山梨糖醇单硬脂酸酯,山梨糖醇酐triisostearate,去水山梨糖醇三油酸酯,orbitan三硬酯酸盐,蔗糖cocoate,sucrodilaurate,蔗糖二硬脂酸酯,蔗糖月桂酸盐,蔗糖十四酸盐,蔗糖油酸盐,蔗糖棕榈酸,蔗糖蓖麻醇酸酯,蔗糖硬脂酸盐,蔗糖tribehenate,蔗糖三硬酯酸盐,十四烷基分泌乳汁,硬脂酰分泌乳汁,isostearyl分泌乳汁,十六基分泌乳汁,棕榈基分泌乳汁,cocoyl分泌乳汁,以及它们的混合物。
其它适用的润肤剂包括矿物油,石油,胆固醇,二甲聚硅氧烷,dimethiconol,十八醇,鲸蜡醇,山俞醇,二异丙基己二酸盐,十四烷酸异丙酯,十四烷基十四酸盐,十六基蓖麻醇酸酯,山梨糖醇酐distearate,山梨糖醇酐dilaurate,去水山梨糖醇单硬脂酸酯,去水山梨糖醇月桂酸酯,蔗糖月桂酸盐,蔗糖dilaurate,钠isostearyl lactylate,十二烷基pidolate,聚丙二醇-14丁基醚,聚丙二醇-15硬脂酰醚,以及它们的混合物。
按照本发明,洗剂和霜通常含有溶液载体系统和1中或多种润肤剂。洗剂和霜通常含有约1%至约50%,更宜的是约1%至约20%的润肤剂;约50%至约90%,更宜的是约60%至约80%的水;四肽与三肽混合物和可选的外加护肤活性剂之用量如上述。霜通常比洗剂稠,因为它含有较多的润肤剂或增稠剂。
本发明中的药膏可含动物油或植物油的简单载体基,或半固体的羟(油质的);能吸收水以形成乳化液的吸收膏基;或水溶性载体例如水溶性溶液载体。药膏还可含有稠化剂和/或润肤剂,例如Sagarin,Cosmetics,Science and Technology,2nd Edition,Vol.1,pp.72-73(1972)所描述的稠化剂,该文以收入作参考。例如,药膏可含约2%至约10%的润肤剂,和约0.1%至约2%的稠化剂,四肽与三肽混合物和可选的外加护肤活性剂的含量如上述。
可用于清洗的本发明配方(清洗剂)带有合适的载体,例如上述的载体;除上述用量的四肽与三肽混合物和外加护肤活性剂外,宜含约1%至约90%,较宜的是约5%至约10%的皮肤病学上可接受的表面活性剂。表面活性剂最好选自anionic,nonionic,zwitterionic,amphoteric和ampholytic表面活性剂,以及它们的混合物。这些表面活性剂已为去垢专家所熟知。可用的表面活性剂的非限制性例子包括isoceteth-20,sodiummethyl cocoyl taurate,sodium methyl oleoyl taurate,和sodium lauryl sulfate.关于本处可用的表面活性剂的例子,见1989年1月24日授予Kowcz等人的美国专利4,800,197号,该文已全文收集作参考。此处可用的各类外加表面活性剂见McCutcheon着的Detergents and Emulsifiers,北美版(1986),此书由Allured Publishing Corporation出版公司出版。清洗配方可或可不含常规清洗配方用的其它物质,其含两按行业成熟的用量水平。
清洗配方的物理形状并不很重要。例如,配方可配成梳妆条(toilet bars)状,液体,洗发水,沐浴液,头发调节剂,养发剂,糊,或摩丝(mousses)。漂洗用清洗配方,例如洗发水,要有一个足以是活性剂积存在皮肤或头上的输送系统。宜用的输送系统需要使用不溶性配合物。关于这种输送系统,更完整的说明见1989年5月30日授予Barford等人的美国专利4,835,148号。
本处使用的″基础层(foundation)″一词,指的是液体,半液体,半固体,或固体皮肤化装品,包括但不限于,洗剂,霜,凝胶,糊,糕之类。通常,基础层用在大面积皮肤上,例如面部,以便好看。基础通常用来给胭脂、红彩、粉之类彩色化妆品提供附着基础,意在隐藏皮肤缺陷并给皮肤加上光滑均匀的外表。本发明的基础层包括皮肤病学上可接受的载体,可包括常规的成分如油,颜料,色料,润肤剂,香料,蜡,稳定剂等。可用于本处的载体和该其它成分的例子,见1996年10月31日公布的、授予Canter等人的WO 96/33689号PCT申请;和1994年8月3日英国专利GB 2274585号。
有限方案含四肽A preferred embodiment contains the tetrapeptide氨基乙酸-谷酰胺-Pro-精氨酸(链区识别号:3),它的类似物和它的N--Acyl-验生物,三肽氨基乙酸-组氨酸-赖氨酸,它的类似物和它的N-Acyl-derivatives,和皮肤病学上可接受的载体。特别 是,配方可含N--acyl-tetrapeptide N-棕榈酰-氨基乙酸-谷酰胺-Pro-精氨酸(SEQ ID NO:3),N-acyl-tripeptide N-棕榈酰-氨基乙酸-组氨酸-赖氨酸,和皮肤病学上可接受的载体。
如用在本配方中,外加的肽的用量宜约0.1ppm(0.00001%)至约5,000ppm(0.5%),更好是约1ppm至约100ppm(0.01%),以占配方重量的百分数计。本发明的配方还可含头发定形剂,以给头发定形。固发用的聚合物可以是均聚物,共聚物,三元共聚物等。为便于说明这些聚合物,聚合物内的单节异性单位可称为单体,即可衍生出聚合物的单体。单体可以是离子单体(例如阴离子,阳离子,两性的,两性离子的单体)
阴离子单体的例子包括未饱和unsaturated carboxylic酸单体如acrylic酸,甲基丙烯酸,maleic酸,maleic酸半酯,itaconic酸,fumeric酸,和crotonic酸;未饱和polybasic酸anhydride的半酯如succinic anhydride,phthalic anhydride和带hydroxyl组例如hydroxyethyl acrylate和/或methacrylate如hydroxyethy4 acrylate的此类物质,以及hydroxyethyl methacrylate,hydroxypropyl acrylate和类似物质;带有一个sulfonic acid组例如styrenesulfonic acid,sulfoethyl acrylate and methacrylate,和类似物质的单体;带一个磷酸组例如acid phosphooxyethyl acrylate和methacrylate的单体,3-chloro-2-acidphosphooxypropyl acrylate和methacrylate,等等。
阳离子单体的例子包括从acrylic acid或methacrylic acid衍生的单体,以及在alkyl内带1至5个碳原子的、季化的epihalohydrin产物,如(meth)acryloxypropyltrimethylammonium chloride和(meth)acryloxypropyltriethylammonium bromide;methacrylic acid的胺衍生物或从methacrylic acid or methacrylamide a衍生的胺衍生物,以及带有C1-C6 alkyl组的dialkylalkanolamine如dimethylaminoethyl(meth)acrylate,diethylaminoethyl(meth)acrylate,dimethylaminopropyl(meth)acrylate,或dimethylaminopropyl(meth)acrylamide.
两性单体的例子包括上述(meth)acrylic acids胺衍生物或(meth)acrylamide胺衍生物的两性离子化衍生物,此(meth)acrylamide胺衍生物如dimethylaminoethyl(meth)acrylate,dimethylaminopropyl(meth)acrylamide、是由一种halogenated脂肪酸盐衍生的,此脂肪 酸盐例如是potassium monochloroacetate,sodium monobromopropionate,monochloroacetic酸的aminomethylpropanol盐,monochloroacetic酸的triethanolamine盐之类;以及经过改性的、上述(meth)acrylic酸或(meth)acrylamide的胺衍生物。
非离子单体的例子有C1-C24 alcohols的acrylic或methacrylic酸酯,例如甲醇,乙醇,1-pro57--panol,异丙醇,1-丁醇,异丁醇,1-戊醇,2-戊醇,3-戊醇,甲基二恶戊烷-丁醇,1-甲基1-丁醇,3-甲基1-丁醇,1-甲基1-戊醇,甲基二恶戊烷-戊醇,3-甲基1-戊醇,叔丁醇,环己醇,2-乙(基)1-丁醇,3-庚醇,苯甲醇,2-辛醇,6-甲基1-庚醇,2-乙(基)正己醇,3,5-二甲基正己醇,3,5,5-三甲基-正己醇,1-癸醇,1-十二烷醇,1-十六醇,1-十八碳醇,苯乙烯,氯代苯乙烯,乙烯基酯,例如甲醇,乙醇,1-pro57--panol,异丙醇,1-丁醇,异丁醇,1-戊醇,2-戊醇,3-戊醇,甲基二恶戊烷-丁醇,1-甲基1-丁醇,3-甲基1-丁醇,1-甲基1-戊醇,甲基二恶戊烷-戊醇,3-甲基1-戊醇,叔丁醇,环己醇,2-乙(基)1-丁醇,3-庚醇,苯甲醇,2-辛醇,6-甲基1-庚醇,2-乙(基)正己醇,3,5-二甲基正己醇,3,5,5-三甲基-正己醇,1-癸醇,1-十二烷醇,1-十六醇,1-十八碳醇,苯乙烯,氯代苯乙烯,乙烯基和异丁烯酸,油烯基丙烯酸盐和异丁烯酸,丙烯酸苄酯和异丁烯酸,四氢化糠基丙烯酸盐和-异丁烯酸,1,3-丁二醇二丙烯酸盐和-异丁烯酸,diacetonacrylamide,异冰片基(甲基安非他明)丙烯酸盐,正丁基异丁烯酸,异丁烯酸异丁脂,2-乙基己基异丁烯酸,异丁烯酸甲酯,t-butylacrylate,t-butylmethacrylate,和它们的混合物。
离子性头发定型聚合物的例子有vinyl acetate和crotonic酸的共聚物,vinylacetate,crotonic acid和带α支链的饱和aliphatic monocarboxylic酸例如vinylneodecanoate的vinyl ester三元共聚物;以及methyl vinyl ether与maleic anhydride的共聚物,acrylic共聚物,和含acrylic酸或methacrylic酸的三元共聚物。
阴离子性头发定型聚合物的例子为如下物质组成的共聚物:amino-functionalacrylate单体如lower alkylamino alkyl acrylate、或methacrylate单体如dimethylaminoethylmethacrylate;与相容的以下单体共聚:例如N-vinylpyrrolidone或alkylmethacrylates例如methyl methacrylate及ethyl methacrylate,和ethyl methacrylate及 alkyl acrylates如methyl acrylate和butyl acrylate。
本发明的配方也可含多种其它成分。这些适用的其它成分中有些被同时用于化妆品和个人护理品工业,这些成分在The CTFA Cosmetic Ingredient Handbook(CTFA化妆品成分手册),(2002年第9版)中有描述,兹收入本处作参考。这些成分按常规用量使用。
配方Compositions
按本发明,配方的物理形式并不重要:霜,洗剂,药膏,凝胶,乳化液,分散液,悬浮液,清洗剂,基层,无水制剂(条状,尤其是唇膏条,身体和沐浴用油),淋浴和沐浴用凝胶,洗液,洗发水和头皮处理洗剂,皮肤″香精″浆液,粘附或吸收材料,透入皮肤的贴片,粉等均可带有四肽/三肽混合物、它们的类似物和衍生物、以及这些化合物与其它外加成分的组合物。
本发明还会有许多用途。首先,本发明可作为四肽和三肽的混合物用于化妆品或个人护理品中,并用于化装和个人护理的用途。特别是,按本发明制造的产品可用来帮助减轻可见的老化迹象、包括所有外部可见的可暗中感触到的表现,以及因皮肤老化而智的其它宏观或微观结果。这种征象可由内在或外在因素引起或造成。用本发明来减少这些征象可以是一般地,也可以是特定地用来减少可见的以下征象的发展:组织不连续,皮肤上的线,裂纹,肿块,大孔或皮肤不平整或粗糙,皮肤失去弹性,下垂,皮肤不坚实,皮肤不紧密,皮肤变形后不反弹,褪色,起斑点,菜色,皮肤许多区域颜色过深,角质,不正常差别,过度角化,弹性组织变性,胶原破坏,伸长痕,黑斑圈等。为这些化装目的而使用这些处方会造成皮肤的某种长期变化,但常常会造成各种征象的可见表现的更短时减少。
本发明还可用来制造能预防性地或疗法上调节皮肤状况例如老化迹象、黑斑圈和伸张痕的药物。此种调节包括延迟、减少或防止可见或可感触的不连续。通常,但不时唯一地,这些用处是某些更长期疗法用途的一部分,而不仅是化装或个人护理用途。因此,本皮肤护理配方可用来制造药物,通过此种药物的使用,用于减少需要此种治疗的人的皮肤可见老化怔象,与病人的(使用本发明前的)正常水平相比、减少皱纹和/或增强胶原合成。
改善皮肤状况的方法Methods for Improving Skin Condition
本发明的配方可用于防止和/或减少可见的老化征象,改善皮肤或头发的状况和外观。此种防止和改善包括皮肤的预防性和护理性处理。例如,这些方法意在使皮肤各层和各组织变厚,防止皮肤皮肤变薄,防止或延迟皱纹出现,提高皮肤坚实度和弹性,使嘴唇、头发和指甲变软和/或变光滑,防止和/或减轻骚痒,较少皱纹和洗线,减少伸张痕和黑斑圈,和/或激起胶原I的合成。
此一改善皮肤外观的方法是将有效数量的本发明配方外部使用地涂在皮肤或头发上。所需的数量,使用频率和使用时期取决于配方内四肽/三肽、类似物或衍生物的含量,和与其它外加成分的具体组合,外加成分可是例如药物学上的活性剂、维生素、alphahydroxy酸、等等,以及要求的化装效果的高低。
最好的是,本发明的配方涂在皮肤或头发上,每天1~2次,长期使用,至少1星期,或1个月,3个月,6个月,1年,以长者为好。
每次涂在皮肤上的本配方或产品的数量,宜在约0.1mg/cm2至约10mg/cm2之间。按此方法,可将配方涂在皮肤上并让它留在那里;配方的形式可以是皮肤洗剂,霜,凝胶,泡沫,油膏,糊,乳化液,喷剂,调节剂,滋补剂,化妆品,唇膏,基础层,指甲油,刮胡后用的膏,等等。本配方可用抹刀,抹具或类似的化装工具人工地涂上。也可以用闭塞或半闭塞的贴片,粘附性或非粘附性纸来施用。
实施例子Examples
以下例子进一步说明和论证了本发明范围内的各种实现方案。这些例子只是为了说明的目的,并不能理解为本发明的界限。因为只要不离开本发明的精神和范围,方案会有许多变化。
例1:抗皱纹夜用霜
产品 INCI名称 %
A相
H2O 70.95
Ultrez 10 Carbomer 0.15
B相
甘油Glycerine 甘油 3.50
C相
VolpoS2 Steareth 2 0.40
Crodafos CES Cetearyl alcohol dicetyl
phosphate & ceteth
10phosphate 4.00
DC 345 Cyclohexasiloxane 2.00
Crodamol OSU Dioctyl succinate 7.00
Volpo S10 Steareth 10 1.20
Nipastat Mixed parabens 0.30
D相
山梨酸酯Sorbate 山梨酸酯 0.10
E相
H2O 2.50
NaOH 38% Sodium hydroxyde 0.30
F相
香水Perfume 香料Fragrance 0.10
G相
此乳化液的配制方法如下:A相:将Ultrez 10分散在水内并让他膨胀20分钟,然后加入B相;加热至75C°B;将C相单独加热至75℃。将此两相混合并搅拌均匀,加入D相,用E相中和,冷却至30℃,然后加入F相和G相,用NaOH调整至pH~6。
由SEDERMA公司出售,公司地址为,29rue du chemin vert-BP 33。78612 Le Perray-en-Yvelines cedex France;次药含有:butylene glycol,carbomer,polysorbate-20,N-棕榈酰-氨基乙酸-谷酰胺-Pro-精氨酸(序列识别号:3)和N-棕榈酰-氨基乙酸-组氨酸-赖氨酸.四肽的浓度为0.005%(重量/重量),三肽的浓度为0.01%,故在该例中三肽的量为0.0003%,四肽的量为0.00015%。
所得的乳化液应适用于脆的、老化了的皮肤,改善细线、皱纹和干燥,减少发红和骚痒。
例2:减少眼周围的皱纹(在体内)Decrease in the wrinkles around the eyes(in vivo)
15位眼周有皱纹的中年女志愿者参加了使用例1的霜的一项研究。眼边的皱纹通过调查表以自我评估计方式和标准的皮肤复制法来衡量。简单地说,此法是将聚合物涂到眼区上,硬化后可将此聚合物剥去、露出皮肤表面的一个″负″轮廓。然后用轮廓仪器测量皱纹深度、长度、容积等。然后,按科目,由参加者将例1的霜产品涂在1只眼的目标区域,每天2次,共56天;另一只眼则涂不含肽的对照物。所涂的量依科目而异。不过,两眼的用量应一致。复制品的测定从0天到56天均进行。结果表明,在涂过例1的处方的眼区,皱纹大大减少,深度减少达60%。而且,此中减少为肉眼可见,而用不含肽的同一种霜处理的区域在皮肤老化征象上无重要改善。
例3:提高胶原合成(体外)Increase in synthesis of collagen(in vitro)
在有肽N-棕榈酰-氨基乙酸-谷酰胺-脯氨酸-精氨酸(序列识别号:3)存在的情况下,将人皮肤纤维原细胞在富集有维生素C(1.5和15ppm)的两种培养基内培养72小时,肽的浓度有两种,即2.5ppm和3.6ppm。培养后,将培养基收集起来,用MTT化验法评估细胞的生存能力。然后由ELISA进行每个细胞溶解产物的胶原测定。试验进行3次。
与此同时,应在同一条件下但无肽时进行负对照物的测试。
下面表2的结果表,与空白(无肽)试验相比,明胶原合成增加:
表2
例4:带皮肤变白作用的抗皱纹霜Anti-wrinkle cream with skin whitening activity
成分Ingredients %by wt
去离子水Water Deionised - qs 100
Carbomer - 0.10
山梨酸钾Potassium Sorbate - 0.10
Transcutol - 3.00
甘油Glycerin Croda 8.00
Volpo S2[Steareth 2] Croda 0.60
Crodafos CES[Cetearyl Alcohol(and)
Dicetyl Phosphate(and)Ceteth 10 Phosphate] Croda 4.00
DC 344[Cyclomethicone] Dow Corning 2.00
Crodamol GTCC[Caprylic/Capric Triglyceride] Croda 10.00
Crill 3[Sorbitan Stearate] Croda 1.60
Mixed Parabens - 0.30
氢氧化钠Sodium Hydroxide 30% - 0.35
去离子水Water Deionised - 3.50
MATRIXYL Sederma 3.00
[Glycerine(and)Butylene Glycol(and)
Arcostaphylus uva leaf extract and Mitracarpus
Scaber extract]*) Sederma 3.00
是一种皮肤增亮成分,有SEDERMA公司出售(1996年11月19日授予的专利WO 98/05299)。此处方可按例1所述的方法配制。
例5:抗伸张痕霜Anti Stretch-Mark Cream
成分Ingredients %by wt
组分A
去离子水Water Deionised - qs 100
Ultrez 10[Carbomer] Noveon 0.40
组分B
GlycerinCroda 5.00
Phenova[Phenoxyethanol(and)Mixed Parabens] Crodarom 0.80
组分C
Crodamol OP[Ethylhexyl Palmitate] Croda 4.00
Crodacol CS90[Cetearyl alcohol] Croda 0.50
Crodamol ML[Myristyl Lactate] Croda 0.30
Crillet 1[Polysorbate 20] Croda 1.00
组分D
Pemulen TR2[Acrylates/C 10-30 Alkyl Acrylate Noveon 0.20
(and)Crosspolymer]
DC 345[Cyclomethicone] Dow Corning 2.00
组分E
山梨酸钾Potassium Sorbate - 0.10
组分F
水Water- 6.00
氢氧化钠Sodium Hydroxide 38% - 0.60
组分G
Darutoside(Siegesbeckia Orientalis Extract)SEDERMA 2.00
Darutoside是一种分子,供处理伸张痕用,由SEDERMA公司出售。
此乳化液的制备方法如下:A相:将Ultrez 10分散在水中并让它膨胀20分钟,加入B相;加热至70℃。将C相单独加热至75℃。将两种相混合并搅拌均匀,加入D相,用E相中和,冷却至30℃,然后加入F井目和G相,用NaOH调整至pH~6。
例6:润面凝胶Moisturising Face Gel
成分Ingredients %by wt
组分A
Ultrez 10[Carbomer] Noveon 0.20
去离子水Water Deionised - 足量100
组分B
GlycerinCroda 3.00
Phenova[Phenoxyethanol(and)Mixed Parabens]Crodarom 0.80
组分C
Crillet 1[Polysorbate 20] Croda 0.50
组分D
山梨酸钾Potassium Sorbate - 0.10
组分E
Pemulen TR1[Acrylates/C10-30 Alkyl Acrylate Noveon 0.20
Crosspolymer]
DC 345[Cyclomethicone] Dow Corning 3.00
组分F
水Water- 4.00
氢氧化钠Sodium Hydroxide 38% - 0.40
组分G
(and)Glycerin(and)PEG-8(and)Carbomer]SEDERMA 5.00
例7:抗年龄抚慰日用霜Anti-age Soothing Day Cream
成分Ingredients %by wt
组分A
去离子水Water Deionised - qs 100
Ultrez 10[Carbomer] Noveon 0.20
组分B
山梨酸钾Potassium Sorbate - 0.10
组分C
Butylene Glycol - 2.00
Phenova[Phenoxyethadol(and)Mixed Parabens]Crodarom 0.80
组分D
Crill 3[Sorbitan Stearate] Croda 1.00
Crillet 3[Polysorbate 60] Croda 2.50
DC 200[Dimethicone] Dow Corning 2.50
Crodamol TN[Isotridetyl Isononanoate] Croda 5.00
Crodamol GTCC[Caprylic/Capric Triglyceride] Croda 5.00
Crodamol SS[Cetyl Esters] Croda 1.00
Super Hartolan[Lanolin Alcohol] Croda 0.50
Super Sterol Ester[C10-C30 Cholesterol/Lanosterol esters] 0.30
Crodacol CS90[Cetearyl Alcohol] Croda 3.00
组分E
去离子水Water Deionised - 2.50
氢氧化钠Sodium Hydroxide 38% - 0.25
组分F
[Butylene Glycol(and)water(and)Laureth-3(and)
Hydroxyethylcellulose(and)
Acetyl-Dipeptide-1-cetylester] SEDERMA 4.00
此处方可按例5的程序配制
例8:用于成熟皮肤的异黄酮膏霜Cream for Mature Skin with Isoflavones
成分Ingredients %by wt.
組分A
Ultrez 10[Carbomer] Noveon 0.20
Water Deionised - qs 100
組分B
Glycerin- 3.50
組分C
Potassium Sorbate - 0.10
組分D
Volpo S10[Steareth 10] Croda 1.50
Crodafos CES[Ceterayl Alcohol Dicetyl Phosphate Croda 3.50
(and)Ceteth-10 Phosphate]
DC 200[Dimethicone] Dow Corning 2.00
Crodamol OSU[Diethylhexyl Succinate] Croda 7.00
Mixed Parabens - 0.30
Crill 3[Sorbitan Stearate] Croda 0.40
組分E
Sodium Hydroxide 38% - 0.20
Water Deionised - 4.00
組分F
STEROCARETM [Trifolium Pratense(Clover)Flower Extract(and)Glycerin(and)Butylene
Glycol(and)Lecithin]SEDERMA 3.00
MATRIXYL SEDERMA 3.00
例9:防脱发用的头发洗剂
成分Ingredients %by wt
組分A
Water deionised - Qs 100
組分B
Mixed Parabens - 0.14
Butylene Glycol - 2.00
組分C
Pal-Gly-His-Lys 0.0005
Pal-Gly-Gln-Pro-Arg(SEQ ID NO:3) 0.0003
Ethanol 10.00
組分D
Crillet 1(Polysorbate 20) Croda 1.50
Fragrance - 0.10
此处方可按例5的程序配制。
例10:处理黑眼圈用的洗剂Lotion to treat dark circles under the eyes
成分Ingredients %by wt.
組分A
Ultrez 10[Carbomer] Noveon 0.20
去离子水Water Deionised - qs 100
組分B
Glycerin 3.00
组分C
山梨酸钾Potassium Sorbate - 0.10
组分D
Volpo S10[Steareth 10] Croda 1.50
Crodafos CES[Ceterayl Alcohol Dicetyl Phosphate
(and)Ceteth-10 Phosphate] Croda 3.00
DC 200[Dimethicone] Dow Corning 2.00
Crodamol OSU[Diethylhexyl Succinate] Croda 5.00
Mixed Parabens - 0.30
Crill 3[Sorbitan Stearate] Croda 0.40
组分E
氢氧化钠Sodium Hydroxide 38% - 0.20
去离子水Water Deionised - 4.00
组分F
水Water 10.0
棕榈酸-氨基乙酸-组氨酸-赖氨酸Pal-Gly-His-Lys 0.0005
棕榈酸-氨基乙酸-谷酰胺-脯氨酸-精氨酸Pal-Gly-Gln-Pro-Arg 0.00025
去铁胺Deferoxamine 0.001
黄连素Berberine 0.002
此处方可按例1或例5的程序配制。这4种成分组合后能治疗墨斑圈的事实依据是铁螯合剂iron chelator deferoxamine和黄莲素Berberine共同起作用清除血色素残余,肽重新合成的组织使皮肤变厚。去铁胺Deferoxamine可由EDTA,NTA,水解酸hydroxamicacids或其它对有效铁螯合来说是适量的铁螯合剂所替代。黄莲素Berberine可由chrysine或类似的类黄酮替代,以达到消除bilirubine(暗瘀色)的目的。
例11:抗伸张痕凝胶Anti-stretchmark gel
成分Ingredients %by wt.
组分A
去离子水Water Deionised - qs 100
组分B
Butylene Glycol - 5.00
Phenova[Phenoxyethanol(and)Mixed Parabens]Crodarom 0.80
组分C
Crill 3[Sorbitan Stearate] Croda 1.20
Crillet 3[Polysorbate 60] Croda 3.00
DC 200[Dimethicone] Dow Corning 2.00
Crodamol IPM[Isopropyl Myristate] Croda 5.00
Crodamol W[Stearyl Heptanoate] Croda 0.30
Crodamol GTCC[Caprylic/Capric Triglyceride] Croda 5.00
Crodacol CS90[Cetearyl Alcohol] Croda 2.00
组分D
Carbopol 980 at 2%[Carbomer] BF Goodrich 10.00
组分E
山梨酸钾Potassium Sorbate - 0.10
组分F
去离子水Water Deionised - 2.00
氢氧化钠Sodium Hydroxide - 0.20
组分G
水Water 10.0
棕榈酸-氨基乙酸-组氨酸-赖氨酸Pal-Gly-His-Lys 0.0003
棕榈酸-氨基乙酸-谷酰胺-脯氨酸-精氨酸Pal-Gly-Gln-Pro-Arg 0.00015
芸香苷Rutin 0.1
Bowman Birk抑制剂 0.0001
此凝胶可用以下方法配制:将组分B搅拌均匀然后倒入组分A内。将组分(A+B)加热至75℃,将组分C和组分D加热至75℃。用helix stirring螺旋搅拌法将组分C倒入组分(A+B)内,然后将组分D倒入组分(A+B+C)内。加入组分E和组分F。在35℃时将组分G倒入。
Rutin and Bowman Birk抑制剂通过使组织再生,抑制蛋白质破坏和加强胶原纤维交联,从而有助于抗伸张痕活性。它们可由类似黄酮类flavonoids或蛋白酶proteaseenzyme的抑制剂分别替代。
例12:组织再生:肽的协合效应Tissue regeneration:synergistic effects of the peptides
通过以下实验,已确定N-棕榈酰-氨基乙酸-谷酰胺-脯氨酸-精氨酸[N-Palmitoyl-Gly-Gln-Pro-Arg(序列识别号:3)]与N-棕榈酰-氨基乙酸-组氨酸-赖氨酸(N-Palmitoyl-Gly-His-Lys)混合物有组织再生效应:
将正常人的皮肤纤维细胞放在24个well-plate盘内以含10%FCS的DMEM培养24小时,然后漂清。将细胞放入不含FCS但含抗坏血酸的培养基内,将要试验的产品加到细胞上。让细胞与产品接触3天,然后将上浮物取出并冷冻。每次试验都有一份不含溶剂的负对照物和一份对照溶剂(10E-6%of TGF-β)。每项测定都进行n=3次。进行独立于该试验的几次重复。有关分子的化验用Elisa法(Collagen I & IV;Fibronectine)和比色法colorimetric(hyaluronic酸)进行。
表1:根据溶剂(0.08%DMSO in DMEM)变化的百分比:3×10E-4%抗坏血酸水平。
Collagen I | Fibronectin | Collagen IV | Hyaluronic Acid | ||
TGF-β | 10E-6% | +91% | +176% | +4% | +43% |
Pal KTTKS (序列识别号:5) | 1ppm 2ppm 4ppm 8ppm | +8% +30% +48% +93% | +24% +20 +74% +100% | +6% +12% +15% +22% | +3% +26% +28% +31% |
Pal GQPR(序 列识别号:3) | 0.5ppm 1.5ppm 2.5ppm 3.64ppm | +4% -1% +19% +65% | +1% +15% +35% +56% | +5% -8% -5% -14% | -4% +9% -13% -1% |
Pal GHK | 1ppm 3ppm 5ppm 7.3ppm | +9% -11% +11% -9% | +8% +2% -15% +13% | +5% -4% +6% -9% | +3% +11% 0% -1% |
Combination | 1+0.5 3+1.5 5+2.5 7.3+3.64 | +33% +67% +63% +256% | +1% +41% +44% +147% | -4% -10% -5% +20% | +9% +11% +27% +92% |
注意,用来辩识每宗肽的氨基酸的是单字母规则。由控制物确定的基本水平为0%。因而,活性超过0%表明被测试的生物分子中有一个或多个受到激励。
工业上的可应用性
本发明与化学,医药,化妆品和个人护理品工业有关。
Claims (30)
1.一种表面用组合物,组合物含有:
a)0.00001%至0.5%重量百分比的至少一种rigin-四肽和0.00001%至1.0%重量百分比的至少一种GHK-三肽;以及
b)至少一种外加成分;
所述Rigin-四肽为N-棕榈酰-氨基乙酸-谷酰胺-脯氨酸-精氨酸,即N-palmitoyl-Gly-Gln-Pro-Arg,序列识别号:3;
所述GHK-三肽为N-棕榈酰-氨基乙酸-组氨酸-赖氨酸,即N-palmitoyl-Gly-His-Lys。
2.如权利要求1中的表面用组合物,组合物中四肽和三肽的含量比1∶50至50∶1。
3.如权利要求2中的表面用组合物,组合物中四肽和三肽的含量比10∶1至1∶10。
4.如权利要求1中的表面用组合物,组合物中四肽的重量百分比含量大于三肽的重量百分比含量。
5.要求1,2,4中的表面用组合物,组合物中的外加成分适用于角质组织,加在组合物内时无不适的毒性,不兼容性,不稳定性或过敏反应。
6.如权利要求5中的表面用组合物,组合物中的该至少一种外加成分为清洗剂,头发调节剂,皮肤调节剂,头发定形剂,抗头皮剂,头发助长剂,香水,遮光剂,防晒剂,色素,加湿剂,成膜剂,染发剂,化妆剂,清洁剂,稠化剂,乳化剂,湿润剂,润肤剂,防腐剂,除臭剂,皮肤病学上可接受的载体,表面活性剂,磨料,吸收剂,香料,颜料/着色剂,香料油,皮肤感觉剂,收敛剂,抗粉刺剂,抗结块剂,抗起泡剂,抗微菌剂,抗毒剂,粘合剂,生物添加剂,酶,酶抑制剂,酶活化剂,辅酶,植物提取物,神经酰铵,加成肽,缓冲剂,填充剂,螯合剂,化妆用生物杀伤剂,变性药,收敛剂,外用止痛药,聚合物,季铵,直接性增强剂,不透明剂,pH调整剂,推进剂,还原剂,多价螯合剂,皮肤增白和/或光亮剂,皮肤调节剂,皮肤抚慰和/或恢复剂,芦荟,泛酸,尿囊素,红没药酸,甘草酸二钾,皮肤处理剂,增厚剂,维生素。
7.如权利要求6中的组合物含有至少一种是皮肤病学上可接受的载体。
8.如权利要求6中的表面用组合物还含有芸香苷和Bowman Birk抑制剂以及一种皮肤病学上可接受的载体。
9.如权利要求6中的表面用组合物还含有外加成分小檗碱或羟黄酮和一种螯合剂及一种皮肤病学上可接受的载体。
10.一种组合物,该组合物的组成为:至少一种rigin-四肽,至少一种GHK-三肽和至少一种外加成分的混合物,在作用于受过处理的皮肤细胞上时,该混合物显示出有胶原质I的合成;
所述Rigin-四肽为N-棕榈酰-氨基乙酸-谷酰胺-脯氨酸-精氨酸,即N-palmitoyl-Gly-Gln-Pro-Arg,序列识别号:3;
所述GHK-三肽为N-棕榈酰-氨基乙酸-组氨酸-赖氨酸,即N-palmitoyl-Gly-His-Lys。
11.如权利要求10中的表面用组合物,组合物中所述的四肽与三肽的含量比为100∶1至1∶100。
12.如权利要求11中的表面用组合物,组合物中所说的四肽与三肽的含量比为50∶1至1∶50。
13.如权利要求10中的表面用组合物,组合物中四肽的重量百分比含量大于三肽的含量。
14.如权利要求10中的表面用组合物,组合物中的至少一种外加成分为清洗剂,头发调节剂,头发调节剂,皮肤调节剂,头发定形剂,抗头皮剂,头发助长剂,香水,遮光剂,防晒剂,色素,加湿剂,薄膜生成剂,染发剂,化妆剂,清洁剂,稠化剂,乳化剂,湿润剂,润肤剂,防腐剂,除臭剂,皮肤病学上可接受的载体,表面活性剂,磨料,吸收剂,香料,染色/着色剂,香料油,皮肤感觉剂,收敛剂,抗起泡剂,抗粉刺剂,抗结块剂,抗泡沫剂,抗微菌剂,抗毒剂,粘合剂,生物学添加剂,酶,酶抑制剂,酶活化剂,辅酶,植物提取物,神经酰铵,加成肽,缓冲剂,填充剂,螯合剂,化妆用生物杀伤剂,变性药,收敛剂,外用止痛药,聚合物,季铵,直接性增强剂,不透明剂,pH调整剂,推进剂,还原剂,多价螯合剂,皮肤增白和/或光亮剂,皮肤调节剂,皮肤抚慰和/或恢复剂,芦荟,泛酸,尿囊素,红没药酸,甘草酸二钾,皮肤处理剂,增厚剂,维生素。
15.一种化妆品组合物,组合物含有:
a)0.00001%至5.0%w/w的至少一种ALAMCAT-四肽和0.00001%至10.0%w/w的至少一种组氨酸三肽;
b)至少一种外加成分;
所述ALAMCAT四肽为N-棕榈酰-氨基乙酸-谷酰胺-脯氨酸-精氨酸,即N-palmitoyl-Gly-Gln-Pro-Arg,序列识别号:3;
所述组氨酸-三肽为N-棕榈酰-氨基乙酸-组氨酸-赖氨酸,即N-palmitoyl-Gly-His-Lys。
16.如权利要求15中的表面用组合物,组合物内的四肽与三肽的含量比为50∶1至1∶50。
17.如权利要求16中的表面用组合物,组合物中的三肽的重量百分比含量大于四肽的含量。
18.如权利要求15中的表面用组合物,组合物中的外加成分适用于涂在角质组织上,加入到组合物内时无不适的毒性,不兼容性,不稳定性和过敏反应。
19.如权利要求15或17中的表面用组合物,组合物中的至少一种外加成分为清洗剂,头发调节剂,头发调节剂,皮肤调节剂,头发定形剂,抗头皮剂,头发助长剂,香水,遮光剂,防晒剂,色素,加湿剂,薄膜生成剂,染发剂,化妆剂,清洁剂,稠化剂,乳化剂,湿润剂,润肤剂,防腐剂,除臭剂,皮肤病学上可接受的载体,表面活性剂,磨料,吸收剂,香料,颜料/着色剂,香料油,皮肤感觉剂,收敛剂,抗起泡剂,抗粉刺剂,抗结块剂,抗泡沫剂,抗微菌剂,抗毒剂,粘合剂,生物学添加剂,酶,酶抑制剂,酶活化剂,辅酶,植物提取物,神经酰铵,加成肽,缓冲剂,填充剂,螯合剂,化妆用生物杀伤剂,变性药,收敛剂,外用止痛药,聚合物,季铵,直接性增强剂,不透明剂,pH调整剂,推进剂,还原剂,多价螯合剂,皮肤增白和/或光亮剂,皮肤调节剂,皮肤抚慰和/或恢复剂,芦荟,泛酸,尿囊素,红没药酸,甘草酸二钾,皮肤处理剂,增厚剂,维生素。
20.如权利要求19中的表面用组合物,组合物中的外加成分为芸香苷和Bowman Birk抑制剂以及一种皮肤病学上可接受的载体。
21.如权利要求19中的表面用组合物,组合物中的外加成分为小檗碱或羟黄酮和一种螯合剂及一种皮肤病学可接受的载体
22.一种减少可见老化迹象的方法,方法包括:在有老化迹象、需要处理的人体皮肤区域上施用如权利要求1的组合物,每天至少一次,使用周期至少为足以使皮肤该区域的可见老化迹象减少为止。
23.一种减少可见老化迹象的方法,方法包括:在有老化迹象、需要处理的人体皮肤区域上施用如权利要求10的组合物,每天至少一次,使用周期至少为足以使皮肤该区域的可见老化迹象减少为止。
24.一种减少可见老化迹象的方法,方法包括:在有老化迹象、需要处理的人体皮肤区域上施用如权利要求15的组合物,每天至少一次,使用周期至少为足以使皮肤该区域的可见老化迹象减少为止。
25.一种减少可见伸张痕的方法,方法包括:在有伸张痕、需要处理的人体皮肤区域上施用如权利要求8的组合物,每天至少一次,使用周期至少为足以使皮肤该区域的可见老化迹象减少为止。
26.一种减少可见伸张痕的方法,方法包括:在有伸张痕、需要治疗的人体皮肤区域上施用如权利要求15的组合物,每天至少一次,使用周期至少为足以使皮肤该区域的可见老化迹象减少为止。
27.一种减少可见伸张痕的方法,方法包括:在有伸张痕、需要处理的人体皮肤区域上施用如权利要求20的组合物,每天至少一次,使用周期至少为足以使皮肤该区域的可见老化迹象减少为止。
28.一种减少眼下黑斑圈的方法,方法包括:在有眼下黑斑圈、需要处理的人体皮肤区域上施用如权利要求9的组合物,每天至少一次,使周期至少为足以使皮肤该区域的可见黑斑圈减少为止。
29.一种减少眼下黑斑圈的方法,方法包括:在有眼下黑斑圈、需要处理的人体皮肤区域上施用如权利要求15的组合物,每天至少一次,使用周期至少为足以使皮肤该区域的可见黑斑圈减少为止。
30.一种减少眼下黑斑圈的方法,方法包括:在有眼下黑斑圈、需要处理的人体皮肤区域上施用如权利要求21的组合物,每天至少一次,使用周期至少为足以使皮肤该区域的可见黑斑圈减少为止。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2003/014019 WO2005048968A1 (en) | 2003-11-17 | 2003-11-17 | Compositions containing mixtures of tetrapeptides and tripeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1893911A CN1893911A (zh) | 2007-01-10 |
CN1893911B true CN1893911B (zh) | 2010-12-29 |
Family
ID=32668711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2003801109853A Expired - Lifetime CN1893911B (zh) | 2003-11-17 | 2003-11-17 | 含有四肽和三肽混合物的配方 |
Country Status (9)
Country | Link |
---|---|
US (1) | US6974799B2 (zh) |
EP (1) | EP1686957B1 (zh) |
JP (1) | JP4256389B2 (zh) |
KR (1) | KR101045658B1 (zh) |
CN (1) | CN1893911B (zh) |
AT (1) | ATE548022T1 (zh) |
AU (1) | AU2003296248A1 (zh) |
ES (1) | ES2381359T3 (zh) |
WO (1) | WO2005048968A1 (zh) |
Families Citing this family (177)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030194445A1 (en) * | 2001-11-12 | 2003-10-16 | Kuhner Carla H. | Compositions and methods of use of peptides in combination with biocides and/or germicides |
FR2836042B1 (fr) * | 2002-02-15 | 2004-04-02 | Sederma Sa | Compositions cosmetiques ou dermopharmaceutiques pour diminuer les poches et cernes sous les yeux |
US20060198800A1 (en) * | 2003-08-14 | 2006-09-07 | Natalie Dilallo | Skin care compositions including hexapeptide complexes and methods of their manufacture |
WO2005016364A1 (en) * | 2003-08-14 | 2005-02-24 | Guthy-Renker Corporation | Skin care composition including hexapeptide complexes and methods of their manufacture |
WO2006005455A2 (en) * | 2004-07-09 | 2006-01-19 | Dsm Ip Assets B.V. | Amino, amino acid or peptide conjugates of retinoic acid |
DE102004055541A1 (de) * | 2004-11-17 | 2006-05-18 | Henkel Kgaa | Kosmetische und dermatologische Zusammensetzungen zur Behandlung reifer Haut |
US20060110439A1 (en) * | 2004-10-22 | 2006-05-25 | Dynamis Therapeutics, Inc. | Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds |
ATE506938T1 (de) * | 2004-12-29 | 2011-05-15 | Labo Cosprophar Ag | Kosmetische zusammensetzung zum aufbringen auf die haut zur entspannung von mimikfalten |
FR2880802B1 (fr) * | 2005-01-14 | 2008-12-19 | Sederma Soc Par Actions Simpli | Composition cosmetique ou dermopharmaceutique contenant un extrait d'euglene |
JP4452203B2 (ja) * | 2005-03-30 | 2010-04-21 | 株式会社ナリス化粧品 | 美白化粧料 |
NZ580951A (en) * | 2005-04-29 | 2011-06-30 | Cubist Pharm Inc | Therapeutic compositions |
JP2007031375A (ja) * | 2005-07-28 | 2007-02-08 | Kyowa Hakko Kogyo Co Ltd | 肌質改善用経口剤 |
US7566464B2 (en) * | 2005-09-01 | 2009-07-28 | Belfer William A | Cosmetic composition to accelerate repair of functional wrinkles |
FR2890310B1 (fr) | 2005-09-06 | 2009-04-03 | Sederma Soc Par Actions Simpli | Utilisation des protoberberines comme agents regulant l'activite de l'unite pilosebacee |
JP4033877B2 (ja) | 2005-09-29 | 2008-01-16 | 株式会社ファンケル | I型コラーゲン産生促進用組成物 |
DE102006046076A1 (de) * | 2005-10-14 | 2007-04-19 | Henkel Kgaa | Kosmetische und dermatologische Zusammensetzungen mit Oligopeptiden und Apfelextrakt |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
FR2894144B1 (fr) * | 2005-12-05 | 2009-05-15 | Oreal | Utilisation du dipeptide tyrosine-arginine dans une composition cosmetique ou pour la preparation d'un medicament |
WO2007070795A2 (en) * | 2005-12-12 | 2007-06-21 | The Trustees Of Columbia University In The City Of New York | Broad spectrum non-traditional preservative system |
US20070134184A1 (en) * | 2005-12-13 | 2007-06-14 | Stephen Pheiffer | Organic therapeutic and cosmetic preparation |
US7807625B2 (en) * | 2006-01-18 | 2010-10-05 | Grant Industries, Inc | Anti-wrinkle composition |
KR100955212B1 (ko) * | 2006-01-27 | 2010-04-29 | (주)프로스테믹스 | 지방유래 줄기세포를 이용한 성장인자의 대량 생산방법 |
US20070183994A1 (en) * | 2006-02-03 | 2007-08-09 | Toma's, L.L.C. | Self-tanning product having slimming, firming and toning properties associated therewith |
US8404648B2 (en) * | 2006-02-16 | 2013-03-26 | Sederma | Polypeptides KXK and their use |
US20070237735A1 (en) * | 2006-03-31 | 2007-10-11 | Laboratoires Dermo-Cosmetik Inc. | Anti-aging composition, kit and method of use |
ES2283212B1 (es) * | 2006-03-31 | 2008-08-16 | Lipotec S.A. | Peptidos sinteticos utiles en el tratamiento de la piel y su uso en composiciones cosmeticas o dermofarmaceuticas. |
KR101332578B1 (ko) * | 2006-04-28 | 2013-11-25 | 디에스엠 아이피 어셋츠 비.브이. | 기저막의 단백질 합성 자극용 화장료 조성물 |
FR2900573B1 (fr) | 2006-05-05 | 2014-05-16 | Sederma Sa | Nouvelles compositions cosmetiques renfermant au moins un peptide contenant au moins un cycle aromatique bloque |
US8586541B2 (en) | 2006-06-01 | 2013-11-19 | Therapeutic Peptides, Inc. | Polymeric biosurfactants |
US7544375B1 (en) | 2006-06-12 | 2009-06-09 | Swiss Skin Repair, Inc. | Composition |
PT2409988E (pt) | 2006-06-13 | 2015-10-12 | Helix Biomedix Inc | Fragmentos peptídicos para induzir síntese de proteínas da matriz extracelular |
US20080124404A1 (en) * | 2006-06-19 | 2008-05-29 | Jingwen Liu | Hypolipidemic and/or hypocholesteremic compounds obtainable from the goldenseal plant |
US9682256B2 (en) * | 2006-07-14 | 2017-06-20 | Colgate-Palmolive Company | Methods of making compositions comprising films |
FR2904549B1 (fr) * | 2006-08-03 | 2012-12-14 | Sederma Sa | Composition comprenant de la sarsasapogenine |
ITMI20061770A1 (it) * | 2006-09-18 | 2008-03-19 | Carlo Ghisalberti | Metodo cosmetico di riduzione delle occhiaie |
DE102006047529A1 (de) | 2006-10-07 | 2008-04-10 | Evonik Goldschmidt Gmbh | Oligopeptide enthaltende dermatologische Zusammensetzungen zur Steigerung der Hautempfindlichkeit und der neuronalen Reizwahrnehmung |
US7879910B1 (en) | 2006-10-10 | 2011-02-01 | Jan Marini Skin Research, Inc. | Compositions and methods for promoting lush hair growth |
KR20150028308A (ko) * | 2006-12-01 | 2015-03-13 | 안테리오스, 인코퍼레이티드 | 펩티드 나노입자 및 이의 용도 |
BRPI0719756A2 (pt) * | 2006-12-01 | 2014-01-21 | Anterios Inc | Nanopartículas de entidades anfifílicas |
CH696659A9 (it) * | 2007-01-04 | 2007-11-15 | Labo Cosprophar Ag | Composizione cosmetica per il trattamento e/o la prevenzione delle smagllature della pelle |
SI2125878T1 (sl) | 2007-01-05 | 2013-06-28 | Helix Biomedix, Inc. | Kratki bioaktivni peptidi za celično in imunološko modulacijo |
AP2009005028A0 (en) | 2007-04-10 | 2009-12-31 | Univ Tulane | Soluble and membrane-anchored forms of lassa virussubunit proteins |
US10016451B2 (en) | 2007-05-31 | 2018-07-10 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
US20090035228A1 (en) * | 2007-08-02 | 2009-02-05 | Shanta Modak | Skin and surface disinfectant compositions containing botanicals |
EP2166840B1 (en) | 2007-06-20 | 2017-01-11 | The Trustees of Columbia University in the City of New York | Bio-film resistant surfaces |
US9687429B2 (en) * | 2007-06-20 | 2017-06-27 | The Trustees Of Columbia University In The City Of New York | Antimicrobial compositions containing low concentrations of botanicals |
US9511040B2 (en) | 2007-06-20 | 2016-12-06 | The Trustees Of Columbia University In The City Of New York | Skin and surface disinfectant compositions containing botanicals |
US9981069B2 (en) | 2007-06-20 | 2018-05-29 | The Trustees Of Columbia University In The City Of New York | Bio-film resistant surfaces |
US8283314B1 (en) | 2007-07-02 | 2012-10-09 | Jan Marini Skin Research, Inc. | Skin care compositions |
EP2180027B1 (en) * | 2007-07-05 | 2011-10-26 | Nissan Chemical Industries, Ltd. | Novel lipid-tripeptide based hydrogel-forming agent and hydrogel |
ES2406936T3 (es) | 2007-07-13 | 2013-06-10 | Chanel Parfums Beaute | Nuevos agentes blanqueadores peptídicos y composiciones cosméticas que comprenden los mismos |
ES2567706T3 (es) * | 2007-10-29 | 2016-04-26 | Helix Biomedix Inc. | Tetrapéptidos protectores para cuidado cutáneo |
EP2065029B1 (en) | 2007-11-30 | 2013-04-17 | Evonik Goldschmidt GmbH | Personal care and cosmetic composition containing tetrapeptides with the motifs GX1X2G, PX1X2P, or PX1X2K |
ES2324192B1 (es) * | 2008-01-30 | 2010-06-17 | PUIG BEAUTY & FASHION GROUP, S.L. | Derivados peptidicos utiles en el tratamiento, cuidado o limpieza de la piel, mucosa, cuero cabelludo o uñas. |
US20090202581A1 (en) * | 2008-02-12 | 2009-08-13 | Nathalie Schlemer | Cosmetic formulation |
US20090203628A1 (en) * | 2008-02-12 | 2009-08-13 | Jan Marini | Composition, Method And Kit For Treating Skin Disorders And Improving Skin Condition |
CN102387772A (zh) * | 2008-05-29 | 2012-03-21 | 唐纳德·欧文 | 皮肤美容组合物中的寡聚生物表面活性剂 |
CA2726836C (en) * | 2008-06-26 | 2019-06-18 | Anterios, Inc. | Use of nanoemulsions in the manufacture of a medicament for treating skin disorders |
US20100172848A1 (en) * | 2008-08-01 | 2010-07-08 | The Trustees Of Columbia University In The City Of New York | Skin and surface disinfectant compositions containing botanicals |
JP2010053099A (ja) * | 2008-08-29 | 2010-03-11 | Hamari Chemicals Ltd | しわ改善剤 |
FR2939799B1 (fr) | 2008-12-11 | 2011-03-11 | Sederma Sa | Composition cosmetique comprenant des oligoglucuronanes acetyles. |
FR2941231B1 (fr) | 2009-01-16 | 2016-04-01 | Sederma Sa | Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques. |
EP2382231A2 (en) | 2009-01-16 | 2011-11-02 | Sederma | New compounds, in particular peptides, compositions comprising them and cosmetic and dermopharmaceutical uses |
FR2941232B1 (fr) | 2009-01-16 | 2014-08-08 | Sederma Sa | Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques. |
US20120094919A1 (en) * | 2009-03-16 | 2012-04-19 | Graeub Remo | Use of tripeptides |
US20120021029A1 (en) * | 2009-04-17 | 2012-01-26 | Lipotec, S.A. | Peptides used in the treatment and/or care of the skin and/or hair and their use in cosmetic or pharmaceutical compositions |
WO2010122423A2 (en) | 2009-04-22 | 2010-10-28 | Dsm Ip Assets B.V. | Novel composition |
US8388991B2 (en) | 2009-05-01 | 2013-03-05 | Chattem, Inc. | Moisturizing antimicrobial composition |
FR2945939B1 (fr) | 2009-05-26 | 2011-07-15 | Sederma Sa | Utilisation cosmetique du dipeptide tyr-arg pour lutter contre le relachement cutane. |
EP2448577B1 (en) | 2009-06-30 | 2016-09-14 | Derman Biomedicine Co. Ltd. | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
WO2011003696A1 (en) * | 2009-07-10 | 2011-01-13 | Unilever Plc | Hair treatment compositions |
EP2470159A1 (en) | 2009-08-28 | 2012-07-04 | Mary Kay, Inc. | Skin care formulations |
DE102009046780A1 (de) * | 2009-11-17 | 2011-05-19 | Evonik Goldschmidt Gmbh | Tetrapeptide zur Aufhellung der Haut |
US8075901B1 (en) | 2009-11-23 | 2011-12-13 | Waters Sheila F | Cosmetic formulation |
BE1019105A4 (nl) * | 2009-12-11 | 2012-03-06 | Debetencourt Jean Jacques | Emulsion pour annihiler les effets de brulure thermique sur la peau. |
FR2955326B1 (fr) | 2010-01-18 | 2015-01-02 | Sederma Sa | Nouveau compose lipo-phosphate ou lipo-sulfate, compositions le contenant et utilisations cosmetiques et dermopharmaceutiques |
US9180112B2 (en) * | 2010-03-23 | 2015-11-10 | Ermis Labs, LLC | Dermal compositions containing gorgonian extract |
FR2958541B1 (fr) | 2010-04-08 | 2012-05-18 | Sederma Sa | Utilisation cosmetique du geranylgeranyl-2-propanol |
FR2958641B1 (fr) | 2010-04-08 | 2014-12-26 | Sederma Sa | Nouveaux composes de type polyterpenique, compositions cosmetiques, nutraceutiques et pharmaceutiques les contenant et utilisations dans ces domaines. |
EP2382963A1 (en) | 2010-04-29 | 2011-11-02 | Cognis IP Management GmbH | Cosmetic composition containing oligopeptides |
US8232208B2 (en) * | 2010-06-15 | 2012-07-31 | Rohm And Haas Electronic Materials Cmp Holdings, Inc. | Stabilized chemical mechanical polishing composition and method of polishing a substrate |
US10267796B2 (en) * | 2010-10-25 | 2019-04-23 | The Procter & Gamble Company | Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis |
FR2970868B1 (fr) | 2011-01-31 | 2023-10-27 | Sederma Sa | Extrait d'origine vegetale, composition le contenant, procede d'obtention par culture vegetale et utilisations dans les domaines cosmetique, pharmaceutique et cosmeceutique |
WO2012107244A1 (en) | 2011-02-09 | 2012-08-16 | Organobalance Gmbh | Peptide for use in the treatment of skin conditions |
FR2974297B1 (fr) * | 2011-04-21 | 2013-10-04 | Sederma Sa | Nouvelle utilisation cosmetique ou therapeutique du tripeptide ghk |
WO2012166810A1 (en) * | 2011-05-31 | 2012-12-06 | Amplifi Biotechnologies, Inc. | Biologically active tri-peptide |
FR2975904B1 (fr) * | 2011-06-01 | 2013-08-23 | Sederma Sa | Nouvelle utilisation topique, cosmetique ou dermopharmaceutique, d'un melange comprenant un tripeptide du type ghk et un tetrapeptide du type gqpr |
FR2978351B1 (fr) | 2011-07-28 | 2014-02-21 | Sederma Sa | Materiel d'origine vegetale, composition le contenant, et utilisation topique cosmetique |
ES2762405T3 (es) | 2011-11-03 | 2020-05-25 | Univ Columbia | Composición con actividad antimicrobiana sostenida |
US9968101B2 (en) | 2011-11-03 | 2018-05-15 | The Trustees Of Columbia University In The City Of New York | Botanical antimicrobial compositions |
WO2013086094A1 (en) | 2011-12-06 | 2013-06-13 | The Trustees Of Columbia University In The City Of New York | Broad spectrum natural preservative composition |
US9402794B2 (en) | 2011-12-07 | 2016-08-02 | Mary Kay Inc. | Topical skin care formulation |
MX347811B (es) * | 2011-12-20 | 2017-05-15 | Unilever Nv | Composicion humectante que comprende una mezcla de aminopeptido. |
FR2985424B1 (fr) | 2012-01-10 | 2019-03-29 | Sederma | Nouvelle utilisation topique de la zerumbone |
KR101890322B1 (ko) * | 2012-01-13 | 2018-08-21 | 주식회사 엘지생활건강 | 피부 주름 개선 및 탄력 증진용 조성물 |
KR101342488B1 (ko) * | 2012-03-13 | 2013-12-17 | 미원상사주식회사 | 테트라펩타이드 및 이를 함유하는 피부노화 방지 및 항염효능의 화장료 조성물 |
RU2627648C2 (ru) * | 2012-03-20 | 2017-08-09 | Хеликс Байомедикс, Инк. | Короткие антимикробные липопептиды |
KR101410897B1 (ko) | 2012-05-25 | 2014-07-16 | 이스켐주식회사 | 리포산-peg-펩티드 유도체, 이의 제조방법, 및 이를 포함하는 미백 또는 주름개선용 화장료 조성물 |
FR2997299B1 (fr) | 2012-10-30 | 2014-12-26 | Sederma Sa | Association d'extraits de plantes, ingredient actif cosmetique et composition les contenant, et utilisation topique cosmetique |
US9241891B2 (en) * | 2012-10-30 | 2016-01-26 | The Procter & Gamble Company | Personal care compositions comprising self-assembling peptides |
US20140127335A1 (en) * | 2012-11-08 | 2014-05-08 | Concrete & Canvas, LLC | Fragrance primer |
US9808654B2 (en) | 2013-02-11 | 2017-11-07 | Jan Marini Skin Research | Post procedure skin care gel and methods of use thereof |
MX360649B (es) | 2013-03-13 | 2018-11-12 | Anteis Sa | Péptidos para el rejuvenecimiento de la piel y métodos de uso de los mismos. |
ITRM20130199A1 (it) | 2013-04-03 | 2014-10-04 | Irbm Science Park S P A | Peptidi per uso dermatologico e/o cosmetico |
EP2983464A1 (en) | 2013-04-08 | 2016-02-17 | Sederma | Production method of meristematic cells of plantago lanceolata, composition comprising said cells or their cellular extract, and cosmetic, nutraceutical and dermatological uses |
FR3004351B1 (fr) | 2013-04-16 | 2015-03-27 | Sederma Sa | Prevention et traitement des dommages cutanes lies aux infra-rouges |
KR102077983B1 (ko) | 2013-05-29 | 2020-02-17 | 주식회사 젬백스앤카엘 | 피부 주름 개선 및 미백용 조성물 |
KR102077984B1 (ko) | 2013-06-27 | 2020-02-17 | 주식회사 젬백스앤카엘 | 피부 주름 예방 및 개선용 조성물 |
CN103705393A (zh) * | 2013-11-14 | 2014-04-09 | 陕西东大生化科技有限责任公司 | 一种具有选择性美白祛斑剂及其在化妆品的应用 |
WO2015081304A1 (en) * | 2013-11-26 | 2015-06-04 | University Medical Pharmaceuticals Corporation | System and method of delivering a hyaluronic acid composition and a copper composition for treatment of dermatologic conditions |
US20160263092A1 (en) | 2013-12-19 | 2016-09-15 | Twi Biotechnology, Inc. | Therapeutic uses of berberine formulations |
TW201538156A (zh) | 2013-12-19 | 2015-10-16 | Twi Biotechnology Inc | 小蘗鹼配方及其用途 |
CN104817622A (zh) * | 2014-01-30 | 2015-08-05 | 陈光健 | 寡肽cd04及其制备方法和应用 |
CN104817613A (zh) * | 2014-01-30 | 2015-08-05 | 陈光健 | 寡肽cd06及其制备方法和应用 |
CN104817625A (zh) * | 2014-01-30 | 2015-08-05 | 陈光健 | 寡肽cd03及其制备方法和应用 |
CN104817615A (zh) * | 2014-01-30 | 2015-08-05 | 陈光健 | 寡肽cd05及其制备方法和应用 |
FR3018449B1 (fr) | 2014-03-17 | 2017-09-01 | Sederma Sa | Utilisation cosmetique d'un extrait de mirabilis jalapa, ingredient actif et composition cosmetique correspondantes |
GB2525894A (en) * | 2014-05-07 | 2015-11-11 | Boots Co Plc | Skin care composition |
CN105294830A (zh) * | 2014-06-18 | 2016-02-03 | 陈光健 | 一种二肽分子及其制备方法和应用 |
EP3210613A4 (en) | 2014-06-30 | 2018-08-22 | Rohto Pharmaceutical Co., Ltd. | Composition for external application |
FR3024037B1 (fr) | 2014-07-25 | 2018-03-02 | Sederma | Ingredient actif cosmetique ou dermatologique comprenant un melange d'acides dicarboxyliques gras insatures, compositions le comprenant et utilisations cosmetiques ou dermatologiques |
JP2016056116A (ja) * | 2014-09-08 | 2016-04-21 | 株式会社ディーエイチシー | コラーゲン産生促進用組成物 |
EP3226976A1 (en) | 2014-12-04 | 2017-10-11 | Mary Kay, Inc. | Topical skin care composition comprising trifluoroacetyl tripeptide-2 |
WO2016109488A1 (en) | 2014-12-29 | 2016-07-07 | Kimberly-Clark Worldwide, Inc. | Multifunctional base emulsion |
WO2016109517A1 (en) | 2014-12-29 | 2016-07-07 | Kimberly-Clark Worldwide, Inc. | Cosmetic emulsions |
FR3031454B1 (fr) | 2015-01-13 | 2018-05-11 | Sederma | Utilisation de cellules vegetales de leontopodium alpinum pour un traitement cosmetique et ingredient actif cosmetique correspondant |
FR3034013B1 (fr) * | 2015-03-24 | 2018-04-06 | Danielle Roches | Composition cosmetique pour stimuler la croissance et pigmenter les cils la nuit |
FR3034014B1 (fr) * | 2015-03-24 | 2018-04-06 | Danielle Roches | Association de compositions cosmetiques jour et nuit pour stimuler la croissance et pigmenter les cils |
FR3034012B1 (fr) * | 2015-03-24 | 2018-04-06 | Danielle Roches | Composition cosmetique pour stimuler la croissance et pigmenter les cils |
FR3034314B1 (fr) | 2015-03-30 | 2019-10-04 | Sederma | Traitement cosmetique topique de la peau et du cuir chevelu et ingredient actif correspondant a base d'un extrait d'apium graveolens |
WO2016210230A1 (en) | 2015-06-24 | 2016-12-29 | Twi Biotechnology, Inc. | Therapeutic uses of berberine formulations |
ES2806989T3 (es) | 2015-07-16 | 2021-02-19 | Nuritas Ltd | Péptidos antiinflamatorios, y usos de los mismos |
EP3117830A1 (en) | 2015-07-16 | 2017-01-18 | Nuritas Limited | Antibacterial peptides, and uses thereof |
EP3118216A1 (en) | 2015-07-16 | 2017-01-18 | Nuritas Limited | Cellular growth and proliferation promoting peptides, and uses thereof |
EP3118215A1 (en) | 2015-07-16 | 2017-01-18 | Nuritas Limited | Anti-inflammatory peptides, and uses thereof |
EP3117831A1 (en) | 2015-07-16 | 2017-01-18 | Nuritas Limited | Peptides for use in promoting transport of glucose into skeletal muscle |
GB2543822A (en) * | 2015-10-30 | 2017-05-03 | Boots Co Plc | Skin care composition and method thereof |
BR112018010225B1 (pt) * | 2015-11-19 | 2021-07-06 | Avon Products, Inc | Composição tópica para melhorar a saúde e/ou aparência do cabelo, espessar o cabelo e/ou promover o crescimento do cabelo e método para fortalecer, espessar e/ou promover o crescimento de fibras de queratina humanas que utiliza a dita composição |
CN105541966B (zh) * | 2016-01-27 | 2019-01-25 | 安婕妤化妆品科技股份有限公司 | 一种四肽的制备方法及应用 |
BR112018015897B1 (pt) | 2016-02-04 | 2022-03-03 | Alastin Skincare, Inc | Composição tópica anidra para promover a reparação da pele, composições tópicas para promover a restauração da pele, composição tópica para aliviar contusões causadas por um procedimento cosmético e uso das mesmas |
US10493020B2 (en) | 2016-04-14 | 2019-12-03 | The Procter & Gamble Company | Method of improving the appearance of periorbital dyschromia |
WO2018014936A1 (en) | 2016-07-18 | 2018-01-25 | Nuritas Limited | Topical compositions |
EP3541358A1 (en) | 2016-11-21 | 2019-09-25 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
CN110381976A (zh) | 2016-12-05 | 2019-10-25 | 努里塔斯有限公司 | 包括肽wkdeagkplvk的组合物 |
EP3329930A1 (en) | 2016-12-05 | 2018-06-06 | Nuritas Limited | Pharmaceuctical compositions |
EP3329905A1 (en) | 2016-12-05 | 2018-06-06 | Nuritas Limited | Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin |
KR102007078B1 (ko) | 2017-03-24 | 2019-08-05 | (주)셀아이콘랩 | 콜라겐 생성을 촉진시키는 신규한 헵타펩타이드 단량체 및 이량체를 포함하는 피부 노화 방지를 위한 화장품 조성물 |
BR112020002222A2 (pt) | 2017-08-03 | 2020-07-28 | ALASTIN Skincare, Inc. | composições e métodos para melhora da flacidez da pele e do contorno corporal |
CN107496345A (zh) * | 2017-09-01 | 2017-12-22 | 安庆徽云博冠化妆品科技有限公司 | 一种蛋白螯合洗面奶及其制备方法 |
CN109512710A (zh) | 2017-09-18 | 2019-03-26 | 玫琳凯有限公司 | 化妆品组合物及方法 |
WO2019238962A1 (en) | 2018-06-14 | 2019-12-19 | University College Cork - National University Of Ireland, Cork | Peptide for disease treatment |
KR102227522B1 (ko) * | 2018-07-16 | 2021-03-12 | 부산대학교 산학협력단 | GHKWKYMVm 펩타이드를 포함하는 염증성 피부질환의 예방 또는 치료용 약학적 조성물 |
CN108841532A (zh) * | 2018-07-24 | 2018-11-20 | 江苏健祥生态农业有限公司 | 一种桑葚酒 |
US11103455B2 (en) | 2018-08-02 | 2021-08-31 | ALASTIN Skincare, Inc. | Liposomal compositions and methods of use |
FR3084592B1 (fr) * | 2018-08-03 | 2020-10-30 | Laboratoires Cinq Mondes | Composition cosmetique |
GB2576705A (en) * | 2018-08-17 | 2020-03-04 | E Miller Norman | Improvements in or relating to organic material |
SG11202102345SA (en) * | 2018-09-20 | 2021-04-29 | Tautona Group Ip Holding Company L L C | Iron chelating compounds for treating aesthetic skin conditions |
JP7121278B2 (ja) * | 2018-10-24 | 2022-08-18 | 日油株式会社 | 洗浄剤組成物 |
WO2020174093A1 (en) | 2019-02-28 | 2020-09-03 | Bic -Violex S.A. | Skin engaging member for razor cartridge comprising skin active ingredient |
US10898724B2 (en) | 2019-06-11 | 2021-01-26 | Soletluna Holdings, Inc. | Wearable phototherapy apparatus with anti-viral and other effects |
US10716953B1 (en) * | 2019-06-11 | 2020-07-21 | Soletluna Holdings, Inc. | Wearable phototherapy apparatus |
WO2020255138A1 (en) * | 2019-06-20 | 2020-12-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Composites and uses thereof |
FR3099993B1 (fr) | 2019-08-22 | 2021-09-10 | Laboratoires Cinq Mondes | Composition cosmetique |
US20210106506A1 (en) * | 2019-10-11 | 2021-04-15 | Elc Management Llc | Methods for cosmetic skin remodeling |
US20220378681A1 (en) * | 2019-10-18 | 2022-12-01 | Deciem Beauty Group Inc. | Skin care formulation with lipophilic peptides |
FR3107708A1 (fr) | 2020-02-28 | 2021-09-03 | Alganelle | Microalgue recombinante capable de produire des peptides, polypeptides et protéines de KTTKS et leurs dérivés, et leurs procédé et utilisations associés |
KR102483429B1 (ko) * | 2020-05-11 | 2022-12-30 | 웰펩 주식회사 | 항염, 항산화 내지 콜라겐 증식 효능을 가진 헵타펩타이드 및 이를 포함하는 조성물 |
CN111840510A (zh) * | 2020-06-28 | 2020-10-30 | 华中科技大学 | 一组食源性多肽的应用 |
CN112608933B (zh) * | 2020-12-31 | 2023-08-18 | 华南理工大学 | 一种重组蓝铜肽前体-寡肽的高纯度制备方法 |
US20220218584A1 (en) * | 2021-01-13 | 2022-07-14 | Allergan Sales, Llc | Topical composition and method of use |
WO2022157548A1 (en) | 2021-01-24 | 2022-07-28 | Forrest Michael David | Inhibitors of atp synthase - cosmetic and therapeutic uses |
US20220387284A1 (en) * | 2021-05-25 | 2022-12-08 | Allergan Sales, Llc | Topical composition and method of use |
KR102673769B1 (ko) * | 2021-10-14 | 2024-06-10 | 주식회사 이엔코스 | 다크서클 개선용 아이크림 |
US11730694B1 (en) | 2022-05-25 | 2023-08-22 | L'oreal | Hair coloring compositions and methods |
CN117956975A (zh) * | 2022-08-31 | 2024-04-30 | 株式会社莱美迪 | 含有具有皮肤美白活性的肽的组合物 |
CN115998630B (zh) * | 2023-02-17 | 2023-06-06 | 北京普世安生物科技有限公司 | 一种乌发精华液及其制备方法 |
GB2628139A (en) * | 2023-03-15 | 2024-09-18 | Boots Co Plc | Tripeptide and composition thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2784029B1 (fr) * | 1998-10-05 | 2001-01-05 | Pharmascience Lab | Methode de prevention et/ou de traitement cosmetique des vergetures de la peau et utilisation en dermatologie |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686282A (en) * | 1983-08-12 | 1987-08-11 | Immunetech, Inc. | Immunotherapeutic polypeptide agents which block immune complex binding to immunoglobulin Fc receptors |
GB8531118D0 (en) | 1985-12-18 | 1986-01-29 | Allied Colloids Ltd | Copolymers |
EP0330369A1 (en) | 1988-02-16 | 1989-08-30 | Richardson-Vicks, Inc. | Skin conditioning composition |
JP2894715B2 (ja) * | 1989-03-13 | 1999-05-24 | ベイジン リーユエン リーヨン フアシュエ グーフェン ヨウシエン ゴンスー | 皮膚外用剤 |
CA2079485C (en) | 1990-04-26 | 1999-05-11 | Rodney Dean Bush | Chelator compositions comprising oxime compounds |
DE69132363T2 (de) | 1990-04-26 | 2001-03-29 | Procter & Gamble | Chelat-zubereitung, die alpha-diamin-verbindungen enthalten |
JP2609564B2 (ja) * | 1991-05-31 | 1997-05-14 | 政夫 斎藤 | アレルギー性皮膚炎用クリーム及びその製造方法 |
DE4244418A1 (en) * | 1991-12-30 | 1993-07-01 | Gerhard Quelle | Cosmetic and pharmaceutical compsn. contg. specific tri:peptide(s) - is prepd. by controlled hydrolysis of collagen, etc., for stimulating cell respiration or collagen synthesis, etc. |
GB2274585A (en) | 1993-01-23 | 1994-08-03 | Procter & Gamble | Make-up compositions for cosmetic use |
GB2282102B (en) | 1993-09-06 | 1998-02-04 | Uponor Aldyl Ltd | Improvements in or relating to pipe fittings |
US6068834A (en) | 1994-03-04 | 2000-05-30 | The Procter & Gamble Company | Skin lightening compositions |
CN1152865A (zh) | 1994-06-15 | 1997-06-25 | 普罗克特和甘保尔公司 | 对哺乳动物皮肤中色素过度沉着区域的增白方法 |
DE4444238A1 (de) * | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden |
US6060547A (en) | 1995-04-28 | 2000-05-09 | The Proctor & Gamble Company | Film forming foundation |
FR2737406B1 (fr) | 1995-08-04 | 1997-10-24 | Sederma Sa | Gel a activite physique pour produits cosmetiques |
WO1997021423A1 (en) | 1995-12-11 | 1997-06-19 | The Procter & Gamble Company | Topical retinoid composition |
WO1997039733A1 (en) | 1996-04-23 | 1997-10-30 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin b3 compound |
FR2751874B1 (fr) | 1996-08-02 | 1998-08-28 | Sederma Sa | Nouvelles compositions cosmetiques pour embellir et eclaircir la peau |
EP0920445B1 (fr) | 1996-08-23 | 2003-01-02 | Sederma S.A. | Peptides synthetiques et leur utilisation dans les compositions cosmetiques ou dermopharmaceutiques |
FR2761603B1 (fr) | 1997-04-02 | 1999-11-26 | Sederma Sa | Compositions cosmetiques amincissantes |
FR2769502B1 (fr) | 1997-10-14 | 2000-04-14 | Sederma Sa | Compositions a usage cosmetique ou dermopharmaceutique contenant un extrait vegetal obtenu a partir du trefle (trifolium sp.) |
FR2771002B1 (fr) | 1997-11-17 | 2000-03-31 | Sederma Sa | Compositions a usage cosmetique ou dermopharmaceutique contenant un extrait vegetal obtenu a partir des racines de kava piper methysticum |
US6958295B1 (en) * | 1998-01-20 | 2005-10-25 | Tegal Corporation | Method for using a hard mask for critical dimension growth containment |
FR2774590B1 (fr) | 1998-02-12 | 2001-07-13 | Sederma Sa | Compositions a usage cosmetique ou dermopharmaceutique contenant un extrait vegetal obtenu a partir bacopa monnieri (l.) |
FR2783169B1 (fr) | 1998-09-15 | 2001-11-02 | Sederma Sa | Utilisation cosmetique ou dermopharmaceutique de peptides pour la cicatrisation et pour l'amelioration de l'aspect cutane lors du vieillissement naturel ou accelere (heliodermie, pollution) |
FR2788777B1 (fr) * | 1999-01-22 | 2003-01-17 | Sederma Sa | Utilisation cosmetique ou dermopharmaceutique de peptides pour la regulation des dysfonctionnements immunologiques cutanes et dans l'inflammation cutanee induits par le vieillissement ou par les u.v. |
US6492326B1 (en) | 1999-04-19 | 2002-12-10 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
JP4082823B2 (ja) * | 1999-05-06 | 2008-04-30 | 日本メナード化粧品株式会社 | 光毒性抑制剤 |
FR2802413B1 (fr) * | 1999-12-17 | 2003-10-31 | Sederma Sa | Compositions cosmetiques ou dermopharmaceutiques contenant le tripeptide n-palmytoyl-gly-hys-lys, pour eliminer, reduire ou prevenir l'apparition de rides quelles qu'en soient la localisation et la cause |
FR2805161B1 (fr) | 2000-02-23 | 2004-11-19 | Sederma Sa | Compositions a usage cosmetique ou dermopharmaceutique contenant un extrait d'imperata notamment d'imperata cylindrica l. |
JP2002031458A (ja) | 2000-07-14 | 2002-01-31 | Matsushita Electric Ind Co Ltd | 冷蔵庫の解体方法、圧縮装置、及び冷蔵庫の解体装置 |
FR2813188B1 (fr) | 2000-08-25 | 2003-01-17 | Sederma Sa | Utilisation de la tyramine dans des compositions cosmetiques destinees a eclaicir la peau |
WO2002047680A2 (en) * | 2000-12-15 | 2002-06-20 | Galileo Laboratories, Inc. | Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia |
FR2828811B1 (fr) | 2001-08-27 | 2005-08-19 | Sederma Sa | Utilisation de l'huile de luffa cylindrica dans des compositions cosmetiques et dermopharmaceutiques relipidantes |
FR2830195B1 (fr) | 2001-10-03 | 2004-10-22 | Sederma Sa | Compositions cosmetiques et dermopharmaceutiques pour les peaux a tendance acneique |
FR2836042B1 (fr) * | 2002-02-15 | 2004-04-02 | Sederma Sa | Compositions cosmetiques ou dermopharmaceutiques pour diminuer les poches et cernes sous les yeux |
FR2854897B1 (fr) * | 2003-05-12 | 2007-05-04 | Sederma Sa | Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane. |
-
2003
- 2003-11-17 AU AU2003296248A patent/AU2003296248A1/en not_active Abandoned
- 2003-11-17 EP EP03789211A patent/EP1686957B1/en not_active Expired - Lifetime
- 2003-11-17 ES ES03789211T patent/ES2381359T3/es not_active Expired - Lifetime
- 2003-11-17 JP JP2005510711A patent/JP4256389B2/ja not_active Expired - Lifetime
- 2003-11-17 AT AT03789211T patent/ATE548022T1/de active
- 2003-11-17 KR KR1020067009163A patent/KR101045658B1/ko active IP Right Grant
- 2003-11-17 CN CN2003801109853A patent/CN1893911B/zh not_active Expired - Lifetime
- 2003-11-17 WO PCT/EP2003/014019 patent/WO2005048968A1/en active Application Filing
- 2003-12-10 US US10/731,921 patent/US6974799B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2784029B1 (fr) * | 1998-10-05 | 2001-01-05 | Pharmascience Lab | Methode de prevention et/ou de traitement cosmetique des vergetures de la peau et utilisation en dermatologie |
Also Published As
Publication number | Publication date |
---|---|
ES2381359T3 (es) | 2012-05-25 |
KR20060122844A (ko) | 2006-11-30 |
JP4256389B2 (ja) | 2009-04-22 |
WO2005048968A1 (en) | 2005-06-02 |
KR101045658B1 (ko) | 2011-07-01 |
EP1686957A1 (en) | 2006-08-09 |
EP1686957B1 (en) | 2012-03-07 |
ATE548022T1 (de) | 2012-03-15 |
US6974799B2 (en) | 2005-12-13 |
JP2007515381A (ja) | 2007-06-14 |
CN1893911A (zh) | 2007-01-10 |
AU2003296248A1 (en) | 2005-06-08 |
US20040132667A1 (en) | 2004-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1893911B (zh) | 含有四肽和三肽混合物的配方 | |
KR100451280B1 (ko) | 피부 케어 활성제의 배합물을 함유하는 피부 케어 조성물 | |
US20090186826A1 (en) | Cosmetic or dermopharmaceutical compositions of ceramides and polypeptides | |
US20110201562A1 (en) | Formulations and method for treating baldness | |
JP2005503335A (ja) | 糖アミンを含有するスキンケア組成物 | |
JP2002542177A (ja) | 哺乳類のケラチン性組織の状態を調節する方法 | |
JP2003530302A (ja) | 皮膚ケア活性剤を組み合わせて含有する皮膚ケア組成物 | |
WO2009052518A2 (en) | Methods and compositions directed to reduction of facial hair hirsutism in females | |
US20160151270A1 (en) | Peptide-Based Compositions and Methods of Use | |
FR2958541A1 (fr) | Utilisation cosmetique du geranylgeranyl-2-propanol | |
JP2002542179A (ja) | スキンケア活性物質の組合せを含有するスキンケア組成物 | |
KR20020011988A (ko) | 포유류의 케라틴 조직 상태의 조절 방법 | |
JPH0899819A (ja) | 抗真菌性の化粧用および皮膚科用製剤 | |
WO2000069406A1 (en) | Methods of regulating the condition of mammalian keratinous tissue | |
US9943566B2 (en) | NF-κB inhibitor composition for skin health | |
EP1833454A1 (en) | Cosmetic or dermatological compositions of saccharose substitutes | |
ES2244434T3 (es) | Composiciones para el cuidado de la piel que contienen una combinacion de sustancias activas para el cuidado de la piel. | |
MXPA97003471A (en) | Cosmetic composition with fine acid esters retinol insatured chain la |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20101229 |